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GENERAL INTRODUCTION ON COLORECTAL CANCER
Epidemiology and risk factors of colorectal cancer
In the last decade, cancer has replaced cardiovascular disease as the world’s number 
one killer, currently responsible for more than 8 million deaths every year. Among 
the major types of cancer is colorectal cancer (CRC), which annually is diagnosed in 
approximately 1.4 million people and is the cause of death of about 700 thousand 
patients worldwide 1. The lifetime risk of being diagnosed with CRC as inhabitant of 
a developed country is 5-7% 2-5. Incidence is highest for elderly patients, as 70-90% 
of CRC patients is older than 50 years of age 6-9. CRC affects men slightly more often 
than women 1.
In Europe, North America and Australia, CRC incidence is up to ten-fold 
higher than in Africa and Asia, which has often been associated with environmental 
effects on CRC development, although such data may be biased by different life 
expectancies in the different continents  1. Smoking, high consumption of alcohol, 
a diet high on red meat and fatty products, but low on fibres and lack of physical 
activity, which are all typical for lifestyle in developed countries, are commonly 
associated with increased CRC risk 6,10. Furthermore, CRC incidence is significantly 
higher in patients suffering from diabetes mellitus and obesity, which are major 
problems in developed countries 6. The effect of environmental factors on CRC risk 
has been emphasized by migrant studies, showing a rapid increase in CRC incidence 
in the first generation of migrants who have moved from low-risk to high-risk areas 
11,12. Nevertheless, many of the risk factors have not yet been confirmed by well-
designed randomized clinical trials and, therefore, it may be debated to what extent 
these factors affect CRC incidence 10,13-16. 
Next to environmental factors, genetic susceptibility is a major cause of CRC 
development, as 20-30% of CRC is estimated to have a familial component 6,17. In 
fact, the risk of getting CRC is increased two- to four-fold when having a first-degree 
relative with a previous diagnosis of CRC 6,18. Remarkably, only 6% of familial CRC 
are recognized within the context of well-defined hereditary CRC syndromes, such 
as familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal 
 
Table 1. Stage grouping of TNM stages (7th edition) 167 
Stage TNM Tumour spread 
0 Tis, N0, M0 - restricted to mucosa 
I T1, N0, M0 - into submucosa 
 T2, N0, M0 - into muscularis propria 
IIa T3, N0, M0 - into subserosa 
IIb T4a, N0, M0 - through colorectal wall 
IIc T4b, N0, M0 - through colorectal wall and into adjacent tissue 
IIIa T1-T2, N1, M0 - into submucosa or muscularis propria and 1 to 3 regional lymph nodes 
 T1, N2a, M0 - into submucosa and 4 to 6 regional lymph nodes 
IIIb T3-T4a, N1, M0 - into subserosa or through colorectal wall and 1 to 3 regional lymph nodes 
 T2-T3, N2a, M0 - into muscularis propria or subserosa and 4 to 6 regional lymph nodes 
 T1-T2, N2b, M0 - into submucosa or muscularis propria and 7 or more regional lymph nodes 
IIIc T4a, N2a, M0 - through colorectal wall and into 4 to 6 regional lymph nodes 
 T3-T4a, N2b, M0 - into subserosa or through colorectal walls and into 7 or more regional lymph nodes 
 T4b, N1-N2, M0 - into adjacent tissue and 1 or more regional lymph nodes 
IV T1-T4, N1-N2, M1a - into 1 distant organ 
 T1-T4, N1-N2, M1b - into more than 1 distant organ 
 
 
 
 
 
 
 
 
 
Table 2. Imaging modalities for visualisation of CRCLM 
Imaging 
modality Principle Visualisation of 
US distinct reflection of ultrasound pulses by separate tissues anatomy 
CT distinct attenuation of X-rays by separate tissues anatomy 
MRI 
distinct relaxation times of proton spins of separate tissues in 
oscillating magnetic field anatomy + physiology 
PET measurement of radiolabelled biologically active small molecules or monoclonal antibodies biology 
PET/CT subsequent PET and CT imaging  biology + anatomy 
PET/MRI subsequent PET and MRI imaging biology + anatomy + physiology 
US: ultrasonography, CT: computed tomography, MRI: magnetic resonance imaging, PET: positron emission tomography  
 
 
  
9General introduction and outline
1
cancer (HNPCC, also known as Lynch syndrome) 6. In patients with inflammatory 
bowel diseases, such as ulcerative colitis and Crohn’s disease, higher CRC incidence 
rates are reported than in the general population 19,20. Most likely, this is a result of 
the activation of carcinogenic processes by chronic inflammation 21. 
Although incidence rates for CRC have remained stable or even decreased 
in many of the developed countries since the 1980s, the number of CRC patients is 
expected to increase from 19 per 100.000 persons to an estimated 28 per 100.000 
persons worldwide in the next twenty years. Westernization of former low-income 
economy countries such as Japan, Singapore and several Eastern European 
countries, accompanied by resulting lifestyle changes, are the main contributors 
to the estimated increasing incidence. In contrast, mortality rates are expected to 
drop, which can be attributed to the rise of CRC screening programmes in several 
countries and the development and improvement of imaging modalities and 
treatment strategies 1,22-24. 
Staging
To describe the severity of CRC in a patient, several clinicopathological staging 
systems have been developed. Older staging systems, such as Astler-Coller and 
Dukes staging, have generally been replaced by the TNM staging system, which 
Figure 1. (A) Stages of colorectal cancer development. (B) Five-year survival is 90% for 
patients diagnosed with CRC stages 0 to II and decreases to 70% and 13% for patients with 
CRC stages III and IV, respectively.
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is maintained by the American Joint Committee on Cancer (AJCC) and the 
International Union against Cancer (UICC) 25. The TNM staging system describes the 
extent of tumour spread through the wall of the colon and rectum (T), to regional 
lymph nodes (N) and to distant organs (M). Commonly, these TNM stages are 
grouped, resulting in a staging system with stages 0 to IV (Table 1 and Fig. 1A) 26. 
Survival rates significantly decrease with CRC stage: five-year survival is 90% when 
patients are diagnosed with localized CRC (stages 0-II), 70% when regional lymph 
nodes are affected (stage III) and 13% when distant metastases are present (stage 
IV) (Fig. 1B) 27. 
CLINICAL MANAGEMENT OF COLORECTAL CANCER LIVER METASTASIS
Colorectal cancer metastasis
Major cause of death for CRC patients is dissemination to distant organs. The main 
site dissemination occurs to is the liver, which is affected in 36-81% of patients. Next 
to liver, common sites of metastasis are lung (12-54%) and peritoneum (17-41%) 28. 
Colorectal cancer liver metastases (CRCLM) are diagnosed synchronously (i.e. within 
six months) with diagnosis of the primary tumour in 14-25% of patients. However, 
40-60% of patients will eventually develop liver metastases in the course of their 
disease 29-32. Once metastasized, multiple organs often become affected. Only in 25-
40% of patients with CRCLM at time of diagnosis dissemination is confined to liver 
30,33. 
Conventional imaging of colorectal cancer liver metastasis 
Before CRCLM are treated, the affected tissue is elaborately visualized. That is, for 
deciding upon the optimal treatment regimen accurate imaging of the metastases is 
crucial. A variety of imaging modalities is available for optimal tumour visualisation 
(Table 2 and Fig. 2). Computed tomography (CT) and magnetic resonance imaging 
(MRI) are recommended as imaging modalities for the visualization of potential 
CRCLM upon first diagnosis of CRC, when during follow-up ultrasonography (US) 
of the liver is inconclusive or when serum carcinoembryonic antigen (CEA) levels 
are elevated 34. Ultrasound is cheap and readily available but its mean weighted 
sensitivity is only 49-64% (mainly based on per patient sensitivity, which is important 
for determining liver involvement). Moreover, US results are often inconclusive, 
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especially in the case of (systemic therapy-induced) fatty infiltration of the liver 
35,36. For CT, the per lesion sensitivity is 74% (i.e. important for treatment strategy) 
and its per patient sensitivity is 84%, whereas for MRI these values are 80% and 
88% respectively. However, the operational characteristics are a function of lesional 
size: the sensitivity for CRCLM <10 mm is considerably lower for CT (47%) than 
for  MRI (60%), whereas for CRCLM ≥10 mm the sensitivities of both modalities are 
comparable (87% for CT and 89% for MRI) 37. Therefore, MRI is generally preferred 
when a treatment strategy depends on exact mapping of CRCLM 34. The specificity 
of CT is 95% and of MRI 90% 37. 
When CRCLM appear to be resectable or when CT or MRI data are inconclusive, 
positron emission tomography (PET) using the standard tracer fluorine-18 
fluorodeoxyglucose ([18F]FDG) is recommended, particularly to indicate extrahepatic 
Figure 2. Liver metastasis of (A, B, D, F) colorectal cancer and (C, E, G) breast cancer visualized 
with different imaging modalities. (A) Contrast-enhanced ultrasonography (US), (B) computed 
tomography (CT), (C) contrast-enhanced magnetic resonance imaging (MRI), (D-E) [18F]FDG 
positron emission tomography ([18F]FDG PET), (F) combined PET/CT image of (B) and (D), 
(G) combined PET/MRI image of (C) and (E).
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disease which might alter treatment strategy or to help characterizing equivocal CT 
or MRI lesions. Additionally, imaging with [18F]FDG PET is commonly advised when 
recurrent disease is suspected 34. Per lesion sensitivity of [18F]FDG PET is 81% and 
per patient sensitivity is 94%, with a specificity of 96%, although these may also 
depend on lesion size 34,38. 
PET and colorectal cancer liver metastasis
Although PET is not a standard imaging modality at primary presentation, it offers 
great opportunities for CRCLM imaging. The sensitivity of PET is a function of the 
signal-to-noise ratio and, in biological terms, this relates to the level of tracer uptake 
in a target volume compared to the background signal of the tracer 39. At standard 
clinical acquisition protocols, [18F]FDG uptake in normal liver is well-recognizable 
and it is slightly elevated compared to its uptake in the blood pool. Typically, 
CRC metastases are characterized by a high affinity for [18F]FDG, increasing their 
signal-to-noise-ratio 40. Consequently, [18F]FDG PET is particularly useful for the 
detection of CRCLM and extrahepatic metastasis (i.e. staging and restaging) 41,42. 
In 2009, a Dutch multicentre randomized controlled clinical trial demonstrated that 
preoperative assessment with whole body [18F]FDG PET significantly reduces the 
risk of futile liver resections 43. However, the definition of futility has changed since 
then, as more aggressive surgical management has become state-of-the-art. Finally, 
[18F]FDG PET could also be used to predict and evaluate response to chemotherapy 
44. A limitation of PET is the limited morphological information that is provided 42. 
Furthermore, in clinical setting PET images are often blurred due to liver movements 
during measurement caused by respiration. That is, PET images are usually acquired 
in full body mode, allowing the patient to breathe freely during acquisition 39. This 
decreases the post-reconstruction signal-to-noise ratio compromising the ability 
to detect small lesions. Respiratory gating of PET is feasible, but it is difficult to 
implement in a whole body scan. Additionally, limited resolution of the imaging 
system also decreases the capability to detect small lesions (i.e. partial volume 
effect) 39. 
Hybrid PET/CT scanners have become the current standard for PET scanning, 
since CT adds the required anatomical information to PET and it provides a full 
attenuation map within seconds 42,45,46. More recently, hybrid PET/MRI scanners 
have been introduced that simultaneously perform PET and MRI and have appealing 
features in liver imaging 45. 
An important feature of nuclear medicine is that, theoretically, one could 
develop a radiopharmaceutical (tracer) for every biological process, provided 
that a ligand is available which represents the biological process of interest which 
can be radiolabelled with a clinically applicable isotope (e.g. fluorine-18, carbon-11, 
zirconium-89). Ideally, the physical half-life of the PET isotope should match the 
biological half-life of the molecule of biological interest. Commonly, these targeting 
compounds are small molecules or monoclonal antibodies, which interact with key 
proteins of pathogenesis. Labelled with a radioactive isotope, these compounds can 
be transformed into tracers for molecular imaging of the biological processes. For 
example, [18F]FDG is a small molecule which is generally associated with glucose 
consumption and, therefore, high uptake of [18F]FDG may represent an increased 
energy metabolism in the imaged tissue 40. Even though glucose metabolism is a 
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relatively simple process, the exact mechanisms that fully explain [18F]FDG uptake 
are still not yet fully understood 47. The biological potential of PET demonstrates 
its utility beyond conventional staging, as it can be used to answer alternative 
research questions via quantitative characterisation of the investigated tissue 
on a non-invasive manner. Accordingly, it allows to measure and visualize the 
pharmacokinetics and pharmacodynamics of tumour biology or new drugs in 
preclinical setting and, if successful, also in clinical practice. A good example is the 
proliferation tracer fluorine-18 3’-deoxy-3’-fluorothymidine ([18F]FLT ). Compared 
to [18F]FDG, it has a less favourable biodistribution with high normal liver and bone 
marrow uptake that compromises its use in detecting metastases and staging. 
However, for characterisation of lesions, its suboptimal signal-to-noise ratio still 
allows to answer certain research questions, resulting in e.g. the current research 
on  [18F]FLT to measure proliferation in CRCLM 48,49. New PET tracers are constantly 
emerging and, although several have proven to be useful for research purposes, 
compared to [18F]FDG none of the tracers have showed to be superior for CRC 
staging.
Altogether, a variety of imaging modalities is available for the staging and 
characterization of patients with CRCLM. The technique of choice for imaging of 
CRCLM will likely depend on local availability of equipment, resources and operator 
expertise. The preferred preoperative imaging modality should combine high 
specificity with high sensitivity and should provide accurate anatomical, biological 
and physiological information 45. Currently, these features are being combined in 
multi-imaging techniques such as PET/CT or PET/MRI, emphasizing their potential 
to be established as standard imaging modalities for patients with CRCLM. 
 
Treatment of colorectal cancer liver metastasis
Ideally, data on CRCLM anatomy, spread, biology and physiology obtained from 
imaging modalities should help to determine the optimal treatment strategy per 
patient. To date, surgery is preferred as treatment for all CRC stages. For patients 
with CRCLM resection of the affected liver tissue is considered the only curative 
therapy option 50,51. Median survival of patients with untreated CRCLM is 6-12 months 
52,53. Surgical resection has significantly improved five-year survival and currently 
ranges from 36% to 58% 6. For patients with solitary CRCLM, five-year survival even 
is 71% 54. Traditionally, contraindications to CRCLM resection have been the number 
of lesions (which should be less than four), the presence of extrahepatic metastases, 
the size of the CRCLM and advanced age. Additionally, a surgical resection margin 
of at least 1 cm had to be feasible 55,56. Nowadays, resectability is mainly based on 
residual liver function, rather than on the tissue that has been surgically removed. 
At least 20-30% of functional liver should remain, including minimally two adjacent 
liver segments with independent in- and outflow and biliary drainage. Furthermore, 
patients should be physically capable of undergoing surgery, extrahepatic 
metastases should be controllable and complete resection of the CRCLM should be 
feasible 56. Currently, 15-30% of CRCLM are resectable at presentation 56,57. 
Advances in liver surgery strategies and the addition of non-surgical 
techniques, such as radiofrequency ablation (RFA), have increased the number of 
eligible patients for CRCLM resection 6,58. That is, RFA may be used as additional 
treatment tool when complete resection of the CRCLM is not possible 59. Five-year 
14
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survival of patients with resectable CRCLM after treatment with RFA is almost similar 
to survival after resective surgery as determined by retrospective comparative 
studies (17-55%). However, as of yet these data have not been confirmed by 
randomized prospective trials, which until now have failed due to poor recruitment 
58,60-62. As the benefit of RFA treatment alone compared to resective surgery remains 
uncertain, at present RFA alone should not be recommended as standard radical 
treatment for patients with resectable CRCLM 61.
To optimize outcome after CRCLM resection, surgery is often combined with 
systemic therapy in a multidisciplinary setting. Addition of preoperative systemic 
therapy to resective surgery has improved three-year progression-free survival by 
approximately 10%, presumably by eliminating micrometastases and by enhancing 
the likelihood of complete resection via downsizing of the CRCLM 6,63,64. Similarly, 
preoperative systemic therapy can be applied to increase resectability of initially 
unresectable CRCLM. Indeed, downsizing of CRCLM may erase small metastases 
from one liver lobe, enabling resection of metastases in the other lobe, may shrink 
lesions to a size which enables treatment with ablative techniques such as RFA 
and may eliminate lesions in close proximity to major vascular networks 6,56,61,64-66. 
As such, 15-50% of initially unresectable CRCLM can be downstaged to resectable 
56,67. For patients with permanently unresectable metastatic disease, palliative 
systemic therapy remains the mainstay of treatment. However, five-year survival 
rates of such patients remain very poor (<8%) 66. Standard systemic therapy 
regimens prior to 2000 were based on single-agent fluoropyrimidine drugs, such 
as 5-fluorouracil (5FU), combined with folinic acid (leucovorin) 56,66. Median survival 
of CRCLM patients treated with 5FU monotherapy was approximately one year, 
but increased to roughly two years with the addition of oxaliplatin (FOLFOX) and 
irinotecan (FOLFIRI) in combined treatment regimens 6,68. Furthermore, approval 
of treatment with humanized monoclonal antibodies enabled targeted inhibition of 
specific biological processes involved in carcinogenesis. Three monoclonal antibody 
therapies have currently been approved by the US Food and Drug Administration 
(FDA) to treat patients with CRCLM: bevacizumab, targeting the vascular endothelial 
growth factor (VEGF) network, cetuximab and panitumumab, both targeting the 
epidermal growth factor receptor (EGFR) network 6. Bevacizumab has demonstrated 
a significant increase in overall and progression-free survival of CRCLM patients and 
has already been added to standard first line systemic therapy for patients with 
unresectable CRCLM 34,69. The survival benefit of cetuximab and panitumumab is 
restricted to patients with CRCLM that do not contain genetic mutations in KRAS, 
which is the case for approximately 40-45% of CRCLM 6,64,65.
A multidisciplinary approach has become the standard practice for treating 
patients with CRCLM. Surgical resection remains the most effective treatment, 
however, further research is necessary to establish an optimal multimodality 
treatment regimen in which surgical and non-surgical techniques are combined with 
systemic therapy 70. 
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PROGNOSIS AFTER COLORECTAL CANCER LIVER METASTASIS RESECTION
Personalized CRCLM treatment
Historically, most CRCLM patients were treated according to the one-size-fits-all 
principle, resulting in similar treatment strategies for seemingly similar tumours. 
In the last decades, it was realized that effectiveness of CRCLM treatment – and 
consequently patient survival – could be increased by personalization of therapy via 
preoperative assessment of clinicopathological and/or biological factors. At the end 
of the 20th century personalization was mainly based on clinicopathological factors, 
which were used to stratify patients based on the clinical profile of their metastatic 
lesions. Assessment of biological factors has prospered particularly since the early 
2000’s, after the complete human genome was sequenced, but also due to the 
development of novel techniques to analyze the tumour’s genome and proteome 71. 
Together, the clinicopathological and biological factors could be used for tailoring 
of CRCLM treatment and to predict therapy response and outcome. 
Clinicopathological factors 
Which clinicopathological factors affect outcome after CRCLM surgery has been 
examined in a large number of studies, both retrospectively and prospectively. 
Meta-analyses show that factors commonly associated with poor overall survival in 
the majority of studies are number of CRCLM, presence of lymph node metastasis, 
size of the CRCLM, interval between the primary tumour and CRCLM, preoperative 
serum CEA level, presence of extrahepatic disease and surgical resection margin 72-
74. These and other clinicopathological parameters have been combined in various 
clinical risk scores to stratify patients for deciding upon optimal treatment regimens 
and to evaluate the effectiveness of therapeutic interventions. An example is the Fong 
clinical risk score, which may be applied to predict outcome after CRCLM resection 
50. Although some of the suggested preoperative scoring systems appeared useful 
in predicting survival, their prognostic accuracy has frequently been questioned 72-
74. Firstly, data on the external validation of these scoring systems are limited 74,75. 
Secondly, most scores have been designed in the late 1990’s using patient populations 
of the 1980’s and earlier, which makes it debatable whether these are representative 
of today’s patients 72,74. Furthermore, for some of the clinicopathological factors the 
effect on survival may be greater than for others, which suggests that weighted 
scoring systems should be preferred. Most risk assessment systems did not apply 
such weighting 72. On top of that, the scoring systems generally apply categorical 
cut-off values for several clinicopathological factors, which do not take into account 
the continuousness of these factors. Moreover, scores do not account for the clinical 
consequences of varying surgical resection margins or treatment with preoperative 
therapy 76. Survival regularly differs between patients with similar risk scores, 
and therefore, it has been suggested that outcome after CRCLM resection relies 
on more than just the currently applied clinicopathological factors 74. That is, the 
clinicopathological properties of a tumour are largely an indirect consequence of 
biological processes in a tumour, such as genomic alterations, which favour the 
oncogenic process or inhibit tumour suppressors after being translated into proteins. 
This may explain the apparent unreliability of current clinical risk scores. Preferably, 
patient prognosis should be based on the biological factors, measured on genomic 
or proteomic level, that directly underlie tumour development.
16
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Biological factors: hallmarks of CRC
In 2000, an overview was published by Hanahan and Weinberg on the biological 
factors involved in carcinogenesis and an update on these cancer hallmarks was 
provided eleven years later 77,78. It was postulated that cancer development depends 
on the acquisition of a number of hallmark capabilities by normal cells which permit 
their transformation into tumorigenic and ultimately malignant cells. This also 
accounts for the development of colorectal cancer. The hallmarks as proposed by 
Hanahan and Weinberg as well as a number of key proteins for CRC progression 
and metastasis are briefly discussed in the following sections (Table 3). Additionally, 
compounds that target these proteins (i.e. small molecules or monoclonal antibodies) 
are mentioned, which offer opportunities for labelling with imaging ligands or 
isotopes and, consequently, for molecular imaging of the proteins and biological 
processes these proteins are involved in.
Table 3. Overview of several biological processes involved in CRC carcinogenesis and proteins commonly 
associated with these processes  
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Sustained proliferative signalling
One of the most fundamental hallmarks of cancer is sustained proliferative 
signalling. The cell growth-and-division cycle through which normal cells progress 
is tightly regulated by production and degradation of growth-promoting signals. In 
(colorectal) cancer cells, this signalling is deregulated, resulting in overexpression 
of growth factors, their receptors and cell cycle-associated proteins, like epidermal 
growth factor receptor (EGFR), rat sarcoma (Ras), phosphatidylinositide 3-kinase 
(PI3K), aurora kinase A (AURKA), antigen KI-67 (KI-67) and thymidine kinase 1 (TK1), 
to promote cell growth and progression 78-85. EGFR is upregulated in 25-80% of CRC 
patients and plays a major role in CRC progression 79. Patients who lack mutations 
in downstream effectors have shown good response to anti-EGFR therapies (e.g. 
cetuximab, panitumumab) 86,87. Downstream of EGFR, signalling pathways such as 
the Ras signalling pathway and even further downstream also the PI3K signalling 
pathway are operational 88. Gene mutations coding for these pathways occur 
in up to 40% and 30% of CRC, respectively, and are commonly associated with 
tumour development and poor patient survival 80,81. As a result, inhibitors designed 
to block the signalling cascades of PI3K (e.g. PX-866) and Ras (e.g. salirasib) are 
currently being tested in clinical trials 81,89. AURKA expression levels are generally 
elevated in cells during the transition from G2 to M phase and, as such, AURKA 
is often regarded as a proliferation marker 90. Recently, however, it was shown 
that in CRC high AURKA expression is also associated with tumour cell viability, 
invasion, anchorage-independent growth and poor prognosis 91,92. Selective small 
molecule inhibitors of AURKA (e.g. alisertib) have demonstrated anticancer activity 
in various preclinical cancer models and, as a result, some have already entered 
clinical trials 93-95. The capability of proliferation indices as prognostic biomarkers for 
CRC has been assessed frequently and although for primary CRC results have been 
inconclusive, the prognostic role of proliferation markers in CRCLM, such as Ki-67, 
has been more consistent 82. Accordingly, expression of TK1 is higher in colorectal 
carcinomas compared to adenomas and has been associated with CRC tumour 
stage 83. Consequently, PET tracers have been developed to visualize and quantify 
proliferation (e.g. [18F]-3’-deoxy-3’-fluorothymidine (18F]FLT)) and these tracers are 
currently being tested in several types of cancer, including CRC with liver metastasis 
49,96,97. 
Evading tumour suppressors
Next to sustained proliferation, cancer cells must also evade signalling networks 
that constrain proliferation via activation of tumour suppressors. For CRC, as well as 
for many other types of cancer, the most established tumour suppressor is tumour 
protein 53 (TP53) 78,98. Mutation of the TP53 gene occurs in more than 50% of CRC 
and blocking of the tumour suppressing properties of p53 prevents DNA damage-
induced apoptosis. Nevertheless, abrogative p53 signalling has conflictingly been 
associated with prognosis 82. Recently, potassium voltage-gated channel, KQT-
like subfamily, member 1 (KCNQ1) has been identified as a tumour suppressor in 
CRC. Although not much is known about the role of KCNQ1 in cancer, it was shown 
that KCNQ1 may serve as prognostic biomarker for CRC patients. Furthermore, 
knockdown of Kcnq1 in mice resulted in the upregulation of genes involved in the 
EGFR pathway. As such, KCNQ1 may offer new opportunities in treatment and 
monitoring of patients with CRCLM 99.
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Resisting cell death
For maintenance of cell number and normal tissue architecture, cells usually die 
after a limited number of cell cycles. This process is regulated by counterbalancing 
between signals that induce cell death and signals that promote proliferation. In 
CRC, cell death is circumvented by a variety of strategies, mostly involving the 
loss of function of cell death-stimulating factors such as p53, or alternatively, by 
increasing the expression of growth factors and anti-apoptotic regulators, such as 
PI3K or insulin-like growth factor 2 (IGF 2). Next to enhancing cell growth, PI3K 
blocks apoptosis and inhibits autophagy upon upstream activation by growth 
factors 78,100. Increased levels of IGF2 have been implicated in CRCLM and excessive 
IGF2 in tumour cells promotes cell survival and inhibits apoptosis 101,102. Additionally, 
IGF2 overexpression has been related to increased mortality risk of CRC patients 
102,103. As a result, its clinical applicability for early diagnostic tests of CRC is being 
investigated, based on expression in serum or epigenetic changes in CRC patients 
102,104. 
Enabling replicative immortality
Normal cell lineages are allowed only to go through a limited number of successive 
cell cycles. After that, cells usually will enter an irreversible state of senescence, 
in which cells no longer proliferate, but are still viable. Cells which accomplish to 
bypass this senescent state will enter a crisis state, eventually followed by cell death. 
Normally, telomeres protect the endings of a chromosome, but are shortened in each 
proliferation cycle. When after a number of cell cycles the chromosome endings are 
no longer protected by these telomeres, chromosomes become unstable, which 
leads to crisis and eventually cell death. Sometimes, cells manage to escape from 
these proliferation barriers, resulting in their immortalization and it is believed 
that tumour cells require this feature to form macroscopic tumours. P53 plays an 
important role in the detection of such threats for genomic integrity, but in absence 
of its surveillance immortalization of tumour cells is permitted by for example the 
telomerase-enhanced suppression of progressive telomere erosion. Although the 
role of telomerase and its cooperative enhancement of tumorigenesis with TP53 has 
been indicated, a clear definition on its prognostic value and full functions in CRC 
has not yet been provided 78,105.
Inducing angiogenesis
For growing tissues, both normal and cancerous, a continuous supply of nutrients 
and oxygen is required, as is sustained disposal of metabolic waste and carbon 
dioxide. Blood vessels provide for this demand and in normal tissues new blood 
vessels are usually formed only during embryogenesis, female reproductive cycling 
and wound healing, and even then transiently. In cancerous tissues, however, 
this “angiogenic switch” is often permanently turned on to sustain vasculature 
development and tumour growth 78. Vascular endothelial growth factor A (VEGFA) 
is involved in several biological processes associated with angiogenesis and in CRC 
VEGFA protein expression is frequently elevated 106. Further, VEGFA has been 
associated with tumour progression, invasion and metastasis 107,108. Monoclonal 
antibodies specifically inhibiting VEGF (i.e. bevacizumab) have recently been 
added to conventional first-line therapy and have significantly improved outcome 
19
General introduction and outline
1
of patients with advanced CRC 69. Furthermore, the addition of bevacizumab to 
preoperative systemic therapy improved radical resection rates and survival in 
patients with resectable CRCLM 109. Also expression of platelet-derived growth factor 
receptor β (PDGFRβ) has commonly been associated with CRC angiogenesis 110,111. 
Expression levels of PDGFRβ are significantly higher in CRC compared to adenomas 
and approximately 60% of CRC express PDGFRβ 85,110. PDGFRβ is involved in CRC 
dissemination and, accordingly, the efficacy of inhibitors blocking PDGFRβ signalling 
(e.g. sunitinib) is currently being investigated in clinical trials 110,112.
 
Activating invasion and metastasis
Late stage malignancy is characterized by the dissemination of tumour cells to 
distant organs. To disseminate, tumour cells require alterations in shape and 
cell attachments and acquire properties that are commonly associated with 
mesenchymal cells, such as increased invasive capacity and resistance to apoptosis. 
The exact mechanisms that underlie cell invasion and metastasis are still largely 
unclear, but in last decade several key genes for CRC metastasis have been identified 
78. Carcinoembryonic antigen (CEA) has been identified as an important regulator of 
cell polarization, adhesion, anoikis and migration, all processes involved in tumour 
metastasis 113. Increased levels of CEA in CRC patients are commonly associated 
with presence of liver metastasis, explaining its role as the conventional biomarker 
for CRCLM 100. Highly specific radiolabelled monoclonal antibodies targeting CEA 
are currently showing good utility in the treatment and imaging of cancer patients 
114.  Matrix metallopeptidase 9 (MMP9) has been associated with degradation of 
the extracellular matrix, facilitating cell migration and metastasis and consequently 
releasing angiogenic factors such as VEGFA and PDGFRβ. Accordingly, higher 
levels of MMP9 have been measured in serum of CRC patients compared to serum 
of healthy volunteers 115-117. Several MMP inhibitors have been developed, of which 
some selective for MMP9, and although their clinical applicability is currently being 
challenged as a result of their failure in multiple large-scale clinical trials, their use as 
probes for non-invasive imaging of MMP expression is being investigated 118,119. C-X-C 
chemokine receptor type 4 (CXCR4) and its protagonist C-X-C motif chemokine 
12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1), have also been 
associated with metastasis, and additionally with (VEGF-mediated) angiogenesis 
and survival of cancer patients 120-123. In CRC, more particularly, CXCR4 appears to 
be required for the outgrowth of single tumour cells into micrometastases within 
the hepatic environment 124. Furthermore, activation of the CXCL12/CXCR4 axis 
ultimately leads to activation of the EGFR pathway 125. As a consequence, blocking 
studies using small molecule inhibitors (e.g. plerixafor) or monoclonal antibodies 
for CXCR4 have been initiated, investigating the clinical applicability of these 
antagonists for various cancer types 126.
Mutations and genomic instability
Mutations and genomic instability involve changes in the normal nucleic acid 
sequence of cells and rearrangements or aberrant number of chromosomes. 
Normally, the occurrence and prevalence of such defects during the cell cycle is 
minimal, since normal cells are equipped with maintenance systems designed to 
detect and resolve such genomic flaws. In tumour cells, however, these systems 
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are often disrupted by inheritable or sporadic (epi)genetic changes of genes that 
encode for such genomic maintenance systems 78. The role of p53 in the induction 
of apoptosis upon DNA damage was already mentioned, but it also exerts its 
function by the activation of mismatch repair mechanisms involving proteins such 
as MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) (MLH1) and mutS 
homolog 6 (MSH6) 82,127,128. The genes encoding for these mismatch repair proteins 
are commonly germline mutated in patients with hereditary nonpolyposis CRC 
(HNPCC). In microsatellite instable (MSI) tumours, which comprise approximately 
15% of sporadic primary CRC, these genes are often deactivated by mutations and/
or epigenetic silencing 129. CRC patients with MSI primary tumours tend to have 
improved survival compared to patients with microsatellite stable (MSS) tumours 
and, accordingly, only 3% of CRCLM is estimated to be MSI. The use of MSI status 
as a predictor of clinical outcome and systemic therapy response is currently being 
investigated 130,131.
Tumour-promoting inflammation
In general, neoplastic lesions are infiltrated by cells of the immune system. Originally, 
it was suggested that such infiltration was the immune response of the body, 
stimulating the destruction of the growing tumour. Although this is partially true, 
ambiguously, the tumour-associated inflammatory response also triggers the 
release of growth factors and other bioactive molecules that promote biological 
processes such as tumour growth, angiogenesis and metastasis 78. A key regulator 
of the inflammatory response is nuclear factor kappa B (NF-κB), which stimulates 
the expression of protumorigenic proteins such as VEGF and MMP9 and is 
interconnected with important pathways for tumour progression such as the Ras, 
EGFR and PI3K pathways 132-134. Although involved in cell growth, metastasis and 
apoptosis, the predictive and prognostic value of NF-κB in CRC has not yet been 
established 135,136. A downstream target of NF-κB which has also frequently been 
associated with tumour inflammation, is prostaglandin-endoperoxide synthase 
2 (PTGS2), also known as cyclooxygenase-2 (COX-2) 137. PTGS2 is not expressed 
in cells under normal conditions, however, it is constitutively overexpressed in 
80-85% of CRCs 132,138-140. In CRC, PTGS2 is involved in invasion, proliferation and 
tumour cell viability and in genetic knockout mouse models, inhibition of PTGS2 
significantly reduced the formation of adenocarcinomas in small intestine and 
colon 141-143. Furthermore, upregulation of PTGS2 leads to prostaglandin E2 (PGE2)-
mediated transactivation of EGFR 144,145. Inhibition of PTGS2 using non-steroidal anti-
inflammatory drugs (NSAIDs), such as aspirin, or selective small molecule inhibitors, 
such as celecoxib, has proven to effectively decrease relapse and mortality for CRC 
patients 146-149. 
Deregulating cellular energetics
The energy metabolism of neoplastic cells is often disturbed. Under normoxic 
conditions, cells usually convert glucose into pyruvate via glycolysis, which is then 
converted into carbon dioxide in the mitochondria by oxidative phosphorylation. 
The mitochondria require oxygen to function, so under anaerobic conditions energy 
production via glycolysis is favoured. In tumour cells, the energy metabolism is 
generally redirected towards glycolysis, even when sufficient oxygen is provided 
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(i.e. the “Warburg effect”). To counterbalance for the increased demand for glucose, 
cancer cells upregulate the expression of glucose transporters to increase glucose 
influx in the cells. Elevated levels of solute carrier family 2, facilitated glucose 
transporter, member 1 (SLC2A1), also known as glucose transporter type 1 (GLUT1), 
have been reported in many cancer types, amongst which CRC 78,150. Upregulation 
of SLC2A1 in CRC has been associated with tumour progression, metastasis and 
poor prognosis 150-153. The current gold standard tracer for PET imaging, [18F]FDG, 
relies mainly on uptake of [18F]FDG in malignant cells by membranous SLC2A1 and 
increased tracer uptake has been associated with poor prognosis after CRCLM 
resection 154. The glycolytic pathway is also enhanced by the hypoxic conditions 
under which neoplastic lesions tend to grow. Local oxygen deprivation in the 
tumour’s microenvironment suppresses proteasomic degradation the transcription 
factor hypoxia-inducible factor 1α (HIF1α). Upregulation of  HIF1α, either by hypoxia 
or constitutive downstream activation via e.g. Ras or PI3K, consequently upregulates 
the expression of other proteins involved in CRC progression, like SLC2A1, VEGF, 
MMP9, CEA, CXCR4, IGF2 and PTGS2 78,100,117,138,155-158. As such, overexpression of 
HIF1α has been related to angiogenesis, invasion, metastasis and inflammation and 
increased mRNA and protein levels of HIF1α are commonly reported in CRC 159-161. 
Although a clear association between HIF1α expression and CRC survival has not yet 
been established, specific HIF1α inhibitors have been developed which are currently 
being investigated in clinical trials 155,162,163.
Avoiding immune destruction
The immune system plays an important role in the detection and elimination of 
foreign or aberrant cells in the human body. That this also accounts for incipient 
cancer cells has been indicated by the higher cancer incidence in patients with 
compromised or suppressed immune systems. More specifically, the lack of 
natural killer (NK) cells and cytotoxic and helper T cells has been associated with 
decreased tumour eradication and worse prognosis. Rationally, this may indicate 
that effectively growing tumours have found ways to avoid immune destruction, 
possibly by the recruitment of immunosuppressive inflammatory cells or the 
secretion of immunosuppressive factors, which disable the NK and T cells 78. 
Accordingly, PTGS2-derived PGE2 promotes CRC progression via the accumulation 
and activation of myeloid-derived suppressor cells, which are natural suppressors of 
NK and T cells 164. Likewise, VEGFA inhibits the maturation of dendritic cells, thereby 
stimulating the conversion of conventional T cells into regulatory T cells, which 
secrete immunosuppressive cytokines such as interleukin-10 (IL-10) and transforming 
growth factor β (TGFβ) 165. CEA has also been associated with immunosuppression 
and, furthermore, artificial CEA-antigen presenting cells were not able to trigger 
an effective T cell response 166. Altogether, such data demonstrate the role of 
tumour-induced immunosuppression as a tool for CRC progression and support 
the development of novel immunotherapeutic approaches for the treatment of CRC 
patients.
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Molecular imaging of biological prognostic factors
The potential benefit of using biological factors involved in CRCLM carcinogenesis 
to personalize treatment based on biological properties of the CRCLM has been 
emphasized by several studies 74. Using biological prognostic factors, patients 
can be stratified according to their biological tumour profile, rather than their 
clinical risk score 72-74. Visualisation of key proteins involved in biological processes 
important for CRCLM progression e.g. using PET may aid in distinguishing between 
clinicopathologically similar lesions. For many of these key proteins specific small 
molecules or monoclonal antibodies have been developed to slow down or stop 
tumour growth and such compounds are excellent candidates to be transformed 
into novel probes for molecular imaging. PET has become readily available in the 
past decade, so that personalization of cancer treatment based on molecular 
imaging profiles can be implemented, provided that valid radiopharmaceuticals are 
available. PET-imageable prognostic and predictive CRCLM biomarkers now need 
to be identified to support development of personalized therapy for these patients 
in conjunction with in vitro biomarkers. 
AIMS AND OUTLINE OF THIS THESIS
Aims
Currently, survival of patients with CRCLM is particularly low. Visualization of 
prognostic biomarkers for patients with CRCLM using non-invasive molecular 
imaging modalities may contribute to improve survival rates of this patient 
population by facilitating personalized cancer therapy based on individual biological 
tumour profiles. This thesis focuses on the identification of such biomarkers in a large 
cohort of CRCLM patients who underwent resective surgery. Further, it describes 
the development of a novel PET tracer for the molecular imaging of expression of a 
prognostic biomarker identified in this study. 
Outline
This thesis describes the investigation of proteins involved in important biological 
processes associated with CRCLM progression, which could be used for molecular 
imaging. Chapter 2 focuses on the individual and combined prognostic value of 
HIF1α, SLC2A1 and VEGFA expression, which are associated with deregulated 
cellular energetics, for patients with resectable CRCLM. Their prognostic value is 
assessed in several patient subgroups and their added prognostic value to standard 
clinicopathological prognostic factors is investigated. 
Similarly, chapter 3 describes the prognostic value of EGFR and PTGS2 
expression, which are involved in inflammation-promoted tumour growth and play 
an important role in cancer progression and metastasis. Also for these proteins the 
individual and combined prognostic value is evaluated in (subgroups of) patients 
with resectable CRCLM and their added value to standard clinicopathological 
prognostic factors is assessed.
In chapter 4 the prognostic value of AURKA expression is determined. AURKA 
expression is involved in various functional processes for tumour progression, such 
as proliferation, cell viability, invasion and anchorage-independent growth, and 
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has shown prognostic value in earlier CRC stages. In a number of subgroups its 
prognostic value is evaluated and its independency of established clinicopathological 
prognostic factors is examined.  
In chapter 5 a number of potentially prognostic molecular markers is selected 
and combined in a classification and regression trees (CART) analysis to determine 
the most optimal prognostic combination of biomarkers for patients with resectable 
CRCLM. Additionally, in order to evaluate the possibility to predict protein expression 
levels in CRCLM based on expression levels in the primary tumour, expression levels 
of the selected biomarkers in CRCLM were compared with expression levels in their 
corresponding primary tumours.
Non-invasive assessment of tumour biology using molecular imaging 
techniques such as PET may contribute to improving outcome after CRCLM resection 
by personalization of cancer treatment. Chapter 6 describes the development and 
preclinical validation of a novel PET tracer for the molecular imaging of AURKA 
expression. A small molecule specifically designed to inhibit AURKA expression is 
labelled with radioisotopes for the in vitro and in vivo assessment of cellular AURKA 
protein levels.
A summary of the main results of this thesis is presented in chapter 7. Results 
are discussed and future perspectives provided.
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ABSTRACT
Purpose
To investigate the individual and combined prognostic value of HIF1α, SLC2A1 and 
VEGFA in a multi-institutional cohort of patients with resected colorectal cancer 
liver metastasis (CRCLM).
Background 
In the majority of CRCLM patients, resection appears not to be curative, despite 
its curative intent. Overexpression of hypoxia-inducible factor 1α (HIF1α), glucose 
transporter 1 (SLC2A1; also known as GLUT1) and vascular endothelial growth factor 
A (VEGFA) have been associated with tumour progression and poor prognosis of 
CRC patients. 
Methods 
Tissue microarrays were generated using CRCLM and patient-matched primary CRC 
from patients who underwent CRCLM resection between 1990 and 2010. Prognostic 
value of HIF1α, SLC2A1 and VEGFA was determined by immunohistochemistry. 
A 500-fold cross-validated hazard rate ratio (HRRav) for overall survival was 
calculated. 
Results
HIF1α, SLC2A1 and VEGFA expression could be evaluated in 328, 350 and 335 
patients, respectively. High SLC2A1 expression was associated with good prognosis 
(HRRav0.67; P(HRR>1)<.01) and high VEGFA expression to poor prognosis 
(HRRav1.84; P(HRR<1)=.02), also after multivariate analysis including established 
clinicopathological prognostic variables (HRRav0.67; P(HRR>1)<.01 and HRRav1.50; 
P(HRR<1)=.02, respectively). SLC2A1 showed prognostic value particularly in 
patients treated with systemic therapy (P<.01), while the prognostic value of VEGFA 
expression was mainly observed in patients not treated with systemic therapy 
(P<.01). Prognosis was especially poor in patients with both low SLC2A1 and high 
VEGFA expression (P<.01). HIF1α expression was not associated with survival. 
Conclusions
SLC2A1 and VEGFA expression are prognostic molecular biomarkers for CRCLM 
patients with added value to established clinicopathological variables.
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INTRODUCTION
Approximately one out of two colorectal cancer (CRC) patients develop metastases 
during the course of disease, with dissemination to the liver in approximately 
50-70% of cases 1. Historical five year survival rates of CRC patients with liver 
metastasis (CRCLM) did not exceed 10% 2. However, survival of CRCLM patients 
eligible for curative resection of the affected liver tissue, occasionally combined with 
radiofrequency ablation (RFA), has significantly improved 3. Selection of patients 
for CRCLM resection is based on clinicopathological prognostic parameters  and 
staging including 18F-labeled fluorodeoxyglucose ([18F]FDG) PET 4-6. Despite 
the significant improvements in CRC staging and therapy, only 36-58% of these 
patients will survive for more than five years after liver resection with curative intent, 
indicating that better prognostic biomarkers are needed 2,4. 
Hypoxia and hypoxia-inducible factors (HIF) are considered master 
regulators of metastasis. Activation of HIF1 has significant effects on several 
biological processes, in particular the metabolic shift in tumour cells from oxidative 
phosphorylation to glycolysis (i.e. Warburg effect), induction of angiogenesis, and 
increased metastasis 7-9. While HIF1α mRNA and protein expression levels are higher 
in primary CRC compared to normal colon tissue or adenomas, no clear relation 
between its expression and survival of CRC patients has been found. Moreover, 
its putative role as a prognostic biomarker seems to be inconsistent for different 
cancer types 10-12.
The metabolic shift from aerobic oxidation to anaerobic glycolysis results in an 
increased cellular demand for glucose, which is achieved by increased expression 
of membranous glucose transporters. Overexpression of the solute carrier family 2 
(facilitated glucose transporter), member 1 protein SLC2A1, also known as glucose 
transporter type 1 or GLUT1, is partly regulated by HIF1α and has been associated 
with tumour progression, metastasis and poor prognosis 10,13-17. 18F-FDG PET imaging 
capitalizes on (deoxy)glucose uptake via SLC2A1, and increased tracer uptake in 
CRCLM has been associated with unfavourable outcome after resection 18.
HIF1 activation also stimulates the release of the potent angiogenesis-
stimulating factor vascular endothelial growth factor VEGF 19,20. VEGF expression is 
frequently elevated in tumour tissues and has been related to tumour progression, 
invasion and metastasis 21. Moreover, VEGF overexpression is an indicator of poor 
prognosis in various types of cancer 22,23. Therapeutic agents such as the monoclonal 
antibody bevacizumab specifically target VEGF, and addition of bevacizumab to 
conventional first-line therapy has significantly improved outcome of patients with 
advanced CRC 24. In addition, preoperative systemic therapy in combination with 
bevacizumab has improved radical resection rates and survival in patients with 
resectable CRCLM 25.
This study retrospectively investigated the individual and combined 
prognostic value of HIF1α, SLC2A1 and VEGFA expression in various subgroups of 
patients with CRCLM and assessed the added value of these molecular biomarkers 
to established clinicopathological prognostic parameters. Results were validated by 
a 500-fold cross-validation procedure.
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METHODS
Patient study population
Formalin-fixed paraffin-embedded (FFPE) tissue samples were collected of patients 
who underwent CRCLM resection in seven Dutch hospitals affiliated with the 
DeCoDe PET group between 1990 and 2010. A detailed assembling procedure of the 
study population has been described previously 26,27. Summarized, tissue samples 
were collected from one histologically confirmed CRCLM specimen and an adjacent 
control liver tissue specimen. When available, also the corresponding primary 
tumour and adjacent control colon tissue were collected. Patients with multiple 
primary tumours were excluded. Collection, storage and use of clinicopathological 
data and tissue specimens were performed in compliance with the “Code for Proper 
Secondary Use of Human Tissue in The Netherlands”, and approved according to 
local and national regulations 28.
Tissue microarrays
Tissue microarrays (TMAs) were generated according to protocols described 
previously 26,27,29. In brief, from morphologically representative areas of each FFPE 
donor block three core biopsies were taken (diameter 0.6 mm) and transferred into 
TMA recipient paraffin blocks using the 3DHISTECH TMA Master (v1.14, 3DHISTECH 
Ltd., Budapest, Hungary).
Immunohistochemistry
TMA sections of 4 μm were deparaffinized by xylene and rehydrated with a 
decreasing alcohol series. TMAs were immunohistochemically stained for HIF1α 
(1:500, mouse monoclonal antibody, BD Transduction Laboratories, Breda, The 
Netherlands) using catalyzed signal amplification (CSA) system (K1500, Dako, 
Heverlee, Belgium) as described previously 30. For the SLC2A1 staining, antigens 
were retrieved in citric acid (10mM, pH 6) by water bath (97°C) heating. Endogenous 
peroxidase quenching was performed in 0.3% hydrogen peroxidase in methanol 
for 25 minutes. Primary rabbit polyclonal antibody directed against human SLC2A1 
(1:600, Abcam, Cambridge, United Kingdom) was incubated for 1 hour at room 
temperature and detected with secondary anti-rabbit antibodies (Envision Plus, 
Dako, Heverlee, Belgium). For VEGFA staining, antigen retrieval was performed in 
citric acid (10mM, pH 6) by microwave heating. Endogenous peroxidase quenching 
was performed as described above. Primary mouse monoclonal antibody directed 
against human VEGFA isoforms 121, 165 and 189 (1:50, DakoCytomation, Glostrup, 
Denmark) was incubated overnight at 4°C. HRP-coupled polymers were used for 
primary antibody detection (Powervision, Dako, Heverlee, Belgium). Visualization 
was based upon liquid diaminobenzidine substrate chromogen system. Slides were 
counterstained with Mayer’s haematoxylin. FFPE renal cell carcinoma was stained 
as positive control for HIF1α expression and FFPE Caco-2 cells as positive controls 
for SLC2A1 and VEGFA expression. FFPE renal cell carcinoma and Caco-2 cells 
incubated without primary antibody served as negative controls.
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Evaluation of protein expression
For digital capture of the immunohistochemical stainings, the Mirax slide scanner 
system was used, equipped with a 20x objective with a numerical aperture of 0.75 
(Carl Zeiss B.V., Sliedrecht, The Netherlands) and a Sony DFW-X710 Fire Wire 1/3” 
type progressive SCAN IT CCD (pixel size 4.65 x 4.65μm), as described previously 
26,27. Neoplastic epithelial cells in individual core biopsies were semiquantitatively 
scored for frequency (categories 0-25%, 26-50%, 51-75%, 76-100%) and intensity 
(categories negative, weak, moderate, strong) of nuclear HIF1α, membranous 
SLC2A1, and cytoplasmic VEGFA expression using dedicated TMA scoring software 
(v1.14.25.1, 3DHISTECH Ltd.,Budapest, Hungary). All core biopsies were independently 
evaluated by a second investigator, unaware of clinicopathological information at 
time of assessment (weighted kappa value K
w
,HIF1α=0.85, K
w
,SLC2A1=0.83 and 
K
w
,VEGFA=0.78).
Statistical analysis
The prognostic value of protein expression was evaluated by 500-fold cross-
validation 26,27. Per cross-validation cycle, the study population was randomly 
subdivided into a training and validation set of equal size. The optimal cut-off 
for dichotomizing scores in the training set into ‘low’ and ‘high’ expression was 
calculated using receiver operating characteristic (ROC) curve analysis for survival 
data with 3-year overall survival (OS) as the outcome of interest, resulting in a 
cut-off with best trade-off between sensitivity and specificity 31,32. This cut-off 
was then used to dichotomize scores of the corresponding validation set and the 
crude hazard rate ratio (HRR) was calculated in a Cox regression analysis with OS 
as outcome. Furthermore, per cycle a HRR was calculated upon addition of the 
following established clinicopathological prognostic variables in a multivariate Cox 
regression analysis: primary tumour-to-CRCLM interval < 12 months, lymph node 
positivity at time of diagnosis of the primary tumour, maximal CRCLM diameter > 
5.0 cm, number of CRCLM > 1 and serum CEA level > 200 ng/ml 33. The average 
cross-validated hazard rate ratio (HRRav) was calculated from the 500-fold cross-
validation procedure. In addition, the probability of having an actual HRR with 
opposite effect of the cross-validated HRRav was also calculated (i.e. P(HRR>1) for 
HIF1α and SLC2A1; P(HRR<1) for VEGFA). OS was defined as the time in months after 
surgery until death in a follow-up period of 10 years. The relation between protein 
expression and OS in the total patient population and several patient subgroups 
was visualized by Kaplan Meier curves and a P-value was calculated by logrank 
testing, using the most frequently selected cut-off in the cross-validation procedure 
as the optimal cut-off for dichotomization. Correlations between proteins were 
calculated using Pearson’s chi-square test and combined prognostic value of the 
three markers was assessed by stepwise backward regression analysis, also including 
the clinicopathological variables, with P>.1 as exclusion criterion. Excluded from 
analyses were patients who died within 2 months after liver resection, when no data 
was available on survival status or time of survival, or when tissue cores were non-
evaluable due to technical reasons (Fig. 1). All statistical tests were two-sided with P 
values considered significant when <.05. All data reported was REMARK compliant 
34. Statistical analyses were performed using IBM SPSS Statistics 20.0 software 
(SPSS Inc., Illinois, USA) and R Statistics 3.0.1 software (RStudio Inc., Boston, USA). 
36
Chapter 2
RESULTS
Prognostic value of HIF1α, SLC2A1 and VEGFA
A total of 507 patients with resectable CRCLM were available to the current study 
population. CRCLM tissue was obtained from all patients and from 234 patients 
matched primary tumour tissue was also available. Cumulative five-year OS of 
the study population was 41.2% (Supplementary Figure S1). Characteristics of the 
study population have been extensively described previously; a summary of patient 
characteristics is given in Supplementary Table S1 26,27.
Expression of HIF1α, SLC2A1 and VEGFA in CRCLM was visualized by 
immunohistochemistry (Fig. 2). Intensity and frequency of stained CRCLM 
epithelial cells were evaluated for nuclear HIF1α expression in 328 patients (Fig. 1 
and Supplementary Table S2). The cross-validation procedure indicated a trend 
between high frequency of nuclear HIF1α expression and increased OS (HRRav 0.80; 
P(HRR>1)=.06; Supplementary Figure S2A), also upon inclusion of the established 
clinicopathological variables in a multivariate analysis (HRRav 0.77; P(HRR>1)=.06; 
Supplementary Figure S2B). Upon dichotomization of the whole study cohort using 
the most frequently selected cut-off for HIF1α expression in the 500 training sets 
(Supplementary Figure S3A), the cumulative median OS of patients with low HIF1α 
expression was 45 months and of patients with high HIF1α expression 52 months 
(P=.18, Fig. 3A). Intensity scores of nuclear HIF1α expression were not associated 
with OS (data not shown).
For 350 patients, immunohistochemical staining of CRCLM epithelial cells 
was scored for intensity and frequency of membranous SCL2A1 expression (Fig. 1 
and Supplementary Table S2). OS of patients with high intensity scores for SLC2A1 
expression was better than of patients with low SLC2A1 expression (HRRav 0.67; 
P(HRR>1)<.01; Supplementary Figure S2C). Prognostic value of SLC2A1 expression 
Figure 1. Flow diagram of the study cohort. A total of 507 patients with resectable CRCLM 
were available to the current study population. After exclusion of patients with OS shorter 
than 2 months, unknown outcome or OS or due to technical reasons, 328 patients remained 
available for evaluation of HIF1α expression, 350 patients for evaluation of SLC2A1 expression 
and 335 patients for evaluation of VEGFA expression.
CRC patients having had liver resection between 1990 and 2010 (n=507)
Excluded due 
to technical 
reasons (n=71)
Excluded due 
to technical 
reasons (n=49)
Excluded due 
to technical 
reasons (n=64)
Available for HIF1α
evaluation (n=328)
Available for SLC2A1
evaluation (n=350)
Available for VEGFA 
evaluation (n=335)
CRCLM patients available for analysis (n=399)
Excluded from analysis (n=108)
• Survival less than 2 months (n=61)
• Unknown outcome or time of survival (n=47)
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was hardly confounded by the standard clinical and pathological prognostic variables 
(HRRav 0.65; P(HRR>1)<.01; Supplementary Figure S2D). After dichotomization for 
SLC2A1 expression (Supplementary Figure S3B), cumulative median OS of patients 
with low and high SLC2A1 expression was 44 months and 55 months, respectively 
(P=.01; Fig. 3B). Frequency scores of SLC2A1 expression on membranes of CRCLM 
cells were not associated with OS (data not shown). 
VEGFA immunohistochemical staining was scored based on its cytoplasmic 
expression in neoplastic CRCLM epithelium in 335 patients (Fig. 1 and Supplementary 
Table S2). High intensity scores of VEGFA expression were associated with 
decreased OS (HRRav 1.48; P(HRR<1)=.02; Supplementary Figure S2E). Inclusion 
of VEGFA expression in a multivariate analysis together with the established 
clinicopathological variables also demonstrated its independent association with 
poor prognosis (HRRav 1.50; P(HRR<1)=.02; Supplementary Figure S2F). After 
dichotomization for VEGFA expression (Supplementary Figure S3C), cumulative 
median OS of patients with low cytoplasmic VEGFA levels was 61 months and of 
patients with high cytoplasmic VEGFA levels 35 months (P<.01; Fig. 3C). Frequency 
scores of cytoplasmic VEGFA expression were not associated with OS (data not 
shown).
Figure 2. Staining examples of (A) low HIF1α expression, (B) high HIF1α expression , (C) low 
SLC2A1 expression, (D) high SLC2A1 expression, (E) low VEGFA expression and (F) high 
VEGFA expression in epithelium of CRCLM. 
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Figure 3. Kaplan-Meier graphs depicting OS in months for (A,B,C) the total study population, 
and (D,E,F) patients in which CRCLM were not treated with systemic therapy. OS was stratified 
by (A,D) HIF1α expression, (B,E) SLC2A1 expression and (C,F) VEGFA expression. Information 
of systemic therapy was unavailable for n=13, n=12 and n=10 patients of whom tissue samples 
were evaluated for HIF1α, SLC2A1 and VEGFA expression, respectively. P-values were 
calculated using the logrank test.
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Prognostic value of HIF1α, SLC2A1 
and VEGFA expression in patient 
subgroups
The prognostic value of the 
dichotomized scores for HIF1α, 
SLC2A1 and VEGFA expression in 
CRCLM was evaluated separately 
for patients with colon and rectal 
cancer. No association was 
found between HIF1α expression 
and OS, neither in colon cancer 
patients (P=.54; Supplementary 
Figure S4A) nor in rectal cancer 
patients (P=.12; Supplementary 
Figure S4D). A statistically non-
significant trend was observed 
for the association between high 
SLC2A1 expression and OS in both 
colon and rectal cancer patients 
(P=.08; Supplementary Figure 
S4B and P=.09; Supplementary 
Figure S4E, respectively). High 
VEGFA expression in CRCLM 
was significantly associated with 
decreased OS in colon cancer 
patients (P<.01; Supplementary 
Figure S4C), but not in rectal cancer 
patients (P=.21; Supplementary 
Figure S4F).
Next, prognostic value was 
evaluated separately in patients 
either or not treated with systemic 
therapy perioperative to CRCLM 
resection (Supplementary Table 
S3). In neither subgroup HIF1α 
expression was related to OS 
(P=.12; Fig. 3D and P=.46; Fig. 3G, 
respectively). High levels of SLC2A1 
expression were not associated 
with OS in patients not treated 
with systemic therapy (P=.20; 
Fig. 3E), but were associated with 
increased OS in patients treated 
with systemic therapy (P<.01; 
Fig. 3H). High VEGFA expression 
in CRCLM was associated with 
poor OS in patients who were not 
Figure 3 (continued). Kaplan-Meier graphs 
depicting OS in months for (G,H,I) patients in 
which CRCLM were treated with systemic the-
rapy. OS was stratified by (G) HIF1α expres-
sion, (H) SLC2A1 expression and (I) VEGFA 
expression. P-values were calculated using the 
logrank test.
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treated with systemic therapy (P<.01; Fig. 3F), but not in patients who were treated 
with systemic therapy (P=.16; Fig. 3I).
Combined prognostic value of HIF1α, SLC2A1 and VEGFA expression
Considering the biological relation between expression of HIF1, SLC2A1, and 
VEGFA, we investigated the potential added value of combining individual markers. 
HIF1α expression was significantly associated with SLC2A1 expression (P=.02; 
Supplementary Table S4). VEGFA expression was not associated with either HIF1α 
(P=.12) or SLC2A1 expression (P=.85). In the multivariate Cox regression analysis, 
with OS as dependent variable and HIF1α, SLC2A1 and VEGFA expression as well as 
the established prognostic clinicopathological variables as independent variables, 
only SLC2A1 expression (HRR 0.66, 95%CI 0.43-1.00, P=.05) and VEGFA expression 
(HRR 1.53, 95%CI 1.01-2.32, P=.04) were retained in the final model (Supplementary 
Table S5). Prognosis of patients having CRCLM with low SLC2A1 and high VEGFA 
expression levels was significantly worse compared to patients having CRCLM with 
high SLC2A1 and low VEGFA levels (P<.01; Fig. 4A). Moreover, combining SLC2A1 
and VEGFA expression increased the OS difference between these subgroups 
both in patients who were not treated with systemic therapy (P<.01; Fig. 4B) and in 
patients who were treated with systemic therapy (P=.01; Fig. 4C).
Figure 4. Kaplan-Meier graph depicting 
OS in months stratified by combinations 
of SLC2A1 and VEGFA expression 
in CRCLM for (A) the total study 
population, (B) patients who were not 
treated with systemic therapy and (C) 
patients who were treated with systemic 
therapy. HRR compares patients with 
high SLC2A1 and low VEGFA expression 
with patients with low SLC2A1 and 
high VEGFA expression. P-values were 
calculated using the logrank test.
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HIF1α, SLC2A1 and VEGFA expression in patient-matched primary CRC and CRCLM
HIF1α, SLC2A1 and VEGFA expression could be compared for 155, 160 and 135 pairs 
of matched primary CRC and CRCLM tissue specimens, respectively (Supplementary 
Figure S5 and Supplementary Table S6). HIF1α scores were concordant for 55.5% of 
primary CRC-CRCLM pairs (P=.54). SLC2A1 scores were concordant in 56.8% (P=.09) 
and VEGFA scores in 54.1% (P=.44) of CRC-CRCLM pairs. When pairs of primary CRC 
and matched synchronous or metachronous CRCLM were evaluated separately, 
scores were similarly concordant (data not shown). Preoperative systemic therapy 
might affect tissue characteristics at time of surgery, however, when only patients 
were considered not treated with systemic therapy within six months prior to either 
primary CRC or CRCLM resection, scores were similarly concordant ().
DISCUSSION  
We investigated the prognostic value of HIF1α, SLC2A1 and VEGFA protein 
expression in a large series of patients with resectable CRCLM. With 500-fold cross-
validation, we demonstrated that high expression of SLC2A1 in CRCLM epithelial 
cells was an indicator of good prognosis. High levels of VEGFA in CRCLM epithelium, 
on the other hand, were associated with decreased OS. In patients in whom SCL2A1 
expression was low and VEGFA expression was high, prognosis was even worse. 
Expression of HIF1α was not significantly related to OS. The difference in cumulative 
median OS between patients with low and high expression was 11 months for SLC2A1 
and 26 months for VEGFA. Multivariate analysis including HIF1α, SLC2A1 or VEGFA 
expression with established clinicopathological prognostic variables, such as lymph 
node positivity, presence of more than a single CRCLM, maximal CRCLM diameter 
larger than 5.0cm, serum CEA level higher than 200ng/ml, presentation of CRCLM 
within 12 months after diagnosis of the primary tumour, did not substantially affect 
the associations between protein expression and OS.
It has been proposed that hypoxia plays a less prominent role in the 
development of CRCLM than of primary CRC, particularly for the outer cells of a 
metastatic lesion, since the liver has great vascular density 35. HIF-negative tumour 
cells behave more aggressively in hypoxic environments than HIF1-competent cells, 
as they become independent of angiogenic blood supply and therefore increase 
their anti-apoptotic and cell survival capabilities 36-39. This may explain the trend 
between low HIF1α expression and decreased OS and the association between low 
SLC2A1 expression, which positively correlated to HIF1α expression, and decreased 
OS. Although overexpression of HIF1α has been associated with increased survival 
in a variety of cancer types, amongst which prostate, head and neck, lung, ovarian 
and oral squamous cell carcinomas, no such conclusion could be drawn in the study 
population under investigation 11,37,40,41. Possibly, the actual prognostic value of HIF1α 
– and potentially also of SLC2A1 – in our study population has been somewhat 
underestimated. These proteins generally show focal, perinecrotic expression 
patterns and such immunohistochemical staining patterns are less easy to interpret 
when using TMAs compared to when using full tissue sections 10. Alternatively, 
although cells with a glycolytic phenotype have a selective advantage in metastasis, 
it has been demonstrated that the transition from aerobic to anaerobic metabolism 
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is most relevant during early stages of tumour development 9,13. Therefore, the 
prognostic effects of HIF1α expression may be more prominent in early stage disease 
than in advanced disease, because its effects in metastatic lesions may become 
obscured by additional somatic alterations. 
In primary CRC patients, VEGFA overexpression has been linked to decreased 
survival in numerous studies and we now show that expression of VEGFA is also 
related to decreased survival in resectable CRCLM 22. The lack of correlation 
between VEGFA expression and either HIF1α or SLC2A1 expression indicates that 
the prognostic value of VEGFA expression in CRCLM could largely be attributed to 
HIF1alpha-independent activation of VEGFA through other (oncogenic) pathways, 
such as via KRAS, PDGF or TGFβ signalling. Disruption of KRAS in human colon 
carcinoma cells has been associated with decreased VEGF activity, however, 
the clinical relevance of this relation has not yet been determined as efficacy of 
treatment with bevacizumab could not be predicted based on KRAS status 42,43. 
Correspondingly, although it has been demonstrated that VEGF RNA expression 
levels increased upon the introduction of PDGF and TGFβ to vascular cells, 
neither PDGF nor TGFβ protein expression has been associated with prediction of 
bevacizumab therapy response 44,45. Alternatively, increased expression of SLC2A1 
or VEGFA might partly be a result of activation of the upstream effector HIF2α, 
rather than of HIF1α. Although HIF2α expression in CRC has conflictingly been 
associated with tumour progression, it might explain the contrasting prognostic 
effect of SLC2A1 and VEGFA expression observed in the current study 46,47. Further 
investigation is required to confirm the correlations that might exist between these 
markers and the proteins under investigation. 
We also evaluated the potential to predict biomarker expression in CRCLM 
based on its expression level in matched primary CRC samples, since alterations 
occurring during carcinogenesis of the primary tumour are often maintained in 
corresponding CRCLM 48,49. For none of the proteins, however, expression was 
correlated between the primary tumour and matched CRCLM. Similar to hypoxia, 
it has been suggested that angiogenesis is less pronounced in CRCLM compared 
to primary CRC 35,50-52. This may explain the lack of correlation between expression 
of the biomarkers investigated in this study in primary CRC and corresponding 
CRCLM and could imply that determination of their expression in CRCLM, but not 
in the primary tumour, may be clinically useful. Molecular imaging can provide 
such information, which emphasizes its potential as added tool for preoperative 
assessment of patient eligibility for CRCLM resection.
SLC2A1 expression showed similar prognostic value in both CRCLM originating 
from colon and rectal cancer. For VEGFA expression, the prognostic value appeared 
to be limited to colon cancer patients. It has been shown that VEGFA expression 
levels commonly are different for tumours in the proximal and distal parts of the 
colorectum 53. Additionally, VEGFA expression levels are generally lower in colon 
tumours with high level microsatellite instability (MSI), which are more common in 
the right colon 54,55. This might speculate that VEGFA expression plays a different 
role in the carcinogenesis of tumours in different parts of the large intestine and 
could explain why VEGFA expression only has prognostic value in colon cancer 
patients, but not in rectal cancer patients. Unfortunately, the MSI status was not 
known for the patients evaluated in our study, so we could not further investigate its 
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potential confounding effect on the prognostic value of VEGFA. However, only 3% 
of CRCLM is estimated to be MSI and, as such, MSI is suggested only to play a minor 
role in CRCLM compared to primary CRC 56. 
Considering treatment with systemic therapy, SLC2A1 expression appeared 
to be associated with OS mainly in patients treated with systemic therapy. Tumour 
cells responding to therapeutic agents are usually cells with a higher metabolic rate 
than cells which are in a quiescent-like state 57-59. Highly active tumour cells have 
enhanced glycolytic capacity, which results in an upregulation of membranous 
SLC2A1 to meet the increasing demand for glucose 60,61. Overexpression of SLC2A1 
in CRCLM may thus indicate a higher susceptibility of tumour cells to treatment 
with systemic therapy and therefore be a predictor of good prognosis specifically 
in this patient subgroup. VEGFA expression appeared to be a prognostic biomarker 
only in patients who were not treated with systemic therapy. This may indicate 
that conventional systemic therapies affect VEGFA-related biological processes, 
improving survival of patients with a poor prognosis. 
Addition of bevacizumab to standard systemic therapy regimens has greatly 
improved outcome 24,25. Although response to bevacizumab treatment could not 
be predicted based on VEGFA expression, VEGFA levels appeared to be reduced 
significantly following treatment with the antibody 62,63. In the present study 
population, 29 patients had been treated with bevacizumab (Supplementary Table 
S3), of whom VEGFA expression could be evaluated in 20 patients (Supplementary 
Figure S6). Excluding these patients from survival analysis effectively improved 
the prognostic value of VEGFA expression (P<.01), suggesting that treatment with 
bevacizumab improves survival especially of patients with high VEGFA expression. 
In addition to the assessment of VEGFA expression in CRCLM tissue, it may also be 
of interest to assess VEGFA levels in the circulation. Unfortunately, such data was 
not available for the patients in the current study. 
Our results show that the combination of low SLC2A1 and high VEGFA 
expression in CRCLM was associated with poor prognosis, independent of 
treatment with systemic therapy. Therefore, assessment of SLC2A1 levels on top of 
VEGFA expression in CRCLM may improve outcome by selecting patients eligible 
for CRCLM resection and, furthermore, selecting patients highly expressing both 
VEGFA and SLC2A1 as best candidates for additional systemic treatment. 
Assessment of biomarker expression in vivo is commonly performed by 
molecular imaging modalities, such as PET. Tracers generally associated with 
SLC2A1 expression are already used in clinical PET (i.e. [18F]FDG) and addition 
of specific VEGFA tracers (e.g. [89Zr]bevacizumab) are used to visualize VEGFA 
expression. Currently, patients are often selected for CRCLM resection using [18F]
FDG PET imaging, which may cause a selection bias in the study population under 
investigation. That is, increased SLC2A1 expression in CRCLM may result in increased 
uptake of [18F]FDG. In such cases, occult CRCLM are more likely to be discovered 
and subsequently resected, which may result in a favourable prognosis of these 
patients. Nevertheless, high uptake of [18F]FDG in CRCLM has previously also been 
related to worse outcome 18. However, it is not clear to which extent increased tracer 
uptake is caused by epithelial cells or stromal cells, like macrophages; the latter 
generally also have a high glucose consumption, and high macrophage infiltration 
has been related to tumour cell survival in late stage disease 64,65. As many other 
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factors next to SLC2A1 expression affect uptake of [18F]FDG, it remains questionable 
if SLC2A1 expression could be proportionally associated with [18F]FDG uptake 66. 
In conclusion, expression of SLC2A1 and VEGFA are biomarkers for outcome 
after CRCLM resection. Combined, expression of these proteins can be used to 
predict survival irrespective of systemic treatment. Further research is needed to 
externally validate our results and to explore possibilities to stratify patients based 
on SLC2A1, but also on VEGFA expression levels, for example via ex vivo evaluation 
of tumour tissue. 
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Supplementary Table S1. Patient characteristics 26  
  
Clinicopathological variable 
Total Population   
  
Clinicopathological variable 
   Total Population   
n 
/ mean 
/ median 
% 
/ st.dev. 
/ range   
n 
/ mean 
/ median 
% 
/ st.dev. 
/ range 
 
General characteristics     Liver metastasis characteristics      
All 507    Age at liver resection      
Gender       mean (st.dev.) 63.3 0.5  
  male (%) 320 63.1     median (range) 64.3 27.6-83.9  
  female (%) 187 36.9   Synchronous liver metastasis Δ    
OS after liver resection in months     yes (%) Δ 221 43.6  
  mean (st.dev.) 37.2 1.7     no (%) Δ 261 51.5  
  median (range) 27 3.0-212.0     unknown (%) Δ 25 4.9  
       Distribution liver metastases    
          left half 90 17.8  
Primary CRC characteristics            segment 1 (%) 18 3.6  
Age at primary CRC resection            segment 2 (%) 116 22.9  
  mean (st.dev.) 61.9 0.5          segment 3 (%) 135 26.6  
  median (range) 62.8 24.4-83.3          segment 4 (%) 134 26.4  
Primary tumor location       right half 259 51.0  
  left colon (%) 245 48.3          segment 5 (%) 171 33.7  
  right colon (%) 95 18.7          segment 6 (%) 212 41.8  
  rectum (%) 151 29.8          segment 7 (%) 211 41.6  
  unknown (%) 16 3.2          segment 8 (%) 182 35.9  
Histological grade       both left and right half 146 28.8  
  poorly differentiated (%) 38 7.5     unknown 12 2.4  
  moderately differentiated (%) 288 56.8   Maximal CRCLM diameter in cm Δ    
  well-differentiated (%) 14 2.8     mean (st.dev.) 4.1 0.1  
  unknown (%) 167 32.9     median (range) 3.5 0.2-22.0  
Maximal CRC diameter in cm       maximal diameter ≤ 5.0 cm (%) Δ 372 73.4  
  mean (st.dev.) 4.4 0.1     maximal diameter > 5.0 cm (%) Δ 126 24.8  
  median (range) 4 0.2-12.0     maximal diameter unknown (%) Δ 9 1.8  
Positive lymph nodes detected Δ     Number of CRCLM Δ    
  yes (%) Δ 190 37.5     mean (st.dev.) 2 0.1  
  no (%) Δ 154 30.4     median (range) 2 1-12  
  unknown (%) Δ 163 32.1     nr of CRCLM = 1 (%) Δ 248 48.9  
Systemic treatment of primary CRC       nr of CRCLM > 1 (%) Δ 253 49.9  
  colon cancer         nr of CRCLM unknown (%) Δ 6 1.2  
     preoperative (%) 9 2.6   Serum CEA level Δ    
     perioperative (%) 0 0     mean (st.dev.) 101.6 38.5  
     postoperative (%) 91 26.8     median (range) 15 0.5-6625.0  
     none (%) 226 66.5     serum CEA level ≤ 200 ng/ml (%) Δ 166 32.7  
     unknown (%) 14 4.1     serum CEA level > 200 ng/ml (%) Δ 13 2.6  
  rectal cancer       serum CEA level unknown (%) Δ 328 64.7  
     preoperative (%) 25 16.5   Extrahepatic metastases    
     perioperative (%) 1 0.7     yes (%) 36 7.1  
     postoperative (%) 24 15.9     no (%) 423 83.4  
     none (%) 98 64.9     unknown (%) 48 9.5  
     unknown (%) 3 2   Resection in combination with RFA  
 primary tumor location unknown        yes (%) 109 21.5  
     preoperative (%) 1 6.3     no (%) 357 70.4  
     perioperative (%) 0 0.0     unknown (%) 41 8.1  
     postoperative (%) 1 6.3   Systemic treatment of liver metastases  
     none (%) 12 75.0    preoperative (%) 60 11.8  
    unknown (%) 2 12.5    perioperative (%) 12 2.4  
Radiotherapeutic treatment of primary CRC    postoperative (%) 97 19.1  
 yes (%) 113 22.3    none (%) 321 63.3  
 no (%) 392 77.3    unknown (%) 17 3.4  
 unknown (%) 2 0.4       
OS: overall survival; CEA: carcino-embryonic antigen; RFA: radiofrequency ablation; Δ Clinical risk score variable 33  
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Supplementary Table S2. Distribution of scores 
 
Total 
Population 
 
Frequency score n %  
HIF1α    
   0-25% 226 68.9  
   26-50% 56 17.1  
   51-75% 20 6.1  
   76-100% 26 7.9  
SLC2A1    
   0-25% 278 79.4  
   26-50% 42 12.0  
   51-75% 16 4.6  
   76-100% 14 4.0  
VEGFA    
   0-25% 139 41.5  
   26-50% 59 17.6  
   51-75% 22 6.6  
   76-100% 115 34.3  
Intensity score n %  
HIF1α    
   negative 50 15.2  
   weak 124 37.8  
   moderate 63 19.2  
   strong 91 27.8  
SLC2A1    
   negative 93 26.6  
   weak 35 10.0  
   moderate 43 12.3  
   strong 179 51.1  
VEGFA    
   negative 14 4.2  
   weak 79 23.6  
   moderate 141 42.1  
   strong 101 30.1  
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Supplementary Table S3. Systemic therapy and decade of liver resection 26  
 
1990-
2010 
 1990-
1999 
 2000- 
2010 
 1990-
1999 
vs. 
2000-
2010 
 
Clinicopathological variable n* %  n %  n %  P 
All 507   106   398     
CRCLM treated with systemic therapy 169 33.3  22 20.8  146 36.7  .001  
 5FU only 6 3.6  3 13.6  3 2.1  .08  
 5FU + Leucovorin 39 23.1  16 72.7  22 15.1  .001  
 5FU + Leucovorin + Oxaliplatin 15 8.9  0 0.0  15 10.3  .04  
 5FU + Leucovorin + Irinotecan 2 1.2  0 0.0  2 1.4  .47  
 5FU + Leucovorin + other 1 0.6  0 0.0  1 0.7  .61  
 5FU + other 1 0.6  1 4.5  0 0.0  .05  
 Capecitabine only 7 4.1  0 0.0  7 4.8  .17  
 Capecitabine + Oxaliplatin 40 23.7  0 0.0  40 27.4  .001  
 Capecitabine + Oxaliplatin + Bevacizumab 27 16.0  0 0.0  27 18.5  .006  
 Capecitabine + Oxaliplatin + Bevacizumab + Cetuximab 2 1.2  0 0.0  2 1.4  .47  
 Capecitabine + Oxaliplatin + other 3 1.8  0 0.0  3 2.1  .37  
 Capecitabine + other 6 3.6  2 9.1  4 2.7  .46  
 Chemotherapeutic agent unknown 20 11.8  0 0.0  20 13.7  .02  
* Decade of liver resection unknown for n=3 patients, of which n=1 patients received systemic therapy.  
 
 
 
 
 
 
Supplementary Table S4. Level of concordance between biomarker expression 
  low  SLC2A1  high SLC2A1  Total Chi-square 
low HIF1α  n = 141 
35.6% 
 n = 130 
32.8% 
 n = 271 
68.4% 
P=.02 high HIF1α  n = 49 12.4%  
n = 76 
19.2%  
n = 125 
52.0% 
Total  
n = 190 
48.0%  
n = 206 
52.0%  n = 396 
  low VEGFA  high VEGFA  Total Chi-square 
low HIF1α  n = 184 
47.4% 
 n = 78 
20.1% 
 n = 262 
67.5% 
P=.12 high HIF1α  
n = 98 
25.3%  
n = 28 
7.2%  
n = 126 
32.5% 
Total  
n = 282 
72.7%  
n = 106 
27.3%  n = 388 
  low SLC2A1  high  SLC2A1  Total Chi-square 
low VEGFA  n = 146 
35.4% 
 n = 153 
37.1% 
 n = 299 
72.6% 
P=.85 high VEGFA  
n = 54 
13.1%  
n = 59 
14.3%  
n = 113 
27.4% 
Total  n = 200 
48.5% 
 n = 212 
51.5% 
 n = 412 
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Supplementary Table S5. Multivariate Cox regression analysis 
 Covariate HRR 95%CI P 
primary tumor-to-CRCLM interval < 12 months 1.12 0.74-1.70 .60 
lymph node positivity at time of diagnosis of the primary tumor 1.45 0.95-2.21 .09 
maximal CRCLM diameter > 5.0 cm  1.22 0.77-1.94 .40 
number of CRCLM > 1  1.28 0.85-1.94 .25 
serum CEA level > 200 ng/ml 0.80 0.55-1.17 .26 
HIF1α expression 0.84 0.54-1.31 .44 
SLC2A1 expression  0.66 0.43-1.00 .05 
VEGFA expression 1.53 1.01-2.32 .04 
HRR: hazard rate ratio; 95%CI: 95% confidence interval 
 
 
 
 
 
Supplementary Table S6. Level of concordance between biomarker expression in primary CRC and 
corresponding CRCLM 
   expression in primary CRC    
Chi square 
ex
pr
es
sio
n 
in
 C
RC
 li
ve
r m
et
as
ta
se
s 
HIF1α  low  high  Total 
low  n = 66 
42.6% 
 n = 46 
29.7% 
 n = 112 
72.3% 
P=.54 high  n = 23 14.8%  
n = 20 
12.9%  
n = 43 
27.7% 
Total  
n = 89 
57.4%  
n = 66 
42.6%  n = 155 
SLC2A1  low  high  Total Chi square 
low  n = 57 
35.6% 
 n = 25 
15.6% 
 n = 82 
51.2% 
P=.09 high  n = 44 27.5%  
n = 34 
21.2%  
n = 78 
48.8% 
Total  
n = 101 
63.1%  
n = 59 
36.9%  n = 160 
VEGFA  low  high  Total Chi square 
low  n = 52 
38.5% 
 n = 43 
31.9% 
 n = 95 
70.4% 
P=.44 high  
n = 19 
14.1%  
n = 21 
15.6%  
n = 40 
29.6% 
Total  
n = 71 
52.6%  
n = 64 
47.4%  n = 135 
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Supplementary Figure S1. Kaplan-Meier graph depicting OS in months of the total study 
population. Patients with OS less than 2 months and unknown outcome or time of OS were 
removed from analysis 26
 
Supplementary Table S7. Level of concordance between biomarker expression in primary CRC and 
corresponding CRCLM of patients that were not treated with systemic therapy within six months 
preoperative to primary tumor resection and/or liver resection 
   expression in primary CRC    Chi square 
ex
pr
es
sio
n 
in
 C
RC
 li
ve
r m
et
as
ta
se
s 
HIF1α  low  high  Total 
low  n = 51 
41.5% 
 n = 32 
26.0% 
 n = 83 
67.5% 
P=.31 high  
n = 22 
17.9%  
n = 18 
14.6%  
n = 40 
32.5% 
Total  n = 73 
59.3% 
 n = 50 
40.7% 
 n = 123 
SLC2A1  low  high  Total Chi square 
low  n = 49 37.7%  
n = 23 
17.7%  
n = 72 
55.4% 
P=.19 high  
n = 33 
25.4%  
n = 25 
19.2%  
n = 58 
44.6% 
Total  n = 82 
63.1% 
 n = 48 
36.9% 
 n = 130 
VEGFA  low  high  Total Chi square 
low  n = 43 39.1%  
n = 39 
35.5%  
n = 82 
74.5% 
P=.13 high  
n = 10 
9.1%  
n = 18 
16.4%  
n = 28 
25.5% 
Total  n = 53 
48.2% 
 n = 57 
51.8% 
 n = 110 
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Supplementary Figure S2. Distribution of the cross-validated HRRs after (A) univariate analysis 
of HIF1α expression, (B) multivariate analysis of HIF1α expression, (C) univariate analysis of 
SLC2A1 expression, (D) multivariate analysis of SLC2A1 expression, (E) univariate analysis of 
VEGFA expression and (F) multivariate analysis of VEGFA expression with OS as outcome.
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Supplementary Figure S3. Distribution of the selected cut-off points for frequency and 
intensity scores in the training sets of (A) HIF1α expression, (B) SLC2A1 expression and (C) 
VEGFA expression. Cut-off points for (A) frequency scores are (1) 1-25% vs. 26-100%, (2) 
1-50% vs. 51-100%, (3) 1-75% vs. 76-100% and for (B,C) intensity scores (1) negative vs. weak, 
moderate, strong, (2) negative, weak vs. moderate, strong, (3) negative, weak, moderate vs. 
strong. Stainings were dichotomized using the most frequently selected cut-off in the training 
sets.
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Supplementary Figure S4. Kaplan-Meier graphs depicting OS in months for (A,B,C,) patients 
with CRCLM originating from colon cancer and (D,E,F) patients with CRCLM originating from 
rectal cancer. OS was stratified by (A,D) HIF1α expression, (B,E) SLC2A1 expression and (C,F) 
VEGFA expression. Origin of primary tumor (colon or rectum) was unkown for n=8, n=5 and 
n=7 patients of whom tissue samples were evaluated for HIF1α, SLC2A1 and VEGFA expression, 
respectively. P-values were calculated using the logrank test.
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Available for HIF1α 
correlation analysis 
(n=155)
Available for SLC2A1 
correlation analysis 
(n=160)
CRC patients having had liver resection between 1990 and 2010 (n=507)
Primary CRC specimens unavailable (n=273)
Available for VEGFA 
correlation analysis 
(n=135)
Excluded due 
to technical 
reasons (n=79)
Excluded due 
to technical 
reasons (n=74)
Excluded due 
to technical 
reasons (n=99)
Supplementary Figure S5. Flow diagram of patients of whom primary tumor specimens were 
available.
Supplementary Digital Figure S6. Kaplan-Meier graphs depicting OS in months, stratified by 
VEGFA expression for (A) patients in which CRCLM were not treated with bevacizuamb and 
(B) patients in which CRCLM were treated with bevacizumab. Information of treatment with 
Bevacizuamb was unavailable for n=10 patients of whom tissue samples were evaluated for 
VEGFA expression.
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ABSTRACT
Background 
Resection of colorectal cancer liver metastasis (CRCLM) with curative intent has 
long-term benefit in approximately 40% of cases. Prognostic biomarkers are needed 
to improve clinical management and reduce futile surgeries. Expression of epidermal 
growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2; 
also known as cyclooxygenase-2 or COX2) has been associated with carcinogenesis 
and survival. We investigated the prognostic value of EGFR and PTGS2 expression 
in patients with resected CRCLM.
Methods
Formalin-fixed paraffin-embedded CRCLM tissue and corresponding primary 
tumour specimens from a multi-institutional cohort of patients who underwent liver 
resection between 1990 and 2010 were incorporated into tissue microarrays (TMAs). 
TMAs were stained for EGFR and PTGS2 by immunohistochemistry. The hazard rate 
ratio (HRR) for the association between expression in CRCLM and overall survival 
(OS) was calculated using a 500-fold cross-validation procedure. 
Results
EGFR and PTGS2 expression could be evaluated in 323 and 351 patients, respectively. 
EGFR expression in CRCLM was associated with poor prognosis (HRR 1.54; P<.01) 
with a cross-validated HRR of 1.47 (P=.03). PTGS2 expression was also associated 
with poor prognosis (HRR 1.60; P<.01) with a cross-validated HRR of 1.63 (P<.01). 
Expression of EGFR and PTGS2 remained prognostic after multivariate analysis with 
standard clinicopathological variables (cross-validated HRR 1.51; P=.02 and cross-
validated HRR 1.59; P=.01, respectively). Stratification for the commonly applied 
systemic therapy regimens demonstrated prognostic value for EGFR and PTGS2 
only in the subgroup of patients who were not treated with systemic therapy (HRR 
1.78; P<.01 and HRR 1.64; P=.04, respectively), with worst prognosis when both 
EGFR and PTGS2 were highly expressed (HRR 3.08; P<.01). Expression of PTGS2 in 
CRCLM was correlated to expression in patient-matched primary tumours (P=.02, 
69.2% concordance).
Conclusions
EGFR and PTGS2 expression are prognostic molecular biomarkers with added value 
to standard clinicopathological variables for patients with resectable CRCLM.
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Prognostic value of EGFR and PTGS2 
INTRODUCTION
Colorectal cancer (CRC) is the third most prevalent cancer type worldwide and 
the second leading cause of cancer mortality in developed countries, which is 
mainly due to haematogenous dissemination to the liver 1,2. Liver resection is the 
only intentionally curative treatment option for patients with CRC liver metastases 
(CRCLM). Patient eligibility relies on standard prognostic clinicopathological 
variables such as presence of multiple liver metastases, positive lymph nodes at 
time of primary tumour resection, maximal CRCLM diameter larger than 5cm, and 
presentation of metastases within 12 months after diagnosis of the primary tumour 
3-6. However, 5-year survival rates hardly exceed 40% indicating the need for better 
prognostic biomarkers to improve clinical management of CRCLM patients 7.
Activation of the tyrosine kinase receptor EGFR triggers RAS/RAF/MAPK 
signalling and promotes proliferation, angiogenesis and metastasis, rendering EGFR 
as a clinical target for cancer therapy 8. Likewise, increased expression of PTGS2 
leads to increased production of PGE2 which promotes cancer cell growth through 
EP2 receptor-mediated signalling 9. Inhibition of PTGS2, e.g. by non-steroidal anti-
inflammatory drugs such as aspirin, has been shown to reduce CRC incidence as well 
as to improve clinical outcome following CRC surgery 10,11. Importantly, there exists 
a complex interplay between EGFR and PTGS2 expression. EGFR activation can 
induce PTGS2 expression in colon cancer cells 12. In turn, upregulation of PTGS2 leads 
to PGE2-mediated transactivation of EGFR 
13,14. Both EGFR and PGE2 can activate the 
PI3-kinase signalling pathway. While activating mutations in PIK3CA are potential 
biomarkers for resistance to treatment with anti-EGFR monoclonal antibodies in 
metastatic CRC, some patients with PIK3CA mutations may benefit from treatment 
with the PTGS2 inhibitor aspirin 10,15,16. These data underscore the potential biological 
and clinical relevance of EGFR and PTGS2 expression in metastatic CRC. In the 
current retrospective study we assessed the prognostic value of EGFR and PTGS2 
expression in CRCLM of patients who underwent liver resection with curative intent.
MATERIALS AND METHODS
Patient study population
The patient study population was selected as previously described 17. In brief, patients 
were identified who underwent CRCLM resection in one of seven Dutch hospitals 
affiliated with the DeCoDe PET group between 1990 and 2010. Formalin-fixed 
paraffin-embedded (FFPE) tissue specimens were collected from one histologically 
confirmed CRCLM sample and adjacent control liver tissue. When available, also the 
corresponding primary tumour and adjacent control colon tissue were collected. 
Patients with multiple primary tumours were excluded. Collection, storage and use 
of clinicopathological data and tissue specimens were performed in compliance 
with the “Code for Proper Secondary Use of Human Tissue in The Netherlands”, and 
approved according to local and national regulations 18.
60
Chapter 3
Tissue microarrays
Tissue microarrays (TMAs) were generated as previously described 17,19. Briefly, three 
tissue core biopsies of 0.6 mm in diameter were punched from morphologically 
representative areas of all FFPE donor blocks and transferred into TMA recipient 
paraffin blocks using the 3DHISTECH TMA Master (v1.14, 3DHISTECH Ltd., Budapest, 
Hungary).
Immunohistochemistry
TMA sections (4 μm) were deparaffinised by xylene and rehydrated with a 
decreasing alcohol series. For EGFR staining, sections were preprocessed with ER2 
(Leica Biosystems, Newcastle, United Kingdom) and incubated with primary mouse 
monoclonal antibody directed against human EGFR (1:25, 15 minutes, Novocastra 
Laboratories, Newcastle, United Kingdom), followed by incubation with secondary 
anti-mouse antibody (8 minutes, Novocastra Detection System, Leica Biosystems, 
Newcastle, United Kingdom) using BondMax Immunostainer (Menarini Diagnostics, 
Firenze, Italy). For PTGS2 staining, antigen retrieval was performed by microwave 
heating in citric acid (10 mM, pH6.0) and endogenous peroxidase quenching in 
0.3% H2O2/methanol (25 minutes). Primary rabbit polyclonal monospecific antibody 
directed against human PTGS2 (1:200, 1 hour, Atlas Antibodies, Stockholm, Sweden) 
was incubated at room temperature. Secondary anti-rabbit antibodies (Envision 
Plus, Dako, Heverlee, Belgium) were incubated for 30 minutes. Secondary antibodies 
were visualised by liquid diaminobenzidine substrate chromogen system. FFPE 
A431 cells were stained as positive controls for EGFR expression and FFPE Caco-2 
cells as positive controls for PTGS2 expression. Incubation without primary antibody 
served as negative control.
Evaluation of protein expression
The Mirax slide scanner system equipped with a 20x objective with a numerical 
aperture of 0.75 (Carl Zeiss B.V., Sliedrecht, The Netherlands) and a Sony DFW-X710 
Fire Wire 1/3” type progressive SCAN IT CCD (pixel size 4.65 x 4.65μm) was used to 
digitally capture the immunohistochemical stainings, as described previously 17. The 
actual scan resolution (effective pixel size in the sample plane) at 20x was 0.23μm. 
Computer monitors used for image analysis were calibrated using the Spyder2PRO 
software (v1.0-16, Pantone Colorvision, Regensdorf, Switzerland). Frequencies of 
neoplastic epithelial cells expressing EGFR at the plasma membrane and PTGS2 at 
the nuclear membrane were scored for individual TMA core biopsies (categories 0%, 
1-25%, 26-50%, 51-75%, 76-100%) using dedicated TMA scoring software (v1.14.25.1, 
3DHISTECH Ltd., Budapest, Hungary). Tissue samples were independently evaluated 
by a second investigator without knowledge of clinicopathological information at 
time of assessment (Kw,EGFR = 84% and Kw,PTGS2 = 85%).
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 20.0 software (SPSS Inc., 
Illinois, USA) and R Statistics 3.0.1 software (RStudio Inc., Boston, USA). Excluded 
from the analyses were patients who died within 2 months after liver resection, 
when no data was available on survival status or time of survival, or when tissue 
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cores were non-evaluable due to technical reasons (Fig. 1). Overall survival (OS) 
was defined as the time in months after surgery until death in a follow-up period 
of 10 years. The prognostic value of EGFR and PTGS2 expression was assessed 
in a 500-fold cross-validation procedure 17. Per cross-validation cycle the study 
population was randomly subdivided in a training and a validation set (50%:50%). 
In each training set, the optimal cut-off for dichotomizing frequency scores into 
‘low’ and ‘high’ expression was calculated using receiver operating characteristic 
(ROC) curve analysis for survival data with 3-year OS as the outcome of interest 
20,21. Frequency scores of the corresponding validation sets were dichotomised using 
this cut-off and a crude hazard rate ratio (HRR) was calculated in a Cox regression 
analysis with OS as outcome. Established clinicopathological prognostic variables 
were included in a multivariate Cox regression analysis 3. The average cross-
validated hazard rate ratio (HRRav) of the validation sets was calculated and the 
P value of the cross-validation analysis was defined as the percentage of cross-
validated HRRs smaller than 1 (HRRav<1).  The relation between protein expression 
and OS in the total study population and a number of population subgroups was 
visualised by Kaplan Meier curves using the most frequently selected cut-off in 
the cross-validation procedure as the optimal cut-off. The potential interaction 
between protein expression and systemic therapy or primary tumour localization 
was investigated using Cox regression. Combined prognostic value of EGFR and 
PTGS2 expression were assessed by stepwise backward regression analysis with 
P>.1 as exclusion criterion. Correlations were calculated using Pearson’s correlation 
test. All statistical tests were two-sided with P values considered significant when 
<.05. All data reported was REMARK compliant 22.
CRC patients having had liver resection between 1990 and 2010 (n=507)
Excluded due to 
technical reasons 
(n=48)
Available for PTGS2
evaluation (n=351)
CRCLM patients available for analysis (n=399)
Excluded from analysis (n=108)
• Survival less than 2 months (n=61)
• Unknown outcome/time of survival (n=47)
Excluded due to 
technical reasons 
(n=76)
Available for EGFR
evaluation (n=323)
Figure 1. Schematic overview of the study cohort. 
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RESULTS
Demographic characteristics 
Current study population consisted of 507 patients with CRCLM who were treated 
with liver surgery with curative intent. Cumulative five-year OS of the study 
population was 41.2% (Supplementary Fig. S1). Tissue specimens were available 
of all 507 patients, and corresponding primary tumour tissue was obtained for 
234 patients. Characteristics of the patient study population are summarised in 
Supplementary Table S1 and described previously 17. 
EGFR and PTGS2 expression are associated with poor prognosis
Tissue specimens were immunohistochemically stained for EGFR and PTGS2 (Fig. 
2). EGFR was scored based on its CRCLM epithelial plasma membrane expression 
in 323 patients (Fig. 1 and Supplementary Table S2). Patients with high EGFR 
expression had a significantly lower OS than patients with low EGFR expression 
(HRRav 1.47; P=.03; Supplementary Fig. S2A). The total study population was 
dichotomised based on EGFR expression (Supplementary Fig. S3A). Median OS for 
patients with low EGFR expression was 58 months and for patients with high EGFR 
expression 40 months (HRR 1.54, 95%CI 1.12-2.11, P<.01; Fig. 3A). To evaluate whether 
the prognostic value of EGFR expression was independent of established prognostic 
clinicopathological variables, a multivariate analysis was performed including EGFR 
protein expression, primary tumour-to-liver metastasis interval < 12 months, number 
of liver metastases > 1, maximal tumour diameter > 5.0 cm, serum CEA level > 200 
ng/ml, and lymph node positivity at time of diagnosis of the primary tumour. Also 
upon inclusion of these variables, EGFR expression was associated with poor OS 
(HRRav 1.54; P=.02; Supplementary Fig. S2B).
Figure 2. Staining examples of (A) low EGFR expression, (B) high EGFR expression, (C) low 
PTGS2 expression and (D) high PTGS2 expression (arrow) in epithelium of CRCLM. 
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PTGS2 immunohistochemical staining was scored based on its nuclear 
membrane expression in neoplastic CRCLM epithelium in 351 patients (Fig. 1 and 
Supplementary Table S2). High expression of PTGS2 was associated with decreased 
OS (HRRav 1.63; P<.01; Supplementary Fig. S2C). Based on dichotomisation of 
PTGS2 expression (Supplementary Fig. S3B) median OS was 53 months for patients 
with PTGS2-negative CRCLM and 32 months for patients with PTGS2-positive 
CRCLM (HRR 1.60, 95%CI 1.14-2.26, P<.01; Fig. 3B). Multivariate analysis including 
clinicopathological variables showed that PTGS2 expression remained associated 
with poor prognosis (HRRav 1.59; P=.01; Supplementary Fig. S2D). 
When EGFR and PTGS2 expression were combined with standard 
clinicopathological variables in a multivariate analysis, both EGFR (HRR 1.91, 95%CI 
1.31-2.81, P<.01) and PTGS2 (HRR 1.50, 95%CI 1.00-2.26, P=.05) were retained, 
indicating they function as independent prognostic variables. Patients with high 
CRCLM-expression of both EGFR and PTGS2 had a significantly lower OS than 
patients without elevated EGFR and/or PTGS2 expression (HRR 1.88, 95%CI 1.18-
2.98, P<.01; Fig. 3C), with a median OS difference of 43 months between patients 
with and without elevated levels of both EGFR and PTGS2. 
Figure 3. Kaplan-Meier graphs 
depicting OS in months stratified 
by (A) EGFR expression, (B) PTGS2 
expression and (C) combined EGFR 
and PTGS2 expression. (A,B) HRR 
compares patients with high and 
low expression. (C) HRR compares 
patients in whom both EGFR and 
PTGS2 were highly expressed with 
patients in whom neither or either 
EGFR or PTGS2 levels were elevated. 
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Prognostic value of EGFR and PTGS2 expression in patient subgroups
Administration of systemic therapy, pre-, peri- or postoperative to liver resection, 
may affect clinical outcome. Therefore, the prognostic value of EGFR and PTGS2 
was stratified for treatment with systemic therapy (Supplementary Table S3). High 
EGFR and high PTGS2 expression were significantly associated with poor survival in 
patients who did not receive systemic therapy within six months prior to or following 
surgery (HRR 1.78, 95%CI 1.19-2.67, P<.01; Fig. 4A and HRR 1.64, 95%CI 1.04-2.59, 
P=.04; Fig. 4B, respectively). In this subgroup, patients with high CRCLM-expression 
of both EGFR and PTGS2 had particularly poor prognosis (HRR 3.08, 95%CI 1.66-
5.73, P<.01; Fig. 4C). However, in the subgroup of patients who did receive systemic 
therapy, no significant associations between OS and EGFR or PTGS2 expression 
were observed (HRR 1.08, 95%CI 0.63-1.84, P=.78; Fig. 4D and HRR 1.27, 95%CI 0.74-
2.17, P=.40; Fig. 4E, respectively). Similarly, in this subgroup combined expression 
of EGFR and PTGS2 lacked prognostic value (HRR 0.81, 95%CI 0.37-1.77, P=.59; 
Fig. 4F). Notwithstanding these results in the subgroups, the interaction terms for 
treatment with systemic therapy and either EGFR expression (P=.12) or PTGS2 
expression (P=.33) were not significant.
The prognostic value of EGFR and PTGS2 expression in CRCLM was also 
separately evaluated in colon and rectal cancer patients. High EGFR expression was 
associated with poor survival of colon cancer patients (HRR 1.71, 95%CI 1.16-2.51, 
P<.01; Supplementary Fig. S4A), which was not observed for rectal cancer patients 
(HRR 1.19, 95%CI 0.66-2.15, P=.57; Supplementary Fig. S4C). PTGS2 expression was 
associated with decreased OS in both colon cancer patients (HRR 1.60, 95%CI 1.06-
2.42, P=.03; Supplementary Fig. S4B) and rectal cancer patients (HRR 1.89, 95%CI 
1.01-3.51, P=.05; Supplementary Fig. S4D). The interaction terms for primary tumour 
location and either EGFR expression (P=.55) or with PTGS2 expression (P=.62) were 
not significant.
EGFR and PTGS2 expression in primary CRC and corresponding CRCLM
As primary CRC tissue material is more readily available for pathological examination 
than CRCLM surgical specimens, we investigated whether EGFR and PTGS2 
expression in the primary tumour were correlated to their expression in patient-
matched CRCLM. EGFR and PTGS2 expression could be evaluated for 141 and 166 
CRC-CRCLM pairs, respectively (Supplementary Fig. S5). Expression of EGFR by 
primary tumours and corresponding CRCLM was inconsistent (P=.51), while PTGS2 
expression was concordant for 69.2% of CRC-CRCLM pairs (P=.02; Supplementary 
Table S4). When patients who received systemic therapy preoperatively to primary 
CRC resection and/or liver resection were excluded from analysis EGFR expression 
remained uncorrelated (P=.61), while for PTGS2 expression the proportion of 
concordant pairs was 70.4% (P<.01; Supplementary Table S5).
DISCUSSION  
We investigated the prognostic value of EGFR and PTGS2 protein expression in 
a large cohort of patients who underwent CRCLM resection with curative intent. 
High expression was associated with poor prognosis, with a difference in median 
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Figure 4. Kaplan-Meier graphs depicting OS in months for (A,B,C) patients in which CRCLM 
were not treated with systemic therapy and (D,E,F) patients in which CRCLM were treated 
with systemic therapy. OS was stratified by (A,D) EGFR expression, (B,E) PTGS2 expression 
and (C,F) combined EGFR and PTGS2 expression. (A,B,D,E) HRR compares patients with high 
and low expression and (C,F) HRR compares patients in whom both EGFR and PTGS2 were 
highly expressed with patients in whom neither or either EGFR or PTGS2 levels were elevated. 
Information of systemic therapy was unavailable for n=11, and n=12 patients of which tissue 
samples were evaluated for EGFR and PTGS2 expression, respectively.
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OS between high and low expression of 18 months for EGFR and of 21 months for 
PTGS2. These differences are substantial, considering the median OS of the total 
study population of only 27 months, and correspond with the prognostic value of 
EGFR and PTGS2 expression observed in earlier stages of CRC 23-28. Moreover, the 
difference in median OS was 43 months between patients with high expression 
of both EGFR and PTGS2 in CRCLM and patients with no elevated levels of EGFR 
and PTGS in CRCLM. Multivariate analysis demonstrated that EGFR and PTGS2 
were prognostic biomarkers independent from each other and from well-known 
clinicopathological prognostic variables, such as positive lymph nodes at time 
of primary tumour resection, presentation of metastases within 12 months after 
diagnosis of the primary tumour, presence of more than a single liver metastasis, high 
serum CEA level, and maximal CRCLM diameter larger than 5.0 cm. Microsatellite 
instability (MSI) is a molecular variable with prognostic value that  has previously 
been associated with EGFR and PTGS2 expression in primary CRC and, as such, 
qualifies as a potential confounding factor 29-32. The MSI status of the patients in 
our cohort was not known, however, as only 3% of CRCLM is estimated to be 
microsatellite-instable 33, the confounding effects of MSI-status are presumed to 
play a minor role in our study population.
Approximately one third of the patients in our study population were 
treated with systemic therapy during the course of their disease. Stratification 
for treatment revealed that the prognostic value of EGFR and PTGS2 expression 
was restricted to the subgroup of patients who did not receive systemic therapy. 
Especially patients with CRCLM that highly expressed both EGFR and PTGS had 
a dismal prognosis. In contrast, EGFR and PTGS2 expression were not associated 
with OS in patients who did receive systemic therapy, suggesting that EGFR and/
or PTGS2 expressing tumours respond well to the commonly used 5FU-based 
chemotherapeutic regimens. Several inhibitors that specifically target EGFR (e.g. 
cetuximab, panitumumab) or PTGS2 (e.g. celecoxib) are being applied in clinical 
practice and significantly improved clinical outcome 8,34. Dual blockade of EGFR 
and PTGS2 by specific inhibitors has proven effective in preclinical setting 35. In 
current study population, only a limited number of patients were treated with such 
inhibitors. That is, only two patients were treated with cetuximab and two patients 
with panitumumab. Therefore, whether these targeted drugs would be beneficial 
to EGFR and/or PTGS2-expressing patients with resectable CRCLM remains to be 
established. 
Colon and rectal cancer are frequently combined in clinical and experimental 
setting, since these cancer types appeared to be very similar on genomic level 
36,37. However, whether colon and rectal cancer should be considered as a single 
entity has often been debated. In the present study, high EGFR expression was 
associated with poor OS of colon cancer patients but not rectal cancer patients. 
This lack of prognostic value in rectal cancer patients may be explained by alteration 
differences in rectal cancer of genes influencing the EGFR/PI3K axis, such as PTEN, 
of which it has been shown that these affect survival of rectal cancer patients, but 
are not associated with survival in colon cancer patients 38.  PTGS2 expression was 
associated with poor survival of both colon and rectal cancer patients. 
We also examined the correlation of protein expression between primary 
CRC and corresponding CRCLM, as alterations present in the primary tumour are 
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frequently also present in the corresponding metastases 39,40. While PTGS2 expression 
in CRCLM was correlated to its expression in patient-matched primary tumours 
(P=.02), this was not the case for EGFR expression (P=.51). Similar differences in 
EGFR expression between primary CRC and CRCLM have been reported by others 
and could be explained by an increase of genetic alterations commonly detected 
during tumour progression and metastasis 41,42. The correlation between PTGS2 
expression in primary CRC and CRCLM may indicate that protein levels in CRCLM 
are to a certain extent predetermined by molecular alterations present in the 
primary CRC. Although predicting PTGS2 expression in CRCLM from its expression 
in the corresponding primary tumour may seem appealing, one should be cautious 
as still 30.8% of PTGS2 expression scores of CRC-CRCLM pairs were discordant. 
The primary CRC-CRCLM correlation observed for PTGS2 expression, and the 
lack of it for EGFR expression, suggests that the role of PTGS2 expression in early 
colorectal carcinogenesis is more prominent than that of EGFR expression. This is 
in accordance with earlier findings that identify alterations of PTGS2 expression as 
early phase events and relate changes in EGFR expression to later stages of cancer 
development 43,44. 
In conclusion, EGFR and PTGS2 expression are prognostic biomarkers for 
patients with resectable CRCLM, predominantly in patients not treated with systemic 
therapy. Further research is required to fully characterise the impact of these and 
other molecular alterations, such as mutation status of the predictive biomarkers 
KRAS, BRAF, and PIK3CA 10, and establish optimal treatment for individual patients 
with CRCLM.
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SUPPLEMENTARY DATA  
 
Supplementary Table S1. Patient characteristics 17  
  
Clinicopathological variable 
Total Population   
  
Clinicopathological variable 
   Total Population   
n 
/ mean 
/ median 
% 
/ st.dev. 
/ range   
n 
/ mean 
/ median 
% 
/ st.dev. 
/ range 
 
General characteristics     Liver metastasis characteristics      
All 507    Age at liver resection      
Gender       mean (st.dev.) 63.3 0.5  
  male (%) 320 63.1     median (range) 64.3 27.6-83.9  
  female (%) 187 36.9   Synchronous liver metastasis Δ    
OS after liver resection in months     yes (%) Δ 221 43.6  
  mean (st.dev.) 37.2 1.7     no (%) Δ 261 51.5  
  median (range) 27 3.0-212.0     unknown (%) Δ 25 4.9  
       Distribution liver metastases    
          left half 90 17.8  
Primary CRC characteristics            segment 1 (%) 18 3.6  
Age at primary CRC resection            segment 2 (%) 116 22.9  
  mean (st.dev.) 61.9 0.5          segment 3 (%) 135 26.6  
  median (range) 62.8 24.4-83.3          segment 4 (%) 134 26.4  
Primary tumor location       right half 259 51.0  
  left colon (%) 245 48.3          segment 5 (%) 171 33.7  
  right colon (%) 95 18.7          segment 6 (%) 212 41.8  
  rectum (%) 151 29.8          segment 7 (%) 211 41.6  
  unknown (%) 16 3.2          segment 8 (%) 182 35.9  
Histological grade       both left and right half 146 28.8  
  poorly differentiated (%) 38 7.5     unknown 12 2.4  
  moderately differentiated (%) 288 56.8   Maximal CRCLM diameter in cm Δ    
  well-differentiated (%) 14 2.8     mean (st.dev.) 4.1 0.1  
  unknown (%) 167 32.9     median (range) 3.5 0.2-22.0  
Maximal CRC diameter in cm       maximal diameter ≤ 5.0 cm (%) Δ 372 73.4  
  mean (st.dev.) 4.4 0.1     maximal diameter > 5.0 cm (%) Δ 126 24.8  
  median (range) 4 0.2-12.0     maximal diameter unknown (%) Δ 9 1.8  
Positive lymph nodes detected Δ     Number of CRCLM Δ    
  yes (%) Δ 190 37.5     mean (st.dev.) 2 0.1  
  no (%) Δ 154 30.4     median (range) 2 1-12  
  unknown (%) Δ 163 32.1     nr of CRCLM = 1 (%) Δ 248 48.9  
Systemic treatment of primary CRC       nr of CRCLM > 1 (%) Δ 253 49.9  
  colon cancer         nr of CRCLM unknown (%) Δ 6 1.2  
     preoperative (%) 9 2.6   Serum CEA level Δ    
     perioperative (%) 0 0     mean (st.dev.) 101.6 38.5  
     postoperative (%) 91 26.8     median (range) 15 0.5-6625.0  
     none (%) 226 66.5     serum CEA level ≤ 200 ng/ml (%) Δ 166 32.7  
     unknown (%) 14 4.1     serum CEA level > 200 ng/ml (%) Δ 13 2.6  
  rectal cancer       serum CEA level unknown (%) Δ 328 64.7  
     preoperative (%) 25 16.5   Extrahepatic metastases    
     perioperative (%) 1 0.7     yes (%) 36 7.1  
     postoperative (%) 24 15.9     no (%) 423 83.4  
     none (%) 98 64.9     unknown (%) 48 9.5  
     unknown (%) 3 2   Resection in combination with RFA  
 primary tumor location unknown        yes (%) 109 21.5  
     preoperative (%) 1 6.3     no (%) 357 70.4  
     perioperative (%) 0 0.0     unknown (%) 41 8.1  
     postoperative (%) 1 6.3   Systemic treatment of liver metastases  
     none (%) 12 75.0    preoperative (%) 60 11.8  
    unknown (%) 2 12.5    perioperative (%) 12 2.4  
Radiotherapeutic treatment of primary CRC    postoperative (%) 97 19.1  
 yes (%) 113 22.3    none (%) 321 63.3  
 no (%) 392 77.3    unknown (%) 17 3.4  
 unknown (%) 2 0.4       
OS: overall survival; CEA: carcino-embryonic antigen; RFA: radiofrequency ablation; Δ Clinical risk score variable 3  
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Supplementary Table S2. Distribution of frequency scores 
 
Total 
Population 
 
Frequency score n %  
EGFR  323 100  
   0% 4 1.2  
   1-25% 133 41.2  
   26-50% 65 20.1  
   51-75% 38 11.8  
   76-100% 83 25.7  
PTGS2 351 100  
   0% 266 75.8  
   1-25% 82 23.3  
   26-50% 1 0.3  
   51-75% 0 0.0  
   76-100% 2 0.6  
 
 
 
 
 
 
Supplementary Table S3. Systemic therapy and decade of liver resection 17  
 
1990-
2010  
1990-
1999  
2000- 
2010 
 1990-
1999 
vs. 
2000-
2010 
 
Clinicopathological variable n* %  n %  n %  P 
All 507   106   398     
CRCLM treated with systemic therapy 169 33.3  22 20.8  146 36.7  .001  
 5FU only 6 3.6  3 13.6  3 2.1  .08  
 5FU + Leucovorin 39 23.1  16 72.7  22 15.1  .001  
 5FU + Leucovorin + Oxaliplatin 15 8.9  0 0.0  15 10.3  .04  
 5FU + Leucovorin + Irinotecan 2 1.2  0 0.0  2 1.4  .47  
 5FU + Leucovorin + other 1 0.6  0 0.0  1 0.7  .61  
 5FU + other 1 0.6  1 4.5  0 0.0  .05  
 Capecitabine only 7 4.1  0 0.0  7 4.8  .17  
 Capecitabine + Oxaliplatin 40 23.7  0 0.0  40 27.4  .001  
 Capecitabine + Oxaliplatin + Bevacizumab 27 16.0  0 0.0  27 18.5  .006  
 Capecitabine + Oxaliplatin + Bevacizumab + Cetuximab 2 1.2  0 0.0  2 1.4  .47  
 Capecitabine + Oxaliplatin + other 3 1.8  0 0.0  3 2.1  .37  
 Capecitabine + other 6 3.6  2 9.1  4 2.7  .46  
 Chemotherapeutic agent unknown 20 11.8  0 0.0  20 13.7  .02  
* Decade of liver resection unknown for n=3 patients, of which n=1 patients received systemic therapy.  
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Supplementary Table S4. Level of concordance between biomarker expression in primary CRC and 
corresponding CRCLM 
   expression in primary CRC    
Chi square 
ex
p
re
ss
io
n
 in
 C
R
C
 li
ve
r 
m
et
as
ta
se
s EGFR  low  high  Total 
low  
n = 58 
41.1% 
 
n = 31 
22.0% 
 
n = 89 
63.1% 
P=.51 high  
n = 31 
22.0% 
 
n = 21 
14.9% 
 
n = 52 
36.9% 
Total  
n = 89 
63.1% 
 
n = 52 
36.9% 
 n = 141 
PTGS2  low  high  Total Chi square 
low  
n = 99 
59.6% 
 
n = 29 
17.5% 
 
n = 128 
77.1% 
P=.02 high  
n = 22 
13.3% 
 
n = 16 
9.6% 
 
n = 38 
22.9% 
Total  
n = 121 
72.9% 
 
n = 45 
27.1% 
 n = 166 
 
 
 
 
 
 
Supplementary Table S5. Level of concordance between biomarker expression in primary CRC and 
corresponding CRCLM of patients that were not treated with systemic therapy within six months 
preoperative to primary tumor resection and/or liver resection 
   expression in primary CRC    
Chi square 
ex
p
re
ss
io
n
 in
 C
R
C
 li
ve
r 
m
et
as
ta
se
s EGFR  low  high  Total 
low  
n = 46 
39.7% 
 
n = 26 
22.4% 
 
n = 72 
62.1% 
P=.61 high  
n = 26 
22.4% 
 
n = 18 
15.5% 
 
n = 44 
37.9% 
Total  
n = 72 
62.1% 
 
n = 44 
37.9% 
 n = 116 
PTGS2  low  high  Total Chi square 
low  
n = 81 
60.0% 
 
n = 25 
18.5% 
 
n = 106 
78.5% 
P<.01 high  
n = 15 
11.1% 
 
n = 14 
10.4% 
 
n = 29 
21.5% 
Total  
n = 96 
71.1% 
 
n = 39 
28.9% 
 n = 135 
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Supplementary Figure S1. Kaplan-Meier graph depicting OS in months of the total study 
population. Patients with OS less than 2 months and unknown outcome or time of OS were 
removed from analysis 17.
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Supplementary Figure S2. Distribution of the cross-validated HRRs after (A) univariate analysis 
of EGFR expression, (B) multivariate analysis of EGFR expression, (C) univariate analysis of 
PTGS2 expression and (D) multivariate analysis of PTGS2 expression with OS as outcome.
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Supplementary Figure S3. Distribution of the selected cut-off points for frequency scores 
in the training sets of (A) EGFR expression and (B) PTGS2 expression. Expression data was 
dichotomized based on the most prevalent cut-off in the training sets. Cut-off points are (1) 0% 
vs. 1-100%, (2) 0-25% vs. 26-100%, (3) 0-50% vs. 51-100%, and (4) 0-75% vs. 76-100%. 
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Supplementary Figure S4. Kaplan-Meier graphs depicting OS in months for (A,C) patients 
with CRCLM originating from colon cancer and (B,D) patients with CRCLM originating from 
rectal cancer. OS was stratified by (A,B) EGFR expression and (C,D) PTGS2 expression. Origin 
of primary tumor (colon or rectum) was unknown for n=7 patients of which tissue samples 
were evaluated for EGFR and PTGS2 expression.
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CRC patients having had liver resection between 1990 and 2010 (n=507)
Primary CRC specimens unavailable (n=273)
Excluded due to 
technical reasons 
(n=68)
Available for PTGS2
evaluation (n=166)
Excluded due to 
technical reasons 
(n=93)
Available for EGFR
evaluation (n=141)
Supplementary Figure S5. Flow diagram of patients of whom primary tumor specimens were 
available.
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ABSTRACT
Background
Five-year survival after resection of colorectal cancer liver metastasis (CRLCM) is 
less than 30%. We recently found that aurora kinase A (AURKA) drives 20q gain-
associated tumour progression and is associated with disease recurrence. This 
study evaluates the prognostic value of AURKA expression in CRCLM of patients 
who underwent liver resection.
Methods
Tissue microarrays (TMAs) were generated using formalin-fixed paraffin-embedded 
CRCLM and matched primary tumor from a multi-institutional cohort of  patients 
with CRCLM who underwent liver resection between 1990 and 2010. TMAs were 
stained for AURKA by immunohistochemistry and a hazard rate ratio (HRR) for the 
association between overall survival (OS) and nuclear AURKA expression in CRCLM 
was calculated. Results were validated by 500-fold cross-validation.
Results
AURKA expression was evaluated in CRCLM of 343 patients. High AURKA 
expression was associated with poor OS (HRR 1.55, P<.01), with a cross-validated 
average HRR of 1.57 (P=.02). Average HRR was adjusted for established prognostic 
clinicopathological variables in a multivariate analysis (average HRR 1.66; P=.02). 
AURKA expression in CRCLM was correlated to its expression in corresponding 
primary tumor (P<.01).
Conclusions
AURKA protein expression is a molecular biomarker with prognostic value for 
patients with CRCLM, independent of established clinicopathological variables. 
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INTRODUCTION
Annually, more than 1.2 million people are diagnosed with colorectal cancer 
(CRC) worldwide and almost half of them die as a consequence of disseminated 
disease 1. The majority of haematogenous CRC metastases are located in the liver, 
followed by lung and peritoneum 2. Liver resection, occasionally in combination with 
radiofrequency ablation (RFA), is currently the only option with curative intent for 
CRC patients with liver metastases (CRCLM) 3,4. Patients eligible for liver resection 
are selected based on well-established prognostic clinicopathological variables that 
have been combined in a clinical risk score as defined by Fong et al. 5, which was 
supported by others in independent study populations 6-8. Application of molecular 
imaging by 18F-labeled fluorodeoxyglucose ([18F]FDG) PET in combination with 
computed tomography (CT) further reduced the proportion of futile surgeries by 
more than one-third 9. Nevertheless, only approximately 30% of patients survive for 
more than 5 years after surgery. Considering the significant morbidity and mortality 
risk associated with liver resections 9,10, there is a clear need for better prognostic 
biomarkers. 
Aurora kinase A (AURKA) is a cell cycle-regulated kinase involved in spindle 
formation and chromosome segregation 11. AURKA is located on chromosome 20q, 
a genomic region that is frequently amplified in CRC, that has been associated with 
adenoma-to-carcinoma progression, and that is an indicator of poor prognosis 12-
18. We recently demonstrated that AURKA, together with TPX2, drives 20q gain-
associated adenoma-to-carcinoma progression based on correlation of AURKA 
DNA copy number status to mRNA and protein expression levels combined with 
its functional effects on cell viability, anchorage-independent growth and invasion 
19. Furthermore, we demonstrated that high protein levels of AURKA in stage III 
colon cancer, i.e. patients with disseminated cells present in lymph nodes, were 
associated with increased disease recurrence 20. These data indicate that AURKA 
overexpression drives malignant behaviour and imply that AURKA may be a 
prognostic biomarker for CRC. In the present retrospective study we aimed to 
investigate whether AURKA is a prognostic molecular biomarker with added value 
to clinicopathological variables for CRCLM patients selected for liver resection with 
curative intent.
MATERIALS AND METHODS
Patient study population
Patients who underwent liver resection with curative intent, sometimes with addition 
of RFA, in the seven Dutch hospitals affiliated with the DeCoDe PET group were 
identified by cross-referencing surgery and pathology databases using Dutch MeSH 
terms for “colon”, “rectum”, “carcinoma”, “adenocarcinoma”, “colorectal neoplasms”, 
“liver”, “neoplasm metastasis”, and “(hemi)hepatectomy”. Clinicopathological data 
from patients that were operated on between 1990 and 2010 were extracted from 
these databases. Formalin-fixed paraffin-embedded (FFPE) tissue specimens were 
collected from one CRCLM sample and an adjacent control liver sample. When 
available, also the corresponding primary tumour and adjacent control colon tissue 
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were collected. Only specimens of patients with histologically confirmed CRCLM 
were included in the study, while tissue samples of patients with multiple primary 
tumours were excluded. Collection, storage and use of clinicopathological data 
and tissue specimens were performed in compliance with the “Code for Proper 
Secondary Use of Human Tissue in The Netherlands”, and approved in protocol 
2011-03 of our Department of Pathology 21.
Tissue microarrays
A total of 21 TMAs were generated using methodology as described previously 
22,23. In brief, three tissue core biopsies of 0.6mm in diameter were punched from 
morphologically representative areas of all FFPE donor blocks, and transferred into 
TMA recipient paraffin blocks using the 3DHISTECH TMA Master (v1.14, 3DHISTECH 
Ltd., Budapest, Hungary).
Evaluation of AURKA protein expression
Sections of TMAs (4μm) were mounted on glass slides and immunohistochemically 
stained for AURKA (mouse monoclonal, NCL-L-AK2, Novocastra Laboratories, 
Newcastle, United Kingdom) as described previously 13. Immunohistochemical 
stainings were digitally captured using the Mirax slide scanner system equipped 
with a 20x objective with a numerical aperture of 0.75 (Carl Zeiss B.V., Sliedrecht, 
The Netherlands) and a Sony DFW-X710 Fire Wire 1/3” type progressive SCAN IT 
CCD (pixel size 4.65x4.65μm). Actual scan resolution at 20x was 0.23μm. Computer 
monitors were calibrated using Spyder2PRO software (v1.0-16, Pantone Colorvision, 
Regensdorf, Switzerland). TMA core biopsies were scored for intensity of AURKA 
protein expression in nuclei of neoplastic epithelial cells (categories negative, weak, 
moderate, strong) using dedicated TMA scoring software (v1.14.25.1, 3DHISTECH 
Ltd., Budapest, Hungary). For facilitating scoring, a chart with visual analogue 
scales of staining patterns was used. Tissue samples were evaluated unaware of 
corresponding clinicopathological information at time of assessment. Tissue samples 
were independently evaluated by a second investigator in a blinded fashion with 
high inter-observer agreement (K
w
=0.75). 
CRC patients having had liver resection 
between 1990 and 2010 (n=507)
Excluded from analysis (n=108)
• Survival ≤ 2 months (n=61)
• Unknown outcome/time of survival (n=47)
CRCLM patients available for analysis (n=343)
Excluded from analysis due to technical 
reasons (n=56)
Figure 1. Flow diagram of the total study population. 
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Statistical analysis
Overall survival (OS) was defined as the time in months after surgery until death in a 
follow-up period of 10 years. Patients were excluded from analysis if OS ≤ 2 months, 
if OS or survival status were unknown, or if tissue cores could not be evaluated for 
technical reasons (Fig. 1). The prognostic value of AURKA expression was tested in a 
cross-validation procedure, repeated 500 times. In each cross-validation round the 
study population was randomly subdivided in a training set (50%) and validation set 
(50%). The training set was used to determine the optimal cut-off for dichotomising 
intensity scores into ‘low AURKA’ and ‘high AURKA’ staining intensities. This was 
done using receiver operating characteristic (ROC) curve analysis for survival 
data with 3-year OS as the outcome of interest 24-26. The optimal cut-off was 
defined as the point on the ROC curve giving the smallest distance to the point 
(1-specificity,sensitivity) = (0,1) (Supplementary Fig. S1A). Using this cut-off, AURKA 
intensity scores in the validation set were dichotomised and the crude hazard rate 
ratio (HRR) for AURKA expression was calculated in a Cox regression analysis 
with OS as outcome. Additionally, established prognostic clinicopathological 
variables combined in the clinical risk score defined by Fong et al. were included 
in a multivariate Cox regression analysis 5. The average cross-validated hazard rate 
ratio (HRRav) of the validation sets was calculated and the P value of the cross-
validation procedure was defined as the percentage of average cross-validated 
hazard rate ratios smaller than 1 (HRRav<1). To visualise the relation between OS 
and AURKA expression in the total study cohort and a number of cohort subgroups 
Kaplan Meier curves were obtained using the most frequently selected cut-off in the 
training sets as the optimal cut-off and the HRR was calculated using Cox regression 
analysis. Level of concordance of protein expression in primary CRC and CRCLM 
was calculated using Pearson’s chi-square test. All statistical tests were two-sided 
and executed using IBM SPSS Statistics 20.0 software (SPSS Inc., Illinois, USA) or R 
Statistics 14.0 software (RStudio Inc., Boston, USA). P values <.05 were considered 
significant. All data reported was REMARK compliant 27.
A power calculation provided an estimate of the required size of the study 
population. HRR was the primary outcome measure for OS difference between 
patients with ‘low AURKA’ and ‘high AURKA’ expression. Ten-year OS of the study 
population was estimated as 30% and, therefore, the proportion of long-term and 
short-term survivors after liver resection as 30% and 70%, respectively 10. Assuming 
similar proportions of patients with low and high AURKA expression, 227 events 
were required to detect an OS difference between both subgroups with a HRR 
of 1.5. With a follow-up period of 10 years, this required an estimated total study 
population of 361 patients. 
RESULTS
Demographic characteristics 
A study cohort of 507 consecutive CRCLM patients who underwent liver resection 
with curative intent was assembled. CRCLM samples were obtained from all patients, 
and of 234 patients also the corresponding primary CRC samples were collected. 
Demographic characteristics of the cohort are summarised in Table 1. OS after liver 
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resection is depicted in Fig. 2A. Median survival of the cohort was 46 months (range, 
3-212 months), five-year OS was 41.3%. The majority of patients were male (63.1%). 
Median age at time of liver resection was 64.3 years (range, 27.6-83.9 years). The 
primary tumour was of colonic origin in 67.0% of patients and of rectal origin in 
29.8% of patients. In 3.2% of patients the origin of the primary tumour was unknown. 
No positive lymph nodes were detected at time of primary tumour resection in 
30.4% of patients. Metastases presented within 12 months after diagnosis of the 
primary tumour in 43.6% of patients. The median number of liver metastases was 2 
 
Table 1. Patient characteristics  
  
Clinicopathological variable 
Total Population   
  
Clinicopathological variable 
   Total Population   
n 
/ mean 
/ median 
% 
/ st.dev. 
/ range   
n 
/ mean 
/ median 
% 
/ st.dev. 
/ range 
 
General characteristics     Liver metastasis characteristics      
All 507    Age at liver resection      
Gender       mean (st.dev.) 63.3 0.5  
  male (%) 320 63.1     median (range) 64.3 27.6-83.9  
  female (%) 187 36.9   Synchronous liver metastasis Δ    
OS after liver resection in months     yes (%) Δ 221 43.6  
  mean (st.dev.) 37.2 1.7     no (%) Δ 261 51.5  
  median (range) 27 3.0-212.0     unknown (%) Δ 25 4.9  
       Distribution liver metastases    
          left half 90 17.8  
Primary CRC characteristics            segment 1 (%) 18 3.6  
Age at primary CRC resection            segment 2 (%) 116 22.9  
  mean (st.dev.) 61.9 0.5          segment 3 (%) 135 26.6  
  median (range) 62.8 24.4-83.3          segment 4 (%) 134 26.4  
Primary tumor location       right half 259 51.0  
  left colon (%) 245 48.3          segment 5 (%) 171 33.7  
  right colon (%) 95 18.7          segment 6 (%) 212 41.8  
  rectum (%) 151 29.8          segment 7 (%) 211 41.6  
  unknown (%) 16 3.2          segment 8 (%) 182 35.9  
Histological grade       both left and right half 146 28.8  
  poorly differentiated (%) 38 7.5     unknown 12 2.4  
  moderately differentiated (%) 288 56.8   Maximal CRCLM diameter in cm Δ    
  well-differentiated (%) 14 2.8     mean (st.dev.) 4.1 0.1  
  unknown (%) 167 32.9     median (range) 3.5 0.2-22.0  
Maximal CRC diameter in cm       maximal diameter ≤ 5.0 cm (%) Δ 372 73.4  
  mean (st.dev.) 4.4 0.1     maximal diameter > 5.0 cm (%) Δ 126 24.8  
  median (range) 4 0.2-12.0     maximal diameter unknown (%) Δ 9 1.8  
Positive lymph nodes detected Δ     Number of CRCLM Δ    
  yes (%) Δ 190 37.5     mean (st.dev.) 2 0.1  
  no (%) Δ 154 30.4     median (range) 2 1-12  
  unknown (%) Δ 163 32.1     nr of CRCLM = 1 (%) Δ 248 48.9  
Systemic treatment of primary CRC       nr of CRCLM > 1 (%) Δ 253 49.9  
  colon cancer         nr of CRCLM unknown (%) Δ 6 1.2  
     preoperative (%) 9 2.6   Serum CEA level Δ    
     perioperative (%) 0 0     mean (st.dev.) 101.6 38.5  
     postoperative (%) 91 26.8     median (range) 15 0.5-6625.0  
     none (%) 226 66.5     serum CEA level ≤ 200 ng/ml (%) Δ 166 32.7  
     unknown (%) 14 4.1     serum CEA level > 200 ng/ml (%) Δ 13 2.6  
  rectal cancer       serum CEA level unknown (%) Δ 328 64.7  
     preoperative (%) 25 16.5   Extrahepatic metastases    
     perioperative (%) 1 0.7     yes (%) 36 7.1  
     postoperative (%) 24 15.9     no (%) 423 83.4  
     none (%) 98 64.9     unknown (%) 48 9.5  
     unknown (%) 3 2   Resection in combination with RFA  
 primary tumor location unknown        yes (%) 109 21.5  
     preoperative (%) 1 6.3     no (%) 357 70.4  
     perioperative (%) 0 0.0     unknown (%) 41 8.1  
     postoperative (%) 1 6.3   Systemic treatment of liver metastases  
     none (%) 12 75.0    preoperative (%) 60 11.8  
    unknown (%) 2 12.5    perioperative (%) 12 2.4  
Radiotherapeutic treatment of primary CRC    postoperative (%) 97 19.1  
 yes (%) 113 22.3    none (%) 321 63.3  
 no (%) 392 77.3    unknown (%) 17 3.4  
 unknown (%) 2 0.4       
OS: overall survival; CEA: carcino-embryonic antigen; RFA: radiofrequency ablation; Δ Clinical risk score variable  
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(range, 1-12) with a median size of 3.5cm (range, 0.2-22.0cm). Extrahepatic disease 
was present in 7.1% of patients. Chemo- and/or antibody-based therapy during 
the months prior to or following liver resection was received by 33.3% of patients 
(Supplementary Table S1). Additional perioperative radiofrequency ablation (RFA) 
of liver metastases was performed in 21.5% of patients.
Presence of more than one liver metastasis was inversely and significantly 
related to OS (HRR 1.38; 95%CI 1.04-1.83; P=.03). Positive lymph nodes at time of 
primary tumour resection and presentation of metastases within 12 months after 
diagnosis of the primary tumour both tended to be associated with decreased OS 
(HRR 1.39; 95%CI 0.99-1.96; P=.06 and HRR 1.24; 95%CI 0.93-1.66; P=.14, respectively). 
Maximal diameter of the metastasis and serum CEA levels were not associated 
with OS (HRR 1.05; 95%CI 0.76-1.46; P=.75 and HRR 0.94; 95%CI 0.37-2.36; P=.90, 
respectively). No significant differences in OS were observed between patients 
having had surgery between 1990 and 1999 versus patients who were operated on 
after 1999 (HRR 1.09; 95%CI 0.80-1.50; P=.58; Supplementary Fig. S2). 
AURKA expression is associated with poor prognosis
Immunohistochemical staining of AURKA expression could be evaluated for 
343 patients (Fig. 1) and AURKA nuclear staining intensity of neoplastic CRCLM 
epithelium was scored (Fig. 3 and Supplementary Table S2). The cross-validated 
HRRav for AURKA expression was 1.57 (P=.02; Fig. 4A), indicating a significant 
association between high levels of AURKA in CRCLM and decreased OS. The cut-off 
between the categories negative, weak and moderate on one hand and strong on the 
other emerged in >95% of cross-validation cycles as most optimal (Supplementary 
Fig. S1B). When dichotomising the total study population based on this cut-off, a 
difference of 16 months in median OS was observed (HRR 1.55; 95%CI 1.11-2.17; P<.01; 
Fig. 2B) between patients with low AURKA expression (median OS 51 months) and 
high AURKA expression (median OS 35 months). 
Next, a multivariate Cox regression analysis was performed to evaluate 
whether the prognostic value of AURKA protein expression was independent of 
established prognostic clinicopathological variables, i.e. primary tumour-to-liver 
metastasis interval ≤ 12 months, number of liver metastases > 1, maximal tumour 
diameter > 5.0cm, and lymph node positivity at time of diagnosis of the primary 
tumour. The HRRav after multivariate analysis was 1.66 (P=.02; Fig. 4B), indicating an 
autonomous association between AURKA expression and OS. 
 
Prognostic value of AURKA expression in patient subgroups
Preoperative systemic therapy can affect tissue characteristics at the time of surgery 
and may bias immunohistochemical analysis of AURKA expression. When excluding 
patients who had received systemic treatment within six months preoperative to 
liver resection (n=281), results were similar to those of the total study population 
(HRR 1.52; 95%CI 1.03-2.23; P=.03; Supplementary Fig. S3), indicating lack of 
significant bias. 
Next, the effects of systemic therapy regardless of administration time 
point (i.e. pre-, peri- or postoperative to liver resection) were analyzed. AURKA 
overexpression tended to be associated with poor survival, both in the subgroup of 
patients that did not receive systemic treatment (HRR 1.46; 95%CI 0.93-2.29; P=.10; 
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Figure 2. (A) Kaplan-Meier graph depicting OS in months of the total study population. (B-F) 
Kaplan-Meier graphs depicting OS in months stratified by intensity of AURKA expression in 
hepatic metastases (B) of the total population, (C) of patients in which liver metastases were 
not treated with systemic therapy (n=206), (D) of patients in which liver metastases were 
treated with systemic therapy (n=124), (E) originating from colon cancer (n=224), and (F) 
originating from rectal cancer (n=112). Information of systemic therapy was unavailable for 
n=13 patients. Origin of primary tumor (colon or rectum) was unkown for n=7 patients. 
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Fig. 2C) and in the subgroup of patients that were treated with systemic therapy 
(HRR 1.55; 95%CI 0.91-2.64; P=.10; Fig. 2D). Furthermore, the prognostic value was 
evaluated separately for CRCLM patients whose primary tumour originated in the 
colon (HRR 1.63; 95%CI 1.05-2.54; P=.03; Fig. 2E) and the rectum (HRR 1.69; 95%CI 
0.98-2.91; P=.06; Fig. 2F). Comparable results were obtained for both tumour sites.
AURKA expression in primary CRC and corresponding CRCLM
Primary CRC tissue material is more readily obtained for pathological examination 
than CRCLM tissue material. Therefore, we investigated whether AURKA expression 
in the primary tumour was correlated to expression in its corresponding liver 
metastasis. For 152 patients both CRCLM and matched primary CRC tissue could be 
evaluated for AURKA staining intensity (Supplementary Fig. S4), revealing 63.8% 
concordant and 36.2% discordant pairs of intensity scores (P<.01; Supplementary 
Table S3). Similar level of concordance was found when patients treated with 
systemic therapy preoperative to primary CRC resection and/or CRCLM resection 
were excluded from analysis, with a level of concordance of 60.4%, and 39.6% 
disconcordant pairs (P<.01; Supplementary Table S4). 
DISCUSSION  
Our data demonstrate that high expression of AURKA in liver metastases of CRC 
patients who underwent liver resection was associated with poor survival (HRR 1.55; 
P<.01), which was validated in a 500-fold cross-validation procedure (HRRav 1.57; 
P=.02). The difference in median OS time between patients with high versus low 
AURKA expressing CRCLM was 16 months. This difference in median OS time is 
substantial, considering a median survival after liver resection of 27 months in our 
total study population. Multivariate analysis revealed that the prognostic value of 
Figure 3. Expression pattern of AURKA in epithelium of CRCLM. Staining intensity of the nuclei 
was evaluated as (A) negative, (B) weak, (C) moderate or (D) strong.
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AURKA expression was independent of prognostic clinicopathological variables, 
such as presence of more than one liver metastasis, positive lymph nodes at time 
of primary tumour resection, maximal CRCLM diameter larger than 5cm, and 
presentation of metastases within 12 months after diagnosis of the primary tumour.
The CRCLM cohort used for the current study lacked prognostic value for 
two established clinicopathological risk factors, i.e. liver metastasis diameter > 
5.0cm and serum CEA > 200 ng/ml.  Some prognostic effects for liver metastasis 
diameter > 5.0cm could be observed in our study population within 30 months 
follow-up after liver resection (HRR 1.48; 95%CI 0.99-2.20; P=.06), an effect that 
diminished when considering a longer follow-up period of 10 years. For CEA serum 
levels data availability was limited (n=179) and the number of patients that exceeded 
the preset threshold of serum CEA levels above 200 ng/ml within this group was 
small (n=13). Therefore, we excluded this variable from the multivariate analysis. 
Resection margin status and presence of extrahepatic metastases are two additional 
clinicopathological prognostic variables regularly used in clinical practice. On 
resection margin status no data was available for current study population, hence, 
this parameter could not be included in the multivariate analysis. Including presence 
of extrahepatic metastases as additional prognostic variable in the multivariate Cox 
regression analysis merely altered the average HRR (HRRav 1.61; P=.02).
The OS of patients having had liver resection in the period from 2000 to 
2010 was not improved compared to patients operated on in the period from 1990 
until 2000 (Supplementary Fig. S2). This observation was somewhat unexpected, 
though could be explained by an increase of patients having been operated on since 
2000 who presented with affected lymph nodes (p=0.05) and/or extrahepatic 
metastases (p=0.04).
Although a clinical risk score is a useful and easily applicable method to select 
patients for liver resection, it is insufficient to represent the complexity of CRC 
biology. Molecular biomarkers have the potential to reveal differences in biological 
behaviour among apparently similar tumour samples. They are indicators of 
Figure 4. Distribution of the cross-validated HRRs after (A) univariate analysis and (B) 
multivariate analysis together with established prognostic clinicopathological variables.
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changes in cancer-related biological processes such as proliferation, differentiation, 
invasion, and angiogenesis, due to their direct or indirect involvement in these 
processes. AURKA has been described to function in proliferation, chromosomal 
instability, anchorage-independent growth, and invasion 19,28-31. Importantly, changes 
in AURKA expression appear to cause rather than to follow differences in these 
biological processes, implying that AURKA is a driver rather than a passenger of 
tumour progression and thereby a direct indicator of tumour biology 19. The present 
study demonstrates that differences in AURKA protein expression in CRCLM are 
also associated with clinical consequences, i.e. overall survival, analogous to our 
previously observed association with disease recurrence in stage III colon cancer 
patients 20. The causal relationship between AURKA overexpression and tumour 
progression, and its association with reduced patient survival in different CRC stages 
may explain why AURKA is a strong and independent prognostic biomarker for CRC. 
Similar to our observations, association of high AURKA protein expression with poor 
survival has been reported for stage III colorectal cancer 32 and for triple negative 
breast cancer 33. However, no such association was found in another study of AURKA 
protein expression in stage I to IV CRC samples 34. In addition, contradictory findings 
have been reported by studies that determined AURKA DNA copy number status, 
one indicating association with tumour progression and another association with 
prolonged survival 35,36. Differences among these and our studies may be explained 
by variation in size and composition of patient cohorts, methodology and reagents 
to determine AURKA expression levels as well as methodology to determine its 
cutoff values for low versus high expression.
The primary tumour of CRCLM is located in either the colon or the rectum, 
two organs that are often combined for experimental analyses. Although 
adenocarcinomas of colon and rectum are hardly distinguishable at the genomic 
level it remains debatable whether colon and rectal cancer should be considered as 
one or two distinct entities 37,38. Our data demonstrated prognostic value of AURKA 
expression in CRCLM irrespective of the intestinal origin of the primary tumour 
(Fig. 2E-F), i.e. colon or rectum, which renders AURKA a candidate biomarker for 
both colon and rectal cancer patients. Next, we examined whether expression of 
AURKA in CRCLM was correlated to its expression in the corresponding patient-
matched primary tumour, since molecular alterations that are acquired during 
early stages of tumour development are likely to be present in the metastases 39,40. 
Conform expectations a significant correlation was found (P<.01), indicating that 
the level of AURKA expression in CRCLM is to a certain extent predetermined by 
molecular alterations in the primary tumour. Although this correlation suggests that 
one may predict the level of AURKA expression in CRCLM based on analysis of its 
corresponding primary tumour, e.g. when CRCLM specimens are not (yet) available, 
it should be noted that AURKA expression was concordant in only 63.8% of CRC - 
CRCLM pairs.
In addition to principally curative liver resection, about one third of all patients 
also received chemotherapy, sometimes combined with antibody-based systemic 
therapy. Commonly used chemotherapeutic agents like Fluorouracil (5-FU) or its 
prodrug capecitabine target mitosis, one of the hallmarks of cancer cells. As AURKA 
is involved in spindle formation and chromosome segregation we hypothesised 
that treatment with anti-proliferative agents might influence its prognostic value 
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as determined in this retrospective study. This turned out not to be the case, as 
similar prognostic effects of AURKA were observed for the groups of patients who 
did and did not receive systemic treatment (Fig. 2C-D). One explanation may be 
that the biological effects of AURKA are not restricted to a role in proliferation. 
In vitro studies demonstrated that AURKA activation can switch cells from a pro- 
to an anti-apoptotic transcriptional program through regulation of mRNA splicing 
31, suggesting that AURKA is a master regulator that affects the function of many 
genes. Other studies showed that AURKA affects anchorage-independent growth 
and invasion, properties that match characteristics that are essential for malignant 
metastasising cells and therefore may highly impact OS 19,28,41. As such, while 
targeting mitosis is currently being challenged as a flawed rationale to treat cancer 
42, targeting of AURKA kinase activity may affect cancer-driving properties other 
than proliferation.
Several small molecule inhibitors have been developed specifically inhibiting 
aurora kinase A rather than the other aurora kinase isoforms. These inhibitors have 
demonstrated anticancer activity in various preclinical cancer models, and some 
have entered clinical trials 11,43,44, Our data suggest that targeted treatment of CRC 
patients with AURKA inhibitors may improve OS, provided that within a given tumour 
AURKA functions as a driver of the carcinogenic process rather than as a passenger 
of the mitotic machinery. Further research is required to establish and validate the 
potential of AURKA as a molecular biomarker to predict patient responsiveness to 
AURKA inhibitors, e.g. at the DNA level through determination of chromosome 20q 
AURKA amplification or at the protein level by immunohistochemical evaluation 
of tumour tissue. Alternatively, AURKA inhibitors may be used for development 
of novel PET tracers to directly visualise and quantify AURKA as a molecular drug 
target within a given patient in vivo, and monitor efficiency of treatment. Therefore, 
we conclude that AURKA expression can serve both as a promising prognostic and 
potentially also predictive biomarker for CRC, which fits current trends towards 
personalised medicine.
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SUPPLEMENTARY DATA
 
Supplementary Table S1. Systemic therapy and decade of liver resection 
 
1990-
2010 
 1990-
1999 
 2000- 
2010 
 1990-
1999 
vs. 
2000-
2010 
 
Clinicopathological variable n* %  n %  n %  P 
All 507   106   398     
CRCLM treated with systemic therapy 169 33.3  22 20.8  146 36.7  .001  
 5FU only 6 3.6  3 13.6  3 2.1  .08  
 5FU + Leucovorin 39 23.1  16 72.7  22 15.1  .001  
 5FU + Leucovorin + Oxaliplatin 15 8.9  0 0.0  15 10.3  .04  
 5FU + Leucovorin + Irinotecan 2 1.2  0 0.0  2 1.4  .47  
 5FU + Leucovorin + other 1 0.6  0 0.0  1 0.7  .61  
 5FU + other 1 0.6  1 4.5  0 0.0  .05  
 Capecitabine only 7 4.1  0 0.0  7 4.8  .17  
 Capecitabine + Oxaliplatin 40 23.7  0 0.0  40 27.4  .001  
 Capecitabine + Oxaliplatin + Bevacizumab 27 16.0  0 0.0  27 18.5  .006  
 Capecitabine + Oxaliplatin + Bevacizumab + Cetuximab 2 1.2  0 0.0  2 1.4  .47  
 Capecitabine + Oxaliplatin + other 3 1.8  0 0.0  3 2.1  .37  
 Capecitabine + other 6 3.6  2 9.1  4 2.7  .46  
 Chemotherapeutic agent unknown 20 11.8  0 0.0  20 13.7  .02  
* Decade of liver resection unknown for n=3 patients, of which n=1 patients received systemic therapy.  
 
 
 
 
 
 
Supplementary Table S2. Distribution of intensity scores 
 
Total 
Population 
 
Intensity score n %  
Negative 51 10.0  
Weak 109 21.5  
Moderate 115 22.7  
Strong 154 30.4  
Non-evaluable 78 15.4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94
Chapter 4
 
Supplementary Table S3. Level of concordance between intensity scores in primary CRC and corresponding 
liver metastasis 
   expression in primary CRC    Chi square 
ex
pr
es
sio
n 
in
 C
RC
 
liv
er
 m
et
as
ta
se
s AURKA  low  high  Total 
low  n = 42 27.6%  
n = 40 
26.3% 
 n = 82 
53.9% 
P<.01 high  n = 15 9.9%  
n = 55 
36.2%  
n = 70 
46.1% 
Total  n = 57 37.5%  
n = 95 
62.5%  n = 152 
 
 
 
 
 
 
Supplementary Table S4. Level of concordance between intensity scores in primary CRC and corresponding 
liver metastasis of patients that were not treated with systemic therapy within six months preoperative to 
primary tumor resection and/or liver resection 
   expression in primary CRC    
Chi square 
ex
pr
es
sio
n 
in
 C
RC
 
liv
er
 m
et
as
ta
se
s AURKA  low  high  Total 
low  n = 38 30.6%  
n = 36 
29.1%  
n = 74 
59.7% 
P<.01 high  n = 13 10.5%  
n = 37 
29.8% 
 n = 50 
40.3% 
Total  n = 51 41.1%  
n = 73 
58.9%  n = 124 
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Supplementary Figure S1. (A) Example of a receiver operating characteristic (ROC) curve for 
intensity scores in one of the training sets, with cut-off points (1) negative vs. weak, moderate, 
strong, (2) negative, weak vs. moderate, strong, and (3) negative, weak, moderate vs. strong. 
The optimal cut-off point for dichotomising intensity scores into low and high AURKA intensities 
(arrow) is the cut-off point with the shortest distance to (1-spec,sens)=(0,1). AUC=0.70. (B) 
Distribution of the selected cut-off points in the training sets.
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Supplementary Figure S2. Kaplan-Meier graphs depicting overall survival in months, stratified 
by decade of liver resection. Patients with overall survival after liver resection of less than 2 
months or with unknown outcome or time of survival (n=108) were excluded from analysis. 
Supplementary Figure S3. Kaplan-Meier graph depicting overall survival in months, stratified 
by intensity of AURKA expression in hepatic metastases of patients that were not treated 
with systemic therapy within six months preoperative to liver resection (n=281). Information of 
systemic therapy was unavailable for n=13 patients. 
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CRC patients having had liver resection 
between 1990 and 2010 (n=507)
Primary CRC specimens unavailable (n=273)
CRCLM patients available for correlation 
analysis (n=152)
Excluded from analysis due to technical 
reasons (n=82)
Supplementary Figure S4. Flow diagram of patients of whom primary tumour specimens were 
available.
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ABSTRACT
Background 
Prognosis of patients with colorectal cancer liver metastasis (CRCLM) is currently 
based on clinicopathological scoring systems. Prognostic biomarkers stratifying 
patients based on tumour biology may have additional value.
Methods 
Tissue micro-arrays (TMAs), containing formalin-fixed paraffin-embedded tumour 
specimens of CRCLM and corresponding primary tumours from a multi-institutional 
cohort of 507 patients who underwent liver resection, were immunohistochemically 
stained for 18 candidate biomarkers. Cross-validated hazard rate ratios (HRRs) for 
overall survival (OS) and the proportion of HRRs with opposite effect (P(HRR<1) 
or P(HRR>1)) were calculated. A classifier was constructed by classification and 
regression tree (CART) analysis and its prognostic value determined by permutation 
analysis. Correlations between protein expression in primary tumour-CRCLM pairs 
were calculated.
Results 
Based on their putative prognostic value, EGFR (P(HRR<1)=.02), AURKA 
(P(HRR<1)=.02), VEGFA (P(HRR<1)=.02), PTGS2 (P(HRR<1)=.01), SLC2A1 
(P(HRR>1)<.01), HIF1α (P(HRR>1)=.06), KCNQ1 (P(HRR>1)=.09), CEA (P(HRR>1)=.05) 
and MMP9 (P(HRR<1)=.07) were included in the CART analysis (n=201). The resulting 
classifier was based on AURKA, PTGS2 and MMP9 expression in CRCLM and was 
associated with OS (HRR 2.79, p<.001), also after multivariate analysis including 
established clinicopathological prognostic variables (HRR 3.57, p<.001). The 
prognostic value of the biomarker-based classifier was superior to the prognostic 
value of the clinicopathological model (p=.001). Prognostic value was highest for 
colon cancer patients (HRR 5.71, p<.001) and patients not treated with systemic 
therapy (HRR 3.48, p<.01). Classification based on protein expression in primary 
tumours could be based on AURKA expression only (HRR 2.59, p=.04).
Conclusions 
A classifier was generated for patients with CRCLM with improved prognostic 
value compared to the standard clinicopathological prognostic parameters. Protein 
expression in CRCLM could partly be predicted based on expression in patient-
matched primary tumours.
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INTRODUCTION
Annually, 700.000 people diagnosed with colorectal cancer (CRC) die as a 
consequence of advanced disease 1. The majority of CRC metastases localize to the 
liver and resection of the affected liver tissue, often combined with radiofrequency 
ablation (RFA), is the sole curative treatment option 2. Selection of patients for liver 
surgery is usually based on established clinicopathological prognostic variables 
3-6. However, as survival after surgery is only 36-58% 7, the prognostic accuracy 
of such scoring systems is disputed 8-12. Accordingly, there is a need for better 
prognostic variables to select patients for treatment based on their tumour biology 
10-12. Potentially, relevant biological information on colorectal cancer liver metastasis 
(CRCLM) could be derived from molecular profiling of the corresponding primary 
tumour, since genomic characteristics of primary and matched metastatic CRC 
lesions overlap to a large extent 13,14. This is of particular interest since specimens of 
the primary tumour are more often readily available for histopathological analysis. 
Proteins involved in key biological processes of CRC have the potency 
to serve as biomarkers for patient stratification 15. Such biological processes 
include sustained proliferation, growth suppressor evasion, apoptosis resistance, 
stimulation of angiogenesis, invasion and metastasis, genome instability, promotion 
of inflammation and deregulation of cellular energetics (Table 1) 15. Genes involved 
in these processes are often mutated in CRC and/or the corresponding proteins 
are aberrantly expressed compared to normal tissue 14,16-30. Expression of several 
of such proteins in primary CRC has been associated with survival. However, the 
prognostic value of most of these proteins has not yet been determined for their 
expression in CRCLM. We have previously demonstrated that protein expression 
levels of EGFR, AURKA, VEGFA, PTGS2 and SLC2A1 are independently associated 
with survival of patients with CRCLM 31-33, and have analyzed the effects of several 
other proteins commonly associated with CRC(LM). The present study aims to 
explore how survival of CRCLM patients could be predicted more accurately by 
combining such markers into a potentially clinically applicable classifier. To this end, 
we investigated the single and combined prognostic value of proteins commonly 
associated with CRC carcinogenesis (Table 1) 34-39. Furthermore, we compared 
biomarker expression between CRCLM and the corresponding primary tumour 
to assess whether prognosis could be predicted based on expression within the 
corresponding primary tumour. 
MATERIALS AND METHODS
Patient study population
Assembly of the study population has been described previously 32. In brief, 
clinicopathological information was obtained from in-hospital clinical and pathology 
databases of 507 consecutive patients with CRCLM who underwent liver resection 
with curative intent between 1990 and 2010 in one of seven Dutch hospitals affiliated 
with the DeCoDe PET group. Corresponding formalin-fixed paraffin-embedded 
(FFPE) tissue samples were collected of one histologically confirmed CRCLM and 
an adjacent control liver specimen. Additionally, of 234 patients tissue specimens of 
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matching primary tumour and adjacent colon tissue were obtained. Only specimens 
of patients with histologically confirmed CRCLM were included in the study, while 
tissue samples of patients with multiple primary tumours were excluded. Collection, 
storage and use of clinicopathological data and tissue specimens were performed 
in compliance with the “Code for Proper Secondary Use of Human Tissue in The 
Netherlands” 40.
Tissue microarrays 
Three core biopsies (diameter 0.6 mm) were taken from morphologically 
representative areas of each FFPE donor block and transferred into tissue 
microarray (TMA) recipient paraffin blocks using the 3DHISTECH TMA Master (v1.14, 
3DHISTECH Ltd., Budapest, Hungary). A detailed protocol of TMA generation has 
been described elsewhere 32.
Immunohistochemistry
Tissue specimens were immunohistochemically stained for proteins involved in the 
development and progression of CRC(LM), based on the availability of adequate 
immunohistochemical antibodies and their potential utility for clinical diagnostics 
Table 1. Overview of several biological processes involved in CRC carcinogenesis and proteins commonly 
associated with these processes 
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EGFR epidermal growth factor 
receptor 
X X X  X    
PI3K phosphatidylinositide 3-kinase X X X  X    
AURKA aurora kinase A X X X  X    
Ki-67 antigen KI-67 X  X      
TK1 thymidine kinase 1 X  X      
KCNQ1 
potassium voltage-gated 
channel, KQT-like 
subfamily, member 1 
X X X      
IGF2 insulin-like growth factor 2 X X X  X    
VEGFA vascular endothelial 
growth factor A 
X  X X X    
PDGFRβ platelet-derived growth 
factor receptor β X X X X X    
CEA carcinoembryonic antigen  X   X    
MMP9 matrix metallo-peptidase 9 X  X X X    
CXCR4 
C-X-C chemokine receptor 
type 4 X  X X X    
CXCL12 C-X-C motif chemokine 12 X  X X X    
MLH1 
MutL homolog 1, colon 
cancer, nonpolyposis type 
2 (E. coli) 
X  X   X   
MSH6 mutS homolog 6   X   X   
PTGS2 
prostaglandin-
endoperoxide syn- 
thase 2 
X X X  X  X  
SLC2A1 
solute carrier family 2, 
facilitated glucose 
transporter, member 1 
X  X  X   X 
HIF1α hypoxia-inducible factor 1α X X X X X  X X 
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or monitoring (Table 1). TMA sections (4 μm) were deparaffinized using xylene and 
rehydrated with a decreasing alcohol series. Endogenous peroxidase was quenched 
for 25 minutes in 0.3% hydrogen peroxidase in methanol. Positive controls and 
procedures of epitope retrieval and antibody incubation are summarized in 
Supplementary Table S1. Incubation of FFPE control tissue and cells without primary 
antibody served as negative controls. Most stainings were performed manually, 
however, stainings for EGFR and Ki-67 were performed using the BondMax 
Immunostainer (Menarini Diagnostics, Firenze, Italy) and Bond TM Epitope Retrieval 
Reagent 2 (Novocastra Laboratories, Newcastle, UK) for antigen retrieval, stainings 
for CEA, MLH1 and MSH6 using the Autostainer Link (Dako, Glostrup, Denmark) 
and Target Retrieval Solution (Dako, Glostrup, Denmark) for antigen retrieval, and 
staining for HIF1α using the catalyzed signal amplification (CSA) system (Dako, 
Glostrup, Denmark). These stainings were performed according to manufacturer’s 
instructions. Secondary antibodies were visualized using diaminobenzidine (DAB) 
substrate chromogen system. Slides were counterstained with Mayer’s haematoxylin.
Evaluation of protein expression
Stained TMAs were digitally captured using the Mirax slide scanner system, 
equipped with a 20x objective with a numerical aperture of 0.75 (Carl Zeiss B.V., 
Sliedrecht, The Netherlands) and a Sony DFW-X710 Fire Wire 1/3” type progressive 
SCAN IT CCD (pixel size 4.65 x 4.65μm), resulting in an actual scan resolution 
(effective pixel size in the sample plane) at 20x of 0.23μm. Stained neoplastic cells 
or stroma were scored for intensity (categories negative, weak, moderate, strong) 
and frequency (categories 0-25%, 26-50%, 51-75%, 76-100%) on computer monitors 
that were calibrated using the Spyder2PRO software (v1.0-16, Pantone Colorvision, 
Regensdorf, Switzerland). Dedicated TMA scoring software (v1.14.25.1, 3DHISTECH 
Ltd.,Budapest, Hungary) was used for scoring. Core biopsies were independently 
evaluated by a second investigator, who at time of assessment was unaware of 
clinicopathological information. For facilitating scoring, a chart with visual analogue 
scales of staining patterns was used.
Statistical analysis
Retrospective assessment of the prognostic value was based on methods described 
previously 32. Briefly, in a 500-fold cross-validation procedure an optimal cut-off 
for classifying expression of individual proteins as ‘low’ or ‘high’ was calculated in 
each training set, based on receiver operating characteristic (ROC) curve analysis 
for survival data 41-43. Crude hazard rate ratios (HRRs) for overall survival (OS) 
were calculated in corresponding validation sets using univariate Cox regression 
analysis and multivariate Cox regression analysis, performed by stepwise backward 
regression with p>.1 as exclusion criterion and including the following established 
clinicopathological prognostic variables: primary tumour-to-CRCLM interval < 12 
months, lymph node positivity at time of diagnosis of the primary tumour, maximal 
CRCLM diameter > 5.0 cm, number of CRCLM > 1 and serum CEA level > 200 ng/
ml 3. For each protein, a cross-validated multivariate HRRav was calculated by 
averaging the multivariate HRRs of the validation sets. The proportion of HRRs in 
the validation sets that demonstrated a reversed effect compared to the cross-
validated HRRav was calculated (i.e. P(HRR>1) or P(HRR<1)). Per candidate biomarker, 
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either the intensity or the frequency immunohistochemistry score with maximum 
deviation from HRRav=1 was selected for further analysis  (Supplementary Table S2). 
Classification and Regression Tree (CART) analysis was used to select the optimal 
prognostic subset of biomarkers from the total set of biomarkers 44. Essentially, 
this is the subset of biomarkers that gives the lowest misclassification error rate for 
three-year survival in a 10-fold cross-validation procedure. Excluded from survival 
analyses were patients with unknown or less than two months survival, patients 
of whom no survival data was available at three years after CRCLM resection or 
when tissue cores were non-evaluable for technical reasons. Overall survival was 
visualized using Kaplan-Meier curves and an uncorrected p-value was calculated 
using logrank testing. Patients with missing scores for the biomarkers of the final 
CART tree were also excluded from these analyses. Subsequently, Cox regression 
analysis was used to obtain a HRR for each CART class compared to the class with 
the highest survival . CART classes were grouped based on similarity of HRRs45. To 
calculate the p-value for the association between class and survival in absence of an 
external validation dataset, we used a correction procedure based on permutation 
analysis of the original dataset. In brief, n=10000 permutation datasets were created 
and for each permutated dataset the optimal classifier and corresponding p-value 
were determined using the procedure as described above. The corrected p-value of 
the CART classifier is the percentage of p-values from the permutated analyses that 
are smaller than the original uncorrected p-value. Analysis of variance (ANOVA) 
was performed to compare the prognostic value of the CART classifier with a 
model based on the clinicopathological variables and a p-value was calculated 
using chisquare testing. Correlation coefficients between protein expression were 
calculated using Pearson’s correlation test. OS was defined as the time in months 
after CRCLM resection until death in a follow-up period of up to 10 years. P values 
were considered significant when <.05. All data reported was REMARK compliant 46. 
Statistical analyses were performed using IBM SPSS Statistics 20.0 software (SPSS 
Inc., Illinois, USA) and R Statistics 14.0 software (RStudio Inc., Boston, USA). All data 
reported was REMARK and TRIPOD compliant 46,47.
RESULTS
Patient characteristics 
Patient characteristics of the study cohort have been described previously and are 
summarized in Supplementary Table S3 32. Cumulative five-year OS after CRCLM 
resection was 41.2% (Supplementary Fig. S1).
Single and combined prognostic value of candidate biomarkers in CRCLM
Our selection of investigated proteins included EGFR, PI3K, AURKA, Ki-67, TK1, 
KCNQ1, IGF2, VEGFA, PDGFRβ, CEA, MMP9, CXCR4, CXCL12, MLH1, MSH6, PTGS2, 
SLC2A1 and HIF1α (Table 1 and Supplementary Fig. S2). After correction for the 
established clinicopathological prognostic variables, high CRCLM expression of 
EGFR (HRRav 1.54; P(HRR<1)=.02), AURKA (HRRav 1.66; P(HRR<1)=.02), VEGFA 
(HRRav 1.50; P(HRR<1)=.02) and PTGS2 (HRRav 1.59; P(HRR<1)=.01) were associated 
with poor prognosis and high expression of SLC2A1 (HRRav 0.65; P(HRR>1)<.01) 
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was associated with good prognosis, as we reported previously (Table 2 and 
Supplementary Fig. S3) 31-33. Although the preset threshold for significance was 
not reached, decreased survival was also suspected for high MMP9 expression 
(HRRav 1.34; P(HRR<1)=.07) and increased survival for high expression of KCNQ1 
(HRRav 0.81; P(HRR>1)=.09), CEA (HRRav 0.63; P(HRR>1)=.05), and HIF1α (HRRav 
0.77; P(HRR>1)=.06), the latter as described previously 33. These nine proteins were 
selected as prognostically most relevant and were combined in the CART analysis. 
The lowest misclassification rate for predicting three-year survival (cross-validated 
error rate 22.5%) was achieved using a classification tree with four classes (Fig. 1), 
based on AURKA, PTGS2 and MMP9 expression in CRCLM (n=201; Supplementary 
Fig. S4A). First, four classes were discerned where class A consisted of patients with 
low AURKA expression in CRCLM, class B of patients with high AURKA, low PTGS2 
and low MMP9 expression, class C of patients with high AURKA, low PTGS2 and 
high MMP9 expression and class D of patients with high AURKA and high PTGS2 
expression. HRRs were calculated for all classes, using class A as reference (Fig. 
1 and Supplementary Fig. S5). Second, classes of patients with similar OS, using 
class A as reference, were grouped in a single class 45. Consequently, classes A 
and B were grouped (HRR<2.0), and classes C and D were grouped (HRR>2.0), 
resulting in class I and class II, respectively. Patient stratification based on these 
two classes was associated with OS (HRR 2.79, corrected p<.001; Fig. 2A). Also 
after multivariate analysis including primary tumour-to-CRCLM interval < 12 months, 
lymph node positivity at time of diagnosis of the primary tumour, maximal CRCLM 
Table 2. Univariate and multivariate average hazard rate ratios of the investigated candidate biomarkers 
 univariate  multivariate 
Biomarker HRRav P(HRR<1) P(HRR>1)  HRRav P(HRR<1) P(HRR>1) 
EGFR 31 1.47     .03 *   1.54     .02 *  
PI3K 0.88  .20  0.80  .20 
AURKA 32 1.57     .02 *   1.66     .02 *  
Ki-67 1.15  .21   1.17 .20  
TK1 1.22  .26   1.31 .23  
KCNQ1 0.81  .09  0.81  .09 
IGF2 0.97  .39  0.96  .37 
VEGFA 33 1.48     .02 *   1.50     .02 *  
PDGFRβ 1.13  .29   1.10 .35  
CEA 0.68  .06  0.63  .05 
MMP9 1.29  .08   1.34 .07  
CXCR4 0.94  .33  0.91  .25 
CXCL12 0.90  .23  0.93  .31 
MLH1 1.16  .23   1.17  .21  
MSH6 0.81  .11  0.82  .13 
PTGS2 31 1.63    <.01 *   1.59      .01 *  
SLC2A1 33 0.67    <.01 *  0.65    <.01 * 
HIF1α 33 0.80  .06  0.77  .06 
HRRav: average hazard rate ratio; P(HRR<1): proportion of HRRs with HRR<1; P(HRR>1): proportion of HRRs with HRR>1 
* P(HRR<1) or P(HRR>1) < .05 
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diameter > 5.0 cm, number of CRCLM > 1 and serum CEA level > 200 ng/ml as 
established clinicopathological prognostic variables, classes I and II were associated 
with OS (HRR 3.57, corrected p<.001). As a prognostic model, the classifier based 
on AURKA, PTGS2 and MMP9 expression was superior to a model only based on the 
established clinicopathological progostic variables (p=.001).
We further evaluated the prognostic value of this classifier after stratifying 
patients for systemic therapy. In patients not treated with systemic therapy, the 
classifier was predictive of poor outcome after CRCLM resection (HRR 3.48, 
corrected p<.01; Fig. 3A). In patients treated with systemic therapy the classifier 
lacked prognostic value (HRR 2.16, corrected p=.25; Fig. 3B). Similarly, we evaluated 
the prognostic value of the classifier in patients with CRCLM originating from colon 
cancer and rectal cancer separately. This revealed that particularly in colon cancer 
patients the classifier was associated with survival (HRR 5.71, corrected p<.001; Fig. 
3C), whereas in rectal cancer patients it was not (HRR 1.95, corrected p=.36; Fig. 
3D).
AURKA expression
PTGS2 expression Class A (n=154)
HRR 1.00
Class B (n=14)
HRR 1.18, p=.60
Class C (n=14)
HRR 2.54, p<.01
Class D (n=19)
HRR 3.08, p<.01
lowhigh
lowhigh
lowhigh
Class II
(n=33)
Class I
(n=168)
MMP9 expression
Figure 1. Classification tree resulting from the Classification and Regression Tree (CART) 
analysis including the nine prognostically most relevant proteins in our study cohort (i.e. EGFR, 
AURKA, VEGFA, PTGS2, SLC2A1, KCNQ1, CEA, MMP9 and HIF1α). The optimal prediction of 
three-year survival was obtained by a classification tree including AURKA, PTGS2 and MMP9 
expression. Class A contained patients with low AURKA expression, class B patients with high 
AURKA, low PTGS2 and low MMP9 expression, class C patients with high AURKA, low PTGS2 
and high MMP9 expression and class D patients with high AURKA and high PTGS2 expression. 
Based on the HRRs of the individual classes, classes A and B were grouped and classes C and 
D were grouped, resulting in classes I and II, respectively. Excluded from analysis were patients 
of whom no data was available on survival status or three-year survival and with unknown 
expression of AURKA, PTGS2 and MMP9. HRR: hazard rate ratio, p: p-value as determined by 
Cox regression analysis.
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Candidate biomarker expression in primary CRC
Primary CRC tissue specimens are often more readily available for pathological 
examination than CRCLM tissue specimens. Therefore, we compared candidate 
biomarker expression between primary CRC and corresponding CRCLM and 
assessed the prognostic value of the classifi er in primary CRC. For 12 out of 18 
candidate biomarkers (67%), expression in primary CRC and corresponding CRCLM 
was positively correlated (r=0.20-0.39; Table 3). Next, we investigated whether the 
classifi er could be applied to predict survival according to biomarker expression 
levels in the primary tumour (n=81; Supplementary Fig. S4B). Based on these 
expression levels, a survival difference was observed between class I and class II 
patients (HRR 2.11, corrected p=.09; Fig. 2B), however, the threshold for signifi cance 
was not reached. MMP9 expression was not correlated between matched primary 
CRC and CRCLM pairs (Table 3).  Omitting MMP9 resulted in a classifi er based on 
AURKA expression only. Classifi cation of patients based on AURKA expression in 
the primary tumour alone, demonstrated that high AURKA expression in the primary 
tumour was associated with decreased survival (HRR 2.59, corrected p=.04).
DISCUSSION  
In a population of CRC patients with resectable liver metastasis, we investigated 
the prognostic value of 18 proteins, which are commonly associated with CRC(LM) 
carcinogenesis. We have previously demonstrated that, individually, expression 
levels of EGFR, AURKA, VEGFA, PTGS2 and SLC2A1 are associated with prognosis 
in CRCLM patients undergoing surgical resection 31-33. In addition, using a similar 
cross-validation procedure, here we indicated that also expression of MMP9, CEA 
Figure 2. Kaplan-Meier graphs depicting OS in months, stratifi ed by the classes resulting from 
the CART and Cox regression analyses, based on expression in (A) CRCLM and (B) primary 
CRC. The p-value is the corrected p-value as determined by permutation analysis. Excluded 
from analyses were patients with unknown or less than two months survival and with unknown 
expression of AURKA, PTGS2 and MMP9.
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and KCNQ1 showed a survival difference, comparable to HIF1α 33, although for these 
proteins the threshold for signifi cance was not reached. We combined expression of 
these nine proteins in a CART analysis and found that the combination of AURKA, 
PTGS2 and MMP9 expression in CRCLM provided the best prediction of three-
year survival after CRCLM resection. Survival was highest for patients with low 
AURKA expression and for patients with high AURKA expression, but low PTGS2 
and low MMP9 expression (class I). Survival was poorest for patients with both 
high AURKA and high PTGS2 expression, and for patients with high AURKA but 
low PTGS2 and high MMP9 expression (class II). After correction for the standard 
clinicopathological prognostic variables in a multivariate analysis, the biomarker-
Figure 3. Kaplan-Meier graphs depicting OS in months of (A) patients in which liver metastases 
were not treated with systemic therapy, (B) patients in which liver metastases were treated with 
systemic therapy, (C) colon cancer patients, and (D) rectal cancer patients, stratifi ed by the 
classes as identifi ed using the Classifi cation and Regression Trees (CART) analysis. Excluded 
from analysis were patients with unknown or less than two months survival, unknown systemic 
therapy or primary tumour localization and with unknown expression of AURKA, PTGS2 and 
MMP9. The p-value is the corrected p-value as determined by permutation analysis.
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based classifier was retained as 
independent prognostic parameter 
for CRCLM patients, with improved 
prognostic value compared to the 
established clinicopathological 
prognostic parameters and stronger 
than when using individual proteins 
31-33.
When stratifying CRCLM 
patients by location of the primary 
tumour in the large intestine, it turned 
out that the classifier performed well 
in patients with liver metastases 
originating from colon cancer, 
but not from rectal cancer. This 
may be explained by the different 
functional roles of the proteins of 
the classification system in colon 
and rectum, e.g. such as has been 
indicated for MMP9 48. In patients 
treated with systemic therapy, the 
classifier also lacked prognostic 
value, which may suggest that 
commonly applied systemic therapy 
regimens improve the survival of 
patients with high expression of 
AURKA, PTGS2 and MMP9 (Class 
II). Accordingly, patients with poor 
prognosis based on this classifier, may benefit from systemic therapy in addition 
to liver resection. More likely, however, survival of patients in class I is decreased 
in this subgroup compared to class I patients in the subgroup not treated with 
systemic therapy. This may reflect a more elaborate metastatic dissemination – 
often leading to the addition of systemic treatment to surgery alone in order to 
improve resectability or remove remnant CRCLM – and a high number of CRCLM 
has frequently been associated with decreased OS 3-6. It should be noted, however, 
that these patient subgroups may be too small to draw firm conclusions from.  
Remarkably, for the majority of candidate biomarkers (67%) expression was 
positively correlated between the primary tumour and corresponding CRCLM. 
These findings are consistent with the common postulate that in CRC molecular 
alterations acquired during early tumour development are likely to be present also 
in the metastases 13,14. As such, this may indicate that to a certain extent expression 
in patient-matched CRCLM could be predicted from expression levels in the 
primary tumour. However, further investigation is required to determine the clinical 
applicability of such correlations. The classifier could not be applied to predict 
survival based on expression of AURKA, PTGS2 and MMP9 in the primary tumour. 
Interestingly, when using AURKA expression only, the survival difference was 
significant. As such, AURKA expression levels in the primary tumour are indicative 
 
Table 3. Correlation between candidate 
biomarker expression in primary CRC and 
patient-matched CRCLM, as calculated using 
Pearson’s correlation test 
Biomarker r p-value 
EGFR  0.03 .77 
PI3K 0.24  <.01 * 
AURKA 0.34  <.01 * 
Ki-67 0.24  <.01 * 
TK1 0.13 .11 
KCNQ1 0.34  <.01 * 
IGF2 0.27  <.01 * 
VEGFA  -0.03 .74 
PDGFRβ 0.31  <.01 * 
CEA 0.20    .01 * 
MMP9 -0.04 .68 
CXCR4 0.20    .01 * 
CXCL12 0.39  <.01 * 
MLH1 0.34  <.01 * 
MSH6 0.21   .02 * 
PTGS2  0.20  <.01 * 
SLC2A1  0.16 .05 
HIF1α  -0.03 .68 
r: Pearson’s correlation coefficient 
* p-value < .05 
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of prognosis for patients with resectable CRCLM. 
Selecting the nine prognostically most relevant biomarkers for CART 
analysis may introduce a minor selection bias. However, as only 18 biomarkers were 
investigated here, this selection effect will be minimal. To avoid overestimation of 
the prognostic effect of the classifier, we corrected the reported P values using 
a series of permutated datasets. Similar correction of the HRRs requires complex 
methodology and, therefore, the HRRs reported in this study may be somewhat 
overestimated. Nevertheless, the survival difference indicated by the classifier is 
significant, as demonstrated by the corrected P values. To confirm the prognostic 
value of the biomarker-based classifier, external validation of the results is desirable. 
In conclusion, we identified and validated a number of proteins with prognostic 
value based on protein expression in CRCLM and combined these in a classifier 
which could be used to predict survival after CRCLM resection. Individually, but also 
combined, these proteins may add value to existing clinicopathological risk scores, 
by taking into account biological information which is neglected by the standard 
clinicopathological prognostic variables in current clinical practice. Resection of 
the CRCLM, possibly in combination with RFA, will remain the preferred treatment 
option, regardless of the biological profile of the CRCLM. However, such a classifier 
may aid in selecting patients who may benefit from adjuvant systemic therapy. As 
such, adding such a biomarker-based classifier to the standard clinicopathological 
parameters for stratification of patients may contribute to improving survival after 
CRCLM resection.
ACKNOWLEDGEMENTS
Funding was supported by the Center for Translational Molecular Medicine, DeCoDe 
project (grant 03O-101). 
REFERENCES
1.  Ferlay J, Soerjomataram I, Ervik M et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality 
Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 
2013.
2.  Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. 
Ann Surg 1979; 189:496-502.
3.  Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for 
metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-318.
4.  Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to 
the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association 
Francaise de Chirurgie. Cancer 1996; 77:1254-1262.
5.  Rees M, Tekkis PP, Welsh FKS et al. Evaluation of long-term survival after hepatic resection for 
metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247:125-135.
6.  Yamaguchi T, Mori T, Takahashi K et al. A new classification system for liver metastases from 
colorectal cancer in Japanese multicenter analysis. Hepatogastroenterology 2008; 55:173-178.
7.  Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer. Lancet 2010; 375:1030-1047.
8.  Leporrier J, Maurel J, Chiche L et al. A population-based study of the incidence, management and 
prognosis of hepatic metastases from colorectal cancer. Br J Surg 2006; 93:465-474.
9.  Ruers TJM, Wiering B, van der Sijp JRM et al. Improved selection of patients for hepatic surgery of 
colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 2009; 50:1036-1041.
10.  Spelt L, Andersson B, Nilsson J et al. Prognostic models for outcome following liver resection for 
colorectal cancer metastases: A systematic review. Eur J Surg Oncol 2012; 38:16-24.
11.  Kanas GP, Taylor A, Primrose JN et al. Survival after liver resection in metastatic colorectal cancer: 
5111
A prognostic classifier 
review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4:283-301.
12.  Spolverato G, Ejaz A, Azad N et al. Surgery for colorectal liver metastases: The evolution of determining 
prognosis. World J Gastrointest Oncol 2013; 5:207-221.
13.  Knijn N, Mekenkamp LJM, Klomp M et al. KRAS mutation analysis: a comparison between primary 
tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104:1020-
1026.
14.  Stange DE, Engel F, Longerich T et al. Expression of an ASCL2 related stem cell signature and IGF2 in 
colorectal cancer liver metastases with 11p15.5 gain. Gut 2010; 59:1236-1244.
15.  Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
16.  Spano JP, Fagard R, Soria JC et al. Epidermal growth factor receptor signaling in colorectal cancer: 
preclinical data and therapeutic perspectives. Ann Oncol 2005; 16:189-194.
17.  Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev 
Cancer 2009; 9:550-562.
18.  Carvalho B, Postma C, Mongera S et al. Multiple putative oncogenes at the chromosome 20q amplicon 
contribute to colorectal adenoma to carcinoma progression. Gut 2009; 58:79-89.
19.  Sillars-Hardebol AH, Carvalho B, de Wit M et al. Identification of key genes for carcinogenic pathways 
associated with colorectal adenoma-to-carcinoma progression. Tumour Biol 2010; 31:89-96.
20.  Neal CP, Garcea G, Doucas H et al. Molecular prognostic markers in resectable colorectal liver 
metastases: a systematic review. Eur J Cancer 2006; 42:1728-1743.
21.  Wu J, Mao Y, He L et al. A new cell proliferating marker: cytosolic thymidine kinase as compared to 
proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res 2000; 20:4815-
4820.
22.  Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a 
review. World J Gastroenterol 2013; 19:5051-5060.
23.  Wehler TC, Frerichs K, Graf C et al. PDGFRalpha/beta expression correlates with the metastatic 
behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. Oncol 
Rep 2008; 19:697-704.
24.  Kokkonen N, Ulibarri IF, Kauppila A et al. Hypoxia upregulates carcinoembryonic antigen expression 
in cancer cells. Int J Cancer 2007; 121:2443-2450.
25.  Emara M, Cheung PY, Grabowski K et al. Serum levels of matrix metalloproteinase-2 and -9 and 
conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers. Clin 
Chem Lab Med 2009; 47:993-1000.
26.  Koizumi K, Hojo S, Akashi T et al. Chemokine receptors in cancer metastasis and cancer cell-derived 
chemokines in host immune response. Cancer Sci 2007; 98:1652-1658.
27.  Yamamoto H, Adachi Y, Taniguchi H et al. Interrelationship between microsatellite instability and 
microRNA in gastrointestinal cancer. World J Gastroenterol 2012; 18:2745-2755.
28.  Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1 and -2 in human colorectal 
cancer. Cancer Res 1995; 55:3785-3789.
29.  de Wit M, Jimenez CR, Carvalho B et al. Cell surface proteomics identifies glucose transporter type 
1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut 
2012; 61:855-864.
30.  Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 
2007; 22:559-572.
31.  Goos JACM, Hiemstra AC, Coupe VMH et al. Epidermal growth factor receptor (EGFR) and 
prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with 
resected colorectal cancer liver metastases. Br J Cancer 2014; 111:749-755.
32.  Goos JACM, Coupe VMH, Diosdado B et al. Aurora kinase A (AURKA) expression in colorectal cancer 
liver metastasis is associated with poor prognosis. Br J Cancer 2013; 109:2445-2452.
33.  Goos JACM, Cuba EMV, Coupé VMH et al. Glucose transporter 1 (SLC2A1) and vascular endothelial 
growth factor A (VEGFA) predict survival after resection of colorectal cancer liver metastasis. Ann 
Surg 2014; In press.
34.   Ingenuity Pathway Analysis (www.ingenuity.com). QIAGEN group 2014.
35.  Sillars-Hardebol AH, Carvalho B, Tijssen M et al. TPX2 and AURKA promote 20q amplicon-driven 
colorectal adenoma to carcinoma progression. Gut 2012; 61:1568-1575.
36.  Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch 
during carcinogenesis. Nat Cell Biol 2000; 2:737-744.
37.  Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16:2927-
2931.
38.  Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 
2010; 16:5928-5935.
39.  Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and 
radiotherapy response. Nat Rev Cancer 2008; 8:425-437.
40.  Stichting FMWV Rotterdam. Code Goed Gebruik van lichaamsmateriaal. Rotterdam: Stichting FMWV 
Rotterdam; 2011.
41.  Zlobec I, Steele R, Terracciano L et al. Selecting immunohistochemical cut-off scores for novel 
biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007; 60:1112-1116.
42.  Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a 
112
Chapter 5
diagnostic marker. Biometrics 2000; 56:337-344.
43.  Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61:92-
105.
44.  Breiman L, Friedman JH, Olshen RA et al.  Classification and regression trees. Boca Raton: Chapman 
& Hall; 1984.
45.  Chen J, Pande M, Huang YJ et al. Cell cycle-related genes as modifiers of age of onset of colorectal 
cancer in Lynch syndrome: a large-scale study in non-Hispanic white patients. Carcinogenesis 2013; 
34:299-306.
46.  McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic 
studies. J Clin Oncol 2005; 23:9067-9072.
47.  Collins GS, Reitsma JB, Altman DG et al. Transparent Reporting of a multivariable prediction model 
for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015; 162:55-
63.
48.  Roeb E, Dietrich CG, Winograd R et al. Activity and cellular origin of gelatinases in patients with colon 
and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer 2001; 92:2680-2691.
5113
A prognostic classifier 
SUPPLEMENTARY DATA  
 
Supplementary Table S1. Immunohistochemical staining protocols 
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EGFR        mouse mAb 1:25, 15min, RT 
Novocastra 
Laboratories  
(Newcastle, UK) 
Bond TM Epitope Retrieval 
Reagent 2 
microwave 
NDS 
A431  
cells 
PI3K   rabbit pAb 1:200, O/N, 4°C 
Atlas Antibodies 
(Stockholm, Sweden) 
10 mM citric acid (pH 6) 
microwave EV 
Caco2 
cells 
AURKA       mouse mAb 1:50, O/N, 4°C 
Novocastra 
Laboratories  
(Newcastle, UK) 
10 mM citric acid (pH 6)  
autoclave 
EV Caco2 
cells 
Ki-67 mouse mAb 1:200, 60min, RT 
Dako 
(Glostrup, Denmark) 
Bond TM Epitope Retrieval 
Reagent 2 
microwave 
NDS tonsil 
TK1   mouse mAb 1:100, 60min, RT Abnova 
(Taipei City, Taiwan) 
10 mM citric acid (pH 6) 
microwave 
PV Caco2 
cells 
KCNQ1  rabbit pAb 1:200, O/N, 4°C 
Santa Cruz 
Biotechnology 
(Dallas, USA) 
10 mM citric acid (pH 6) 
microwave 
EV colon 
IGF2  rabbit pAb 1:500, O/N, 4°C Atlas Antibodies (Stockholm, Sweden) 
10 mM citric acid (pH 6) 
microwave EV 
Caco2 
cells 
VEGFA       mouse mAb 1:50, O/N, 4°C DakoCytomation 
(Glostrup, Denmark) 
10 mM citric acid (pH 6) 
microwave 
PV Caco2 
cells 
PDGFRβ  rabbit mAb 1:50, O/N, 4°C 
Cell Signaling 
Technology 
(Boston, USA) 
10 mM citric acid (pH 6) 
autoclave 
PV kidney 
CEA  mouse mAb 1:200, 60min, RT Biogenex Laboratories (Fremont, USA) 
Target Retrieval Solution 
microwave EV colon 
MMP9   rabbit pAb 1:500, O/N, 4°C 
Thermo Scientific 
(Middletown, USA) 
10 mM citric acid (pH 6) 
microwave EV placenta 
CXCR4 rabbit pAb 1:1000, O/N, 4°C Novus Biologicals (Littleton, USA) 
10 mM citric acid (pH 6) 
microwave EV lung 
CXCL12  mouse mAb 1:400, O/N, 4°C R&D Systems 
(Minneapolis, USA) 
10 mM citric acid (pH 6) 
microwave 
EV Caco2 
cells 
MLH1  mouse mAb 1:50, 60min, RT BD Biosciences (San Diego, USA) 
Target Retrieval Solution 
microwave EV colon 
MSH6 mouse mAb 1:100, 60min, RT BD Biosciences 
(San Diego, USA) 
Target Retrieval Solution 
microwave 
EV colon 
PTGS2 rabbit pAb 1:200, 60min, RT 
Atlas Antibodies 
(Stockholm, Sweden) 
10 mM citric acid (pH 6) 
microwave EV 
Caco2 
cells 
SLC2A1 rabbit pAb 1:600, 60min, RT Abcam 
(Cambridge, UK) 
10 mM citric acid (pH 6) 
water bath 
EV Caco2 
cells 
HIF1α mouse mAb 1:500, 30min, RT 
BD Biosciences 
(San Diego, USA) 
Target Retrieval Solution 
water bath CSA 
renal cell 
carcinoma 
* Control tissues and cells were formalin-fixed paraffin embedded 
mAb: monoclonal antibody; pAb: polyclonal antibody; O/N: overnight; RT: room temperature; EV: Envision Plus (Dako, Glostrup, 
Denmark); PV: Powervision (Dako, Glostrup, Denmark); NDS: Novocastra Detection System (Novocastra Laboratories, Newcastle, UK); 
CSA: Catalyzed Signal Amplification system (Dako, Glostrup, Denmark) 
  
114
Chapter 5
 
Supplementary Table S2. Immunohistochemistry scores with maximum 
deviation from HRRav=1 
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EGFR      X     
PI3K       X    
AURKA    X       
Ki-67        X   
TK1        X   
KCNQ1 X          
IGF2    X       
VEGFA  X         
PDGFRβ          X 
CEA X          
MMP9       X    
CXCR4    X       
CXCL12 X          
MLH1        X   
MSH6        X   
PTGS2   X        
SLC2A1 X          
HIF1α        X   
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Supplementary Table S3. Patient characteristics 32  
  
Clinicopathological variable 
Total Population   
  
Clinicopathological variable 
   Total Population  
n 
/ mean 
/ median 
% 
/ st.dev. 
/ range   
n 
/ mean 
/ median 
% 
/ st.dev. 
/ range 
 
General characteristics     Liver metastasis characteristics      
All 507    Age at liver resection      
Gender       mean (st.dev.) 63.3 0.5  
  male (%) 320 63.1     median (range) 64.3 27.6-83.9  
  female (%) 187 36.9   Synchronous liver metastasis Δ    
OS after liver resection in months     yes (%) Δ 221 43.6  
  mean (st.dev.) 37.2 1.7     no (%) Δ 261 51.5  
  median (range) 27 3.0-212.0     unknown (%) Δ 25 4.9  
       Distribution liver metastases    
          left half 90 17.8  
Primary CRC characteristics            segment 1 (%) 18 3.6  
Age at primary CRC resection            segment 2 (%) 116 22.9  
  mean (st.dev.) 61.9 0.5          segment 3 (%) 135 26.6  
  median (range) 62.8 24.4-83.3          segment 4 (%) 134 26.4  
Primary tumor location       right half 259 51.0  
  left colon (%) 245 48.3          segment 5 (%) 171 33.7  
  right colon (%) 95 18.7          segment 6 (%) 212 41.8  
  rectum (%) 151 29.8          segment 7 (%) 211 41.6  
  unknown (%) 16 3.2          segment 8 (%) 182 35.9  
Histological grade       both left and right half 146 28.8  
  poorly differentiated (%) 38 7.5     unknown 12 2.4  
  moderately differentiated (%) 288 56.8   Maximal CRCLM diameter in cm Δ    
  well-differentiated (%) 14 2.8     mean (st.dev.) 4.1 0.1  
  unknown (%) 167 32.9     median (range) 3.5 0.2-22.0  
Maximal CRC diameter in cm       maximal diameter ≤ 5.0 cm (%) Δ 372 73.4  
  mean (st.dev.) 4.4 0.1     maximal diameter > 5.0 cm (%) Δ 126 24.8  
  median (range) 4 0.2-12.0     maximal diameter unknown (%) Δ 9 1.8  
Positive lymph nodes detected Δ     Number of CRCLM Δ    
  yes (%) Δ 190 37.5     mean (st.dev.) 2 0.1  
  no (%) Δ 154 30.4     median (range) 2 1-12  
  unknown (%) Δ 163 32.1     nr of CRCLM = 1 (%) Δ 248 48.9  
Systemic treatment of primary CRC       nr of CRCLM > 1 (%) Δ 253 49.9  
  colon cancer         nr of CRCLM unknown (%) Δ 6 1.2  
     preoperative (%) 9 2.6   Serum CEA level Δ    
     perioperative (%) 0 0     mean (st.dev.) 101.6 38.5  
     postoperative (%) 91 26.8     median (range) 15 0.5-6625.0  
     none (%) 226 66.5     serum CEA level ≤ 200 ng/ml (%) Δ 166 32.7  
     unknown (%) 14 4.1     serum CEA level > 200 ng/ml (%) Δ 13 2.6  
  rectal cancer       serum CEA level unknown (%) Δ 328 64.7  
     preoperative (%) 25 16.5   Extrahepatic metastases    
     perioperative (%) 1 0.7     yes (%) 36 7.1  
     postoperative (%) 24 15.9     no (%) 423 83.4  
     none (%) 98 64.9     unknown (%) 48 9.5  
     unknown (%) 3 2   Resection in combination with RFA  
 primary tumor location unknown        yes (%) 109 21.5  
     preoperative (%) 1 6.3     no (%) 357 70.4  
     perioperative (%) 0 0.0     unknown (%) 41 8.1  
     postoperative (%) 1 6.3   Systemic treatment of liver metastases  
     none (%) 12 75.0    preoperative (%) 60 11.8  
    unknown (%) 2 12.5    perioperative (%) 12 2.4  
Radiotherapeutic treatment of primary CRC    postoperative (%) 97 19.1  
 yes (%) 113 22.3    none (%) 321 63.3  
 no (%) 392 77.3    unknown (%) 17 3.4  
 unknown (%) 2 0.4       
OS: overall survival; CEA: carcino-embryonic antigen; RFA: radiofrequency ablation; Δ Clinical risk score variable 3  
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Supplementary Figure S1. Kaplan-Meier graph depicting OS in months of the total study 
population. Patients with OS less than 2 months and unknown outcome or time of OS were 
removed from analysis 32.
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Supplementary Figure S2. Staining examples of candidate biomarker expression in CRCLM. 
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Supplementary Figure S3. Distribution of the cross-validated HRRs after univariate and 
multivariate analysis of candidate biomarker expression with OS as outcome.
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Supplementary Figure S4. Flow diagram of patients in the Classification and Regression Trees 
(CART) and/or survival analysis using (A) patients of whom CRCLM tissue was available and 
(B) patients of whom both CRCLM and primary tumour tissue was available.
CRC patients having had liver resection between 1990 
and 2010 (n=507)
Patients with unknown AURKA scores (n=32)
Patients with OS < 2 months, unknown three-
year survival or unknown outcome (n=243)
CRCLM patients available for CART and survival analyses 
(n=201)
Patients with unknown PTGS2 scores (n=12)
Patients with unknown MMP9 scores (n=19)
Matching tissue samples of primary CRC and CRCLM 
(n=234)
Patients with unknown AURKA scores (n=24)
Patients with OS < 2 months or unknown 
outcome (n=125)
Patients available for survival analysis (n=81)
Patients with unknown PTGS2 scores (n=1)
Patients with unknown MMP9 scores (n=3)
CRC patients having had liver resection between 1990 
and 2010 (n=507)
Patients from whom no primary CRC tissue 
was available (n=273)
B
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Supplementary Figure S5. Kaplan-Meier graph depicting OS in months, stratified by the four 
classes resulting from the CART analysis, based on expression in CRCLM. The p-value is the 
corrected p-value as determined by permutation analysis. Excluded from the analysis were 
patients with unknown or less than two months survival and with unknown expression of 
AURKA, PTGS2 and MMP9.
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ABSTRACT
Background
Survival of patients after resection of colorectal cancer liver metastasis (CRCLM) is 
less than 30%. Positron emission tomography (PET) tracers, imaging the expression 
of prognostic biomarkers, may contribute to assign appropriate management to 
individual patients. Aurora kinase A (AURKA) expression is associated with survival 
of patients after CRCLM resection. 
Methods
We synthesized [3H]alisertib and [11C]alisertib, starting from [3H]methyl nosylate 
and [11C]methyl iodide, respectively. We measured in vitro uptake of [3H]alisertib in 
cancer cells with high (Caco2), moderate (A431, HCT116, SW480) and low (MKN45) 
AURKA expression, before and after siRNA-mediated AURKA downmodulation, as 
well as after inhibition of P-glycoprotein (P-gp) activity. We measured in vivo uptake 
and biodistribution of [11C]alisertib in nude mice, xenografted with A431, HCT116 or 
MKN45 cells, or P-gp knockout mice. 
Results
[3H]Alisertib was synthesized with an overall yield of 42% and [11C]alisertib with an 
overall yield of 23±9% (radiochemical purity ≥99%). Uptake of [3H]alisertib in Caco2 
cells was higher than in A431 cells (P=.02) and higher than in SW480, HCT116 and 
MKN45 cells (P<.01). Uptake in A431 cells was higher than in SW480, HCT116 and 
MKN45 cells (P<.01). Downmodulation of AURKA expression reduced [3H]alisertib 
uptake in Caco2 cells (P<.01). P-gp inhibition increased [3H]alisertib uptake in Caco2 
(P<.01) and MKN45 (P<.01) cells. In vivo stability of [11C]alisertib 90 minutes post-
injection was 94.7±1.3% and tumour-to-background ratios were 2.3±0.8 (A431), 
1.6±0.5 (HCT116) and 1.9±0.5 (MKN45). In brains of P-gp knockout mice [11C]alisertib 
uptake was increased compared to uptake in wild-type mice (P<.01).
Conclusions
Radiolabelled alisertib can be synthesized and used for the imaging of AURKA in 
cells with high AURKA expression levels. The exact mechanisms underlying alisertib 
accumulation in cancer cells need further investigation. 
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INTRODUCTION 
Globally, colorectal cancer (CRC) is diagnosed in approximately 1.4 million people 
every year, of whom 50% will die as a consequence of metastatic dissemination 1. The 
majority of patients with disseminated disease suffer from hepatic metastases and 
the preferred treatment is surgery 2. Selection of patients with CRC liver metastasis 
(CRCLM) for resection using [18F]FDG PET could significantly reduce the number 
of futile surgeries, but still five-year survival of these patients does not exceed 
30% 3. Since morbidity and mortality of surgery is considerable, better prognostic 
biomarkers are needed to aid clinicians with selecting the appropriate treatment for 
these patients 3,4. 
Aurora kinase A (AURKA) expression is involved in spindle formation and 
chromosome segregation 5. We have demonstrated that in CRC AURKA is a driver 
of 20q gain-associated adenoma-to-carcinoma progression and that high AURKA 
protein expression is associated with poor prognosis in advanced CRC 6-8. An 
inhibitor that specifically inhibits AURKA is alisertib (MLN8237), which has been 
demonstrated to induce mitotic defects and apoptosis of tumour cells in preclinical 
models. Its potential utility as cancer treatment is currently being investigated in 
clinical trials 5,9,10. Molecular imaging of AURKA expression may add value to current 
patient selection protocols for treatment. In this study, we describe the development 
and preclinical evaluation of radiolabelled alisertib as a tracer for the molecular 
imaging of AURKA expression.  
MATERIALS AND METHODS
General 
Chemicals were obtained from Sigma-Aldrich (Saint Louis, USA) and were used 
without further purification. t-Butyl protected desmetyl alisertib (compound 1) 
and alisertib were kindly provided by Millennium pharmaceuticals (Cambridge, 
USA). [11C]CO2 was produced by an IBA Cyclone 18/9 cyclotron (Louvain-la-
Neuve, Belgium) and [11C]methyl iodide was produced as described previously 11. 
Electrospray ionization mass spectrometry (ESI-MS) was performed using a Bruker 
microTOF-Q instrument (Billerica, USA) in positive ion mode (capillary potential 
of 4500 V). Preparative high-performance liquid chromatography (HPLC) was 
performed on a Luna C18 column (10x250 mm, 5 μm; Phenomenex, Utrecht, The 
Netherlands), using acetonitrile/water/trifluoroacetic acid (45/55/0.1 v/v/v) at 
flow rate 4 mL⋅min-1 and wavelength 254 nm (method A). Analytical HPLC was 
performed on a Luna C18HL column (5x250 mm, 5 μm; Phenomenex, Utrecht, The 
Netherlands), using acetonitrile/water/trifluoroacetic acid (60/40/0.1 v/v/v) at 
flow rate 1 mL⋅min-1 and wavelength 254 nm (method B). Metabolite analysis was 
performed on a Gemini C18 column (10x250 mm, 5μm; Phenomenex, Utrecht, The 
Netherlands) using acetonitrile/water/trifluoroacetic acid (80/20/0.1-30/70/0.1 in 
6 minutes, 30/70/0.1 for 6 minutes, 30/70/0.1-80/20/0.1 in 0.5 minutes, 80/20/0.1 
for 2.5 minutes v/v/v) at flow rate 3 mL⋅min-1 and wavelength 254 nm (method 
C). Sep-pak cartridges were obtained from Waters (Etten-Leur, The Netherlands) 
and the Millex GV filter from Millipore (Amsterdam, The Netherlands). Uptake 
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activity was measured using the 1219 Rackbeta Liquid Scintillation Counter of LKB 
Wallac (Stockholm, Sweden). Quantitative reverse transcription polymerase chain 
reactions (qRT-PCR) were performed in a 7500 Real-time PCR System (Applied 
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Polyvinylidene fluoride 
(PVDF) membranes were imaged using the Odyssey infrared imaging system (LI-
COR, Lincoln, USA).Animal PET imaging was performed using a LSO/LYSO layer 
High Resolution Research Tomograph (HRRT; Siemens/CTI, Knoxville, TN, USA) and 
image data were analyzed using Amide 0.9 12.
Synthesis of [3H]alisertib
[3H]Methyl nosylate (30 MBq) in 40 μl hexane was heated to 80°C for 10 minutes 
under argon flow. The temperature was decreased to 60°C and 1.0 mg (1.9 μmol) of 
compound 1 in 500 μl dimethyl sulfoxide (DMSO) and 2 μl of 5M sodium hydroxide 
in water was added. After 20 minutes, 100 μl of 1M HCl in water was added and 
the temperature was increased to 100°C for 10 minutes. The reaction mixture was 
cooled to 20°C, quenched with 0.5 mL of water and purified using HPLC (method 
A). The fraction containing [3H]alisertib was collected and diluted with 16 mL of 
water. [3H]Alisertib was trapped using a C18 Sep-Pak, which was rinsed with 10 mL 
of water, before eluting the product with 1.5 mL of ethanol. Radiochemical purity 
of the product (retention time 6-8 minutes) was determined by HPLC (method B). 
Unlabelled alisertib was used as reference.
Synthesis of [11C]alisertib
The production of [11C]methyl iodide has been described previously 11. [11C]Methyl 
iodide was added to a solution of 500 μL DMSO containing 1.0 mg (1.9 μmol) of 
compound 1 and 2 μl of 5M sodium hydroxide in water. The temperature was raised 
to 85°C for 5 minutes, 100 μl 1M HCl in water was added and the temperature was 
further increased to 100°C for 7 minutes. The reaction mixture was cooled to 20°C 
and quenched with 0.5 mL of water. This mixture was purified as described above 
(HPLC method A, retention time 11-12 minutes). The product was eluted from the 
Figure 1. Synthesis of radiolabelled alisertib. i: (2a) [3H]methyl nosylate, NaOH, DMSO, 20 
minutes, 60°C; (2b) [11C]methyl iodide, NaOH, DMSO, 5 minutes, 85°C. ii: (3a) HCl, water, 10 
minutes, 100°C; (3b) HCl, water, 7 minutes, 100°C.
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C18 Sep-pak with 1 mL of sterile ethanol, to which 9 mL of sterile and pyrogen-free 
7.09 mM NaH2PO4 in saline was added. The formulation mixture containing [
11C]
alisertib was passed over a Millex GV filter. Radiochemical purity of the product was 
determined by HPLC (method B, retention time 9-10 minutes). Unlabelled alisertib 
was used as reference.
Cell culture and in vitro evaluation 
Colorectal cancer HCT116 and SW480 cells, epidermoid skin cancer A431 cells and 
gastric cancer MKN45 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen, Bleiswijk, The Netherlands) containing 10% fetal bovine serum 
(FBS; Perbio Science, Etten-Leur, The Netherlands). Colorectal cancer Caco2 cells 
were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640; Invitrogen, 
Bleiswijk, The Netherlands) supplemented with 20% FBS. Cells were seeded in T25 
culture flasks (n=5.0x105) or six-wells plates and maintained in a humidified 5% 
CO2 atmosphere at 37°C for two days. [3H]Alisertib (106 cpm) was added in 2 mL 
culture medium and incubated for 1 and 3 hours, respectively. For P-glycoprotein 
(P-gp) blocking studies, 20 μM verapamil (Sigma-Aldrich, Saint Louis, USA) was 
co-incubated. After incubation, the supernatants were discarded and the cell 
monolayers were washed twice with phosphate buffered saline (PBS) solution. Cells 
were put on ice and treated with 400 μL lysis buffer (Cell Signalling Technology, 
Boston, USA) for 5 minutes. Using a cell scraper (Greiner Bio-one, Alphen-aan-
den-Rijn, The Netherlands) the cellular material was solubilised and 2.6 ml PBS was 
added. Cellular uptake of [3H]alisertib was measured using liquid scintillation (LKB 
Wallac, Mount Waverley, Australia). Experiments without (n=3) and with verapamil 
(n=2) were conducted in triplicate.
Western blotting
Whole cell extracts were prepared on ice by scraping cells in ELB buffer, containing 0.3 
ml 5M NaCl, 0.5 ml 1M Hepes (pH 7.4), 0.1 ml 0.5M EDTA, 0.01 ml Nonidet P-40, 0.2 ml 
1x complete protease inhibitor cocktail (Roche, Mannheim, Germany), 0.02 NaF and 
0.2 ml NaVO3 in 9.1 ml water. Per sample, protein content of 10
5 cells (for experiments 
with untransfected cells) or 20 μg of protein content (for siRNA experiments) was 
separated by gel electrophoresis using 10% SDS-polyacrylamide gel electrophoresis 
gels and transferred to PVDF membranes (Amersham Biosciences, Little Chafont, 
UK)). Membranes were blocked for 1 hour at room temperature using blocking 
buffer for fluorescent Western blotting (Rockland, Gilbertsville, USA) and incubated 
with monoclonal anti-AURKA antibodies (1:500; mouse monoclonal, NCL-L-AK2; 
Novocastra Laboratories, Newcastle, United Kingdom) at 4°C overnight and anti-
β-actin antibodies (1:20000; mouse monoclonal; Sigma-Aldrich, Saint Louis, USA) 
for 1 hour at room temperature. Primary antibodies were detected using fluorescent 
red (IRDye680) and green (IRDye800CW) anti-mouse antibodies (1:10000; LI-
COR, Lincoln, USA), respectively. AURKA protein bands were quantified relative to 
loading control β-actin using ImageJ software (v1.46r).   
Transfection 
One day after seeding 1.2x105 HCT116 cells, 1.4x105 SW480 cells, 1.0x105 A431 cells, 
1.2x105 MKN45 cells and 1.5x105 Caco2 cells in six-wells plates, cells were transfected 
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with small interfering RNA (siRNA) pools according to the manufacturer’s 
recommendations.  For HCT116, MKN45 and A431, a final siRNA concentration 
of 10 nM was obtained for both the pool directed against AURKA (siGENOME 
SMARTpool Human AURKA, M-003545-10; ThermoScientific, Waltham, USA) and 
the non-targeting pool (siGENOME Non-Targeting SMARTpool #2, D-001206-
14; ThermoScientific, Waltham, USA), using Lipofectamine RNAiMAX (1:1000; 
Invitrogen, Bleiswijk, The Netherlands) as transfection reagent. For SW480 and 
Caco2, the final siRNA concentration was 30 nM with DharmaFECT3 (1:1000; 
ThermoScientific, Waltham, USA) as transfection reagent. Cellular uptake of 
[3H]alisertib was measured 48 hours after transfection, using methodology as 
described above. For graphical visualization, uptake was normalized based on the 
uptake after 3 hours in cells transfected with non-targeting siRNA. Downmodulation 
of AURKA expression after 48 hours was measured by qRT-PCR as described 
previously 6. 
Animal models 
Athymic nude mice (Harlan, Zeist, The Netherlands) were injected subcutaneously 
in both flanks (2.5x106 cells/flank) with either Caco2 (n=5), A431 (n=22), HCT116 
(n=5), SW480 (n=5) or MKN45 (n=5) cells. FVB (Friend virus B-type) P-gp knockout 
(Mdr1a/b(-/-)) and FVB wild type mice were obtained from Taconic (Hudson, USA). 
Mice (age: 6-8 weeks; weight 20-25 gram) were housed in groups of 5 per cage. 
Mice were provided with standard food (Teklad Global 16% Protein Rodent Diet, 
Harlan, Madison, USA) and water ad libitum in filtertop cages and kept in a room 
with a 12-hour light/dark cycle (temperature 24°C, humidity 60%). Experiments 
started when the tumour volume (T
vol
) was 100-200 mm3, calculated according to 
T
vol
= (length x weight x height)/2 13. Mice were sacrificed after experiments and 
tissues were excised. Animal experiments were carried out in accordance with the 
Dutch law on animal experimentation and were approved by the VU Medical Center 
institutional committee on animal experimentation.
Immunohistochemistry
Excised xenografted tumours were immunohistochemically stained for AURKA 
(mouse monoclonal, NCL-L-AK2, Novocastra Laboratories, Newcastle, UK) as 
described previously and scored for nuclear AURKA expression (categories: low, 
high) 8.
Metabolite analysis
Blood (1 mL) of athymic nude mice (n=4 per time point) was collected 15, 45 and 90 
minutes after injection of 25-75 MBq of radiotracer. Plasma and cells were separated 
by centrifugation (5 minutes, 4000 rpm). The plasma was loaded on a C18 Sep-Pak 
and the polar metabolite fraction was extracted using 3 mL water.  The non-polar 
metabolite fraction was eluted using 2 mL of methanol and was analyzed by HPLC 
(method C).
PET imaging
Tumour uptake of [11C]alisertib was investigated in A431 (n=6), HCT116 (n=5) and 
MKN45 (n=5) xenografted mice, P-gp knock-out mice (n=5) and wild-type mice 
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(n=6). Mice were anaesthetized with 4% and 2% isoflurane in oxygen (1 L·min-1) for 
induction and maintenance, respectively. Mice were positioned on a temperature 
controlled pad in the HRRT 14. For attenuation and scatter correction purposes, a 
6 minutes transmission scan was acquired using a 740 MBq 2-dimensional fan-
collimated 137Cs (662 keV) rotating point source 15. [11C]Alisertib (8.7±1.2 MBq) was 
administered intravenously via retro-orbital injection and a dynamic PET acquisition 
was started (90 minutes). Subsequently, [18F]FDG (5.3±0.9 MBq) was injected 
and a second PET scan was started (60 minutes) for the co-registration of the 
tumours in the xenografted mice. PET data were normalized, and corrected for 
scatter, randoms, attenuation, decay and dead time. [11C]alisertib PET data were 
acquired in 64 bits list mode, and converted into 16 sinograms with frame durations 
increasing from 10x60, 4x300, 6x600 s, while for the [18F]FDG scan emission data 
were acquired in 1 frame of 1800 s. Images were reconstructed using an iterative 
3D ordinary Poisson ordered-subsets expectation-maximization algorithm with 8 
iterations and 16 subsets and a matrix size of 256x256x207, resulting in a cubic 
voxel size of 1.21x1.21x1.21 mm3. (average spatial resolution of resulting images: 3 
mm full width at half maximum 16. The [18F]FDG PET scan was used for drawing the 
region of interest (ROI) of the xenografts. Background ROIs were placed on regions 
containing skin and muscle, but no vital organs 17.
Ex vivo biodistribution
The biodistribution of [11C]alisertib was determined at 10, 30, 60 and 90 minutes 
after injection in A431 xenografted athymic nude mice (n=4 per timepoint). Mice 
were injected intravenously with 7-34 MBq of [11C]alisertib via retro-orbital injection 
and euthanized at the various time points, both under isoflurane anaesthesia. Tissues 
were dissected, weighted and counted for radioactivity in a Wallac Compugamma 
1210 (LKB Wallac, Turku, Finland). 
Statistical analysis
Cellular uptake levels were compared using the paired samples T-test in a linear 
regression model, including cellular uptake, time point of measurement and added 
level of [3H]alisertib as covariates. Uptake in animal models was compared using the 
paired samples T-test in a linear regression model, including xenograft uptake value 
and time as covariates. Uptake levels were considered significantly different when 
P<.05. Statistical analyses were performed using R Statistics 14.0 software (RStudio 
Inc., Boston, USA).
RESULTS
Synthesis 
For in vitro evaluation of the tracer, alisertib was labelled with tritium (3H), since 
in vitro evaluation requires incubation times of several hours (Figure 1). For 
in vivo evaluation, alisertib was labelled with carbon-11 (11C). [3H]Alisertib was 
synthesized with an overall yield of 42%, with a specific activity of 3 GBq⋅μMol-1. 
The radiochemical purity of [3H]alisertib was ≥99% (Supplementary Fig. S1). 
[11C]Alisertib was synthesized with an overall yield of 23±9% (n=11; Supplementary 
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Table S1), with a specific activity of 113±34 GBq⋅μMol-1 at the end of the synthesis 
and high radiochemical purity (≥99%) (Supplementary Fig. S2). Total synthesis time 
starting from end of bombardment was approximately 40 minutes.
In vitro uptake of [3H]alisertib 
AURKA expression was high in Caco2 (AURKA/β-actin ratio 0.91) cells, moderate in 
A431 (AURKA/β-actin ratio 0.49), HCT116 (AURKA/β-actin ratio 0.41) and SW480 
(AURKA/β-actin ratio 0.49) cells, and low in MKN45 (AURKA/β-actin ratio 0.02) 
cells (Figure 2A). 
Uptake of [3H]alisertib in Caco2 cells was significantly higher than in A431 
cells (P=.02), SW480 cells (P<.01), HCT116 cells (P<.01) and MKN45 cells (P<.01) 
(Figure 2B). Similarly, uptake in A431 cells was significantly higher than SW480 cells 
(P<.01), HCT116 cells (P<.01) and MKN45 cells (P<.01). Uptake of [3H]alisertib did not 
differ significantly between SW480, HCT116 and MKN45 cells.
Upon downmodulation of AURKA expression with a siRNA pool directed 
against AURKA, uptake of [3H]alisertib in Caco2 cells was significantly decreased 
(P<.01). No significant differences in [3H]alisertib uptake were observed for A431 
(P=.88), HCT116 (P=.88), SW480 (P=.61) or MKN45 (P=.74) cells. Effectiveness 
of downmodulation was measured using qRT-PCR and Western blotting 
(Supplementary Fig. S3).
To evaluate whether [3H]alisertib is a P-gp substrate, untransfected cells 
were co-incubated with verapamil, which inhibits P-gp. Uptake of [3H]alisertib was 
Figure 2. (A) AURKA protein levels in Caco2, A431, HCT116, SW480 and MKN45 cells, 
visualized by Western blotting (upper lane: AURKA, lower lane: β-actin). (B) Dynamic uptake of 
[3H]alisertib (arbitrary units). 
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significantly increased in Caco2 (P<.01) and MKN45 (P<.01) cells (Supplementary 
Figure S4). No significant differences in [3H]alisertib uptake were observed for A431 
(P=.37), HCT116 (P=.34) and SW480 (P=.18) cells.
Metabolite analysis of [11C]alisertib
Overall efficiency of the workup procedure was >95%. In vivo stability of [11C]alisertib 
was assessed by metabolite analysis in plasma of athymic nude mice. Fifteen minutes 
after injection of 25-75 MBq of [11C]alisertib, 98.2±1.3% of the tracer was still intact 
in plasma, after 45 minutes 97.8±1.3% was still intact and after 90 minutes 94.7±1.3% 
was still intact (Supplementary Fig. S5). 
In vivo uptake of [11C]alisertib
No tumour growth was observed in Caco2 and SW480 xenografted mice. Therefore, 
[11C]alisertib was only investigated in vivo in A431, HCT116 and MKN45 xenografted 
mice. According to immunohistochemical staining of the xenografts, AURKA 
expression was high in A431 xenografts and low in HCT116 and MKN45 xenografts 
(Figure 3).
Maximum accumulation in the xenografts was observed at approximately 25 
minutes after injection (Figure 4). Uptake of the tracer was significantly higher in 
A431 xenografts than in the background region (P<.01), with a maximum uptake 
value of 1.9±0.2% ID/g (Figure 4A). Tumour-to-background ratio after 90 minutes 
was 2.3±0.8 (Figure 5). For HCT116 xenografts, maximum uptake value was 1.1±0.3% 
ID/g, but uptake in tumour and background region was similar (P=.53; Figure 4B). 
For MKN45 xenografts, uptake values were significantly higher compared to the 
background region (P<.01), with a maximum uptake value of 0.92±0.1% ID/g and a 
tumour-to-background ratio after 90 minutes of 1.9±0.5 (Figure 4C and Figure 5). 
Uptake of [11C]alisertib in A431 xenografts was significantly higher than its uptake in 
HCT116 (P<.01) and MKN45 (P<.01) xenografts. No significant uptake difference was 
observed between HCT116 and MKN45 xenografts (P=.09).
Ex vivo biodistribution experiments showed high uptake of [11C]alisertib in 
liver, kidney and ileum (Supplementary Fig. S6). Clearance from blood was slow, 
Figure 3. Immunohistochemical staining of AURKA expression in (A) A431 (high), (B) HCT116 
(low) and (C) MKN45 (low) xenografted tumours. 
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with 1.6±0.3% ID/g remaining after 90 minutes. Uptake in the tumours after 90 
minutes was 1.4±0.3% ID/g, with a mean tumour-to-blood ratio of 0.84 and a mean 
tumour-to-muscle ratio of 1.82.
For in vivo evaluation of [11C]alisertib as a substrate of P-gp, accumulation 
of the tracer was measured in the brain of P-gp knockout mice using dynamic PET 
scanning for 60 minutes. Uptake of [11C]alisertib in the brains of P-gp knockout 
mice was significantly higher than its uptake in the brains of wild-type mice (P<.01, 
calculated at t≥2 minutes; Supplementary Fig. S7).
Figure 4. Summed [18F]FDG and [11C]alisertib PET images and time-activity curves of athymic 
nude mice, xenografted in their flanks with (A) A431, (B) HCT116 and (C) MKN45 cells. Tumours 
are indicated with white arrows. 
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DISCUSSION
We developed a tracer for the molecular imaging of AURKA, by radiolabelling 
the selective AURKA inhibitor alisertib (i.e. MLN8237) with tritium for its in vitro 
evaluation and with carbon-11 for its in vivo evaluation. Both tracers were synthesized 
with fair yield, good specific activity and high radiochemical purity. 
To investigate whether AURKA expression levels corresponded to the in vitro 
uptake of [3H]alisertib, its uptake was compared between cell lines with different 
expression levels of AURKA. Uptake of the tracer was highest in Caco2 cells, in 
which AURKA expression is high. Interestingly, uptake in A431 cells was significantly 
higher than in HCT116 and SW480 cells, which all moderately express AURKA, and 
MKN45 cells, in which AURKA expression is low. Uptake in MKN45 cells was not 
significantly lower than its uptake in HCT116 and SW480 cells. These data resemble 
findings in lymphoma patients, in whom clinical response to treatment with alisertib 
did not correlate to AURKA expression levels in the corresponding tissue sections 
18. Furthermore, these data suggest that to some extent [3H]alisertib is taken up by 
the cells regardless of their cellular AURKA expression levels. Downmodulation of 
AURKA expression using siRNA, which was adequate on both RNA and protein level 
according to qRT-PCR and Western blotting, did lead to a corresponding decrease 
in tracer uptake for Caco2 cells. In the other cell lines, downmodulation of AURKA 
expression did not result in significantly lower uptake of [3H]alisertib. Altogether, 
our data suggest that [3H]alisertib does accumulate in cells by binding to AURKA 
proteins, but that specific binding can only be measured when AURKA levels 
are high enough. Furthermore, the data suggest that uptake is partly attributed 
to other mechanisms than mere binding to AURKA protein alone. Unfortunately, 
no xenografted tumours involving Caco2 cells could be established to further 
investigate this in an in vivo model. 
Figure 5. Tumour-to-background ratios for [11C]alisertib in A431, HCT116 and MKN45 xenografts 
as assessed by dynamic PET scanning.
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Accumulation of [3H]alisertib in cancer cells may be attributed to efflux pumps, 
such as the multidrug transporter P-gp. P-gp is generally expressed on plasma 
membranes with high lateral packing density, such as the blood-brain-barrier, but 
is often also overexpressed on cancer cell membranes. As multidrug efflux pump, 
it is responsible for the efflux of a wide variety of structurally different, commonly 
applied anti-cancer drugs 19,20. Here, we demonstrated that in vitro inhibition of P-gp 
using verapamil significantly increased the accumulation of [3H]alisertib in two of 
the investigated cell lines, which indicates that for these cell lines P-gp is actively 
involved in the export of [3H]alisertib from the intracellular compartment. These data 
agree with the increased accumulation of [11C]alisertib in the brains of P-gp knockout 
mice compared to its uptake in the brains of wild-type mice, which suggests that 
alisertib indeed is a P-gp substrate. Altogether, this demonstrates that uptake of 
alisertib in tumour cells is not only attributed to its binding to intracellular AURKA 
proteins, but also by other cellular mechanisms, such as export via multidrug efflux 
pumps like P-gp.   
Metabolite analysis of [11C]alisertib showed that the tracer was very slowly 
metabolized in vivo, as even after 90 minutes post-injection approximately 95% of 
the tracer was still intact. As such, radiolabeled alisertib could be applied without 
metabolite analysis in mice, which would benefit its practical use.
In vivo evaluation of [11C]alisertib in nude mice, bearing xenografts of A431, 
HCT116 or MKN45, confirmed our results of the in vitro experiments. Also in 
vivo, uptake of radiolabelled alisertib in A431 xenografted mice appeared to be 
significantly higher than in HCT116 and MKN45 xenografted mice. Furthermore, 
uptake corresponded to nuclear AURKA levels within the xenografts, as determined 
by immunohistochemistry. Nevertheless, it remains unclear which mechanisms 
exactly contributed to its cellular uptake. Biodistribution analysis of [11C]alisertib 
demonstrated that uptake was high in metabolic organs such as liver, kidney and 
ileum, which is common for small molecule PET tracers 21. As the current study 
focused on the development of a PET tracer for CRC liver metastasis, high liver 
uptake is undesirable. Indeed, such a tracer is unlikely to outperform the standard 
PET tracer [18F]FDG with regard to detection and staging of CRCLM. Nevertheless, 
for characterization of lesions rather than detection and staging, such a tracer 
may still appear useful for prediction of outcome after treatment. Patient studies 
are required to investigate whether signal-to-background ratios will allow for 
appropriate data analysis. Alternatively, CRCLM characterization may be based 
on tracer uptake in the corresponding primary tumour, since we have previously 
demonstrated that AURKA expression in CRCLM correlates to its expression in the 
corresponding primary tumour 8.  
Altogether, these data show that radiolabelled alisertib accumulated in 
tumour cells, both in in vitro and in vivo models. The question remains, however, 
whether radiolabelled alisertib can be used to specifically image AURKA expression, 
as additional cellular mechanisms – other than just binding to AURKA proteins – 
seem to underlie its uptake in tumour cells. Particularly in the cell line with high 
AURKA expression (i.e. Caco2), protein levels correlated with in vitro uptake of the 
tracer, which confirms its specificity for AURKA expression. Although we could not 
confirm these results in an in vivo model, this may suggest that radiolabelled alisertib, 
potentially in addition with P-gp inhibitors, is specifically useful for the identification 
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of tumours that highly express AURKA. As such, the tracer might be applied to 
select patients with poor prognosis, since we have previously demonstrated that 
high AURKA expression is related to decreased survival 7,8.  
Alisertib is currently being investigated as an inhibitor in several clinical 
trials and is demonstrating beneficial effects for the treatment of several types of 
cancer 5,9,10. The current study suggests that alisertib not only accumulates in tumour 
cells as a result of its binding to AURKA proteins, but that also other mechanisms 
are involved in its cellular uptake. For example, synergetic effects of AURKA and 
EGFR inhibitors have been demonstrated earlier 22. Radiolabelled alisertib may offer 
opportunities for selecting patients who will benefit from alisertib therapy and, as 
such, may contribute to improving outcome after treatment.
CONCLUSION
Radiolabelled alisertib can be used for the imaging of AURKA expression in cancer 
cells, particularly when cellular expression levels are high. However, more research 
is required to fully elucidate the mechanisms that underlie cellular uptake of 
(radiolabelled) alisertib.
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SUPPLEMENTARY DATA   
 
Supplementary Table S1. Optimization of reaction conditions for the synthesis of the t-Butyl protected 
intermediate of [11C]alisertib (compound 2).  
N1 (μmol) t (min) T (°C) solvent base yield (%) 
3.2 10 50 MeCN NaOH 0% 
2.9 10 50 DMSO NaOH 28% 
2.0 5 80 DMSO TBAOH 0% 
2.1 10 80 DMSO NaOH 26% 
2.0 5 90 DMSO K2CO3 7% 
1.8 5 85 DMSO NaOH 42% 
2.0 5 100 DMSO NaOH 29% 
N1: amount of compound 1 added 
 
Supplementary Figure S1. Analytical HPLC radiochromatogram of [3H]alisertib (retention time 
6-8 minutes) demonstrating ≥99% radiochemical purity. 
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Supplementary Figure S2. Analytical HPLC radiochromatogram of formulated [11C]alisertib 
(retention time 9-10 minutes) demonstrating ≥99% radiochemical purity, with (A) the UV 
channel and (B) the radioactive channel.
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Supplementary Figure S3. Downmodulation of AURKA expression using siRNA. (A) 
Representative example of decreased RNA (qRT-PCR, bar graph) and protein levels (Western 
blot) after downmodulation of AURKA expression upon transfection with siRNA (siNT: non-
targeting siRNA pool; siAURKA: siRNA pool directed against AURKA). Normalized dynamic 
uptake of [3H]alisertib in (B) Caco2 (n=3), (C) A431 (n=4), (D) HCT 116 (n=7), (E) SW480 
(n=4) and (F) MKN45 (n=4) cells in which AURKA expression is downmodulated using siRNA, 
compared to transfection with the non-targeting siRNA pool (arbitrary units). P values were 
calculated using the paired samples T-test in a linear regression model.
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Supplementary Figure 4. Dynamic uptake of [3H]alisertib in cancer cells without or with co-
incubation with verapamil. Uptake after co-incubation with verapamil (A) was significantly 
increased in Caco2 cells, (B) was not significantly different in A431 cells, (C) was not 
significantly different in HCT116 cells, (D) was not significantly different in SW480 cells and (E) 
was significantly increased in MKN45 cells. P values were calculated using the paired samples 
T-test in a linear regression model. Experiments (n=2) were conducted in triplicate.
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Supplementary Figure S5. Representative radiochromatogram of the non-polar plasma 
fraction after 15 minutes, showing the intact [11C]alisertib (retention time 11-13 minutes) and one 
unidentified metabolite (retention time 9-10 minutes). 
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Supplementary Figure S6. Ex vivo biodistribution following intravenous injection of 
[11C]alisertib in A431 xenografted athymic nude mice (n=4 per timepoint). Data are expressed 
as percentage injected dose per gram blood or tissue (%ID/g).
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Supplementary Figure S7. Time-activity curve for [11C]alisertib uptake in the brains of 
P-glycoprotein (P-gp) knockout mice and wild-type mice.
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GENERAL DISCUSSION
Personalized therapy for colorectal cancer patients with liver metastasis
Worldwide, approximately 1.4 million people are diagnosed with colorectal cancer 
(CRC) every year. Half of the CRC patients die, mostly as a consequence of 
disseminated disease 1. The major site of metastasis in patients with CRC is the liver, 
which is affected in 36-81% of patients 2. Presence of CRC liver metastases (CRCLM) 
is generally associated with poor prognosis and treatment options for this patient 
population are limited 3. Currently, the only curative option for patients with CRCLM 
is resection of the liver segments that contain metastatic lesions 4,5. Resectability 
is generally based on established clinicopathological prognostic variables, such as 
number of CRCLM, presence of lymph node metastasis, size of the CRCLM, time 
period between diagnosis of the primary tumour and CRCLM, preoperative serum 
carcinoembryonic antigen (CEA) level and presence of extrahepatic disease 4. 
Although some of these parameters have appeared useful in clinical scoring systems 
for predicting survival after surgery, the prognostic accuracy of such clinical risk 
scores is often debated 6-8. Improved methodology for liver surgery and the addition 
of non-surgical techniques, such as radiofrequency ablation (RFA), have increased 
the number of patients who are eligible for CRCLM resection 9,10. Additionally, 
resectability of the CRCLM can be increased via multidisciplinary approaches 
involving systemic therapy 9,11-15. Nonetheless, five-year survival after resection of 
CRCLM is only 36-58% 9.
Current CRCLM imaging is based on anatomy rather than on biology. The 
first diagnosis of CRCLM is generally obtained by standard imaging modalities, 
such as computed tomography (CT) or magnetic resonance imaging (MRI) 16. 
Positron emission tomography (PET), based on the standard tracer fluorine-18 
fluorodeoxyglucose ([18F]FDG), may be used for the detection of extrahepatic 
disease. Although this has improved survival after CRCLM resection, the full potential 
of PET is not completely utilized, since PET also allows for dynamic imaging of 
biological processes 17. For the majority of biological processes a PET tracer can 
be developed by labelling a small molecule or monoclonal antibody that targets 
the biological process with a clinically applicable isotope (e.g. fluorine-18, carbon-11, 
zirconium-89). We focused on the identification and validation of biomarkers 
with added prognostic value to the currently used clinicopathological prognostic 
parameters for patients with CRCLM, which could be visualized using PET. Non-
invasive molecular imaging of such biomarkers will allow for stratification of patients 
based on the biology of a tumour in addition to the clinical profile. This will enable 
personalized treatment of patients with CRCLM, leading to improved survival. 
The biology behind CRCLM: prognostic biomarkers
To investigate the prognostic value of the candidate biomarkers, we assembled a 
multi-institutional cohort of 507 patients who underwent CRCLM resection with 
curative intent between 1990 and 2010 in one of seven Dutch hospitals affiliated 
with the DeCoDe PET group. Tissue micro-arrays (TMAs) were constructed that 
contained formalin-fixed paraffin-embedded tissue specimens of CRCLM of 
all patients and of 234 patients also matched specimens of the primary tumour 
were included. Expression of the candidate biomarkers was visualized using 
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immunohistochemistry and was related to survival in a cross-validation procedure. 
The added prognostic value of the investigated biomarkers compared to the 
established clinicopathological prognostic parameters was assessed in multivariate 
analyses.
Standard clinical PET imaging of CRCLM relies on the uptake of [18F]FDG in 
tumour cells via membranous expression of SLC2A1. Overexpression of SLC2A1 has 
been associated with tumour progression, metastasis and survival of CRC patients 
18-21.  SLC2A1 expression may become upregulated via hypoxia-induced activation of 
proteins such as HIF1α, which has a significant effect on several biological processes, 
including the metabolic shift from aerobic oxidation to anaerobic glycolysis, 
angiogenesis and the increased metastatic potential of tumour cells 22-26. As a 
result, also VEGFA expression can become upregulated, which stimulates tumour 
progression, angiogenesis and metastasis 27. Anti-VEGF therapies are currently 
being utilized in clinical setting and have improved outcome of CRC patients with 
disseminated disease 28,29. In chapter 2 we investigated the prognostic value of 
SLC2A1, HIF1α, and VEGFA expression for patients with CRCLM and demonstrated 
that high expression of SLC2A1 was associated with good prognosis, whereas high 
expression of VEGFA was associated with poor prognosis, also after correction for 
the established clinicopathological prognostic parameters. SLC2A1 expression was 
particularly associated with survival of patients treated with systemic therapy, which 
may be explained by the higher susceptibility to treatment with systemic therapy 
of tumour cells with enhanced glycolytic capacity and thus high SLC2A1 expression 
30-34. Conversely, VEGFA expression was associated with survival of patients not 
treated with systemic therapy. This may suggest that biological processes related 
to VEGFA expression are affected by the conventional systemic therapies, which 
results in improved survival. Especially patients with both low SLC2A1 and high 
VEGFA expression had a poor prognosis. Although expression of HIF1α did show 
some survival difference, the preset threshold for statistical significance was not 
reached. Expression of none of these proteins appeared to correlate with their 
expression in the corresponding primary tumours. Altogether, SLC2A1 and VEGFA 
may be used as prognostic biomarkers for CRCLM, which, when combined, can be 
used to predict survival irrespective of systemic treatment. 
EGFR is a master regulator of CRC carcinogenesis and upon its activation, 
other pathways commonly associated with CRC progression and survival become 
stimulated. Consequently, activation of EGFR promotes proliferation, angiogenesis 
and metastasis 35. As a result, anti-EGFR therapy has been added to standard systemic 
therapy regimens 35. EGFR may induce the overexpression of PTGS2 (also known as 
COX2), which is often associated with tumour-induced inflammation and promotes 
the growth and viability of cancer cells, proliferation and invasion 36,37. Although 
anti-PTGS2 therapy is not part of standard treatment, specific PTGS2 inhibitors 
have significantly improved clinical outcome 38. Furthermore, CRC incidence is 
particularly lower and survival is higher of patients with daily intake of non-steroidal 
anti-inflammatory drugs such as aspirin, which also inhibits PTGS2 expression 39,40. 
In chapter 3, we described the prognostic value of EGFR and PTGS2 expression 
in CRCLM. For both proteins, high expression was associated with decreased 
survival, independent of the established clinicopathological prognostic parameters. 
In patients in which both proteins were overexpressed, prognosis was even 
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worse. EGFR and PTGS2 expression were prognostic particularly in the subgroup 
of patients who were not treated with systemic therapy. The lack of prognostic 
value for both biomarkers in the subgroup of patients who were not treated with 
systemic therapy may imply that EGFR and/or PTGS2 expressing tumours respond 
well to the commonly used chemotherapeutic regimens. For PTGS2, expression in 
the primary tumour correlated to its expression in patient-matched CRCLM, which 
is in accordance with previous findings suggesting that altered PTGS2 expression 
may be considered as an early phase event 41. In conclusion, both EGFR and PTGS2 
expression are prognostic biomarkers for patients with CRCLM with added value to 
the established clinicopathological prognostic parameters. 
AURKA expression in CRC has been associated with adenoma-to-carcinoma 
progression, cell viability, invasion and anchorage-independent growth 42-49. 
Furthermore, in stage III colon cancer patients, increased expression has been related 
to increased disease recurrence 50. Therefore, we investigated the prognostic value 
of AURKA expression for the current study population in chapter 4. High AURKA 
expression in CRCLM was a predictor of poor survival, also after a multivariate 
analysis including the established clinicopathological prognostic parameters. 
Additionally, its expression was correlated between matched primary tumour and 
CRCLM pairs. As such, AURKA expression in CRCLM may be predicted based on 
its expression in the corresponding primary tumour, which is more often readily 
available for tissue analysis. Our data demonstrated that AURKA expression is an 
independent prognostic biomarker for patients with CRCLM. Altogether, these data 
suggest that patients with CRC(LM) may benefit from treatment with anti-AURKA 
therapies. Currently, several AURKA inhibitors are available, which are showing 
promising utility in clinical trials 51-53.
In addition to these proteins, many others are involved in CRC development 
and progression. As such, it would be worthwhile to investigate the prognostic 
value of a number of proteins commonly associated with CRC carcinogenesis 
and to evaluate if prognosis can be predicted more optimally based on the 
combined expression of some of these biomarkers. We selected several candidate 
biomarkers based on their clinical utility and on the extensive literature describing 
their involvement in (colorectal) carcinogenesis. In chapter 5 we investigated 
the individual and combined prognostic value of EGFR, PI3K, AURKA, Ki-67, TK1, 
KCNQ1, IGF2, VEGFA, PDGFRβ, CEA, MMP9, CXCR4, CXCL12, MLH1, MSH6, PTGS2, 
SLC2A1 and HIF1α expression in CRCLM. Next to the individual prognostic value 
of SLC2A1, VEGFA, EGFR, PTGS2 and AURKA expression, we demonstrated that 
expression of KCNQ1, CEA and MMP9 showed some survival differences, although 
these were not statistically different, similar to our findings regarding HIF1α. We 
selected these nine proteins as prognostically most relevant and combined them 
in a classification and regression tree (CART) analysis to define the most optimal 
prognostic classifier. The combination of AURKA, PTGS2 and MMP9 expression 
provided the best prediction of three-year survival after CRCLM resection. This 
classifier demonstrated improved prognostic value compared to the established 
clinicopathological prognostic parameters. We also demonstrated that expression 
levels of the majority of investigated proteins in primary tumours correlated to their 
expression in patient-matched CRCLM. Consequently, the classifier could also be 
applied to expression in the primary tumour for predicting survival after CRCLM 
7149
General discussion and future perspectives
resection. When considering the primary tumour, however, we showed that a more 
accurate prediction of survival could be achieved based on AURKA expression alone. 
Individually, but also combined in a classification system, such biomarkers may add 
value to the existing clinical risk scores by providing biological information on the 
CRCLM, which normally is neglected by the clinical scoring systems. Stratification 
of patients based on the biological properties of a tumour, in combination with the 
clinical profile, may contribute to improving prognosis after CRCLM resection. 
Molecular imaging of prognostic biomarkers
Non-invasive assessment of the prognostic biomarkers using PET will allow for 
patient stratification based on tumour biology. Standard PET imaging is based on 
the uptake of [18F]FDG, which capitalizes on (deoxy)glucose uptake via SLC2A1. 
Although SLC2A1 expression demonstrated prognostic value in the current study 
population, the prognostic value of [18F]FDG uptake has been disputed. That is, it is 
not clear to what extent increased tracer uptake is caused by epithelial cells or by 
stromal cells, of which some may also demonstrate high glucose consumption (e.g. 
macrophages) 54. Therefore, novel PET tracers for the imaging of other promising 
biomarkers are more likely to become clinically applied for patient stratification. 
PET tracers for VEGFA (e.g. zirconium-89 labelled bevacizumab), EGFR (e.g. 
zirconium-89 labelled cetuximab) and PTGS2 (e.g. fluorine-18 labelled celecoxib) 
have already been developed and their prognostic and predictive value is currently 
being investigated in (pre)clinical setting 55-57. For AURKA, however, no tracers for 
PET imaging exist. Therefore, we developed and preclinically evaluated radiolabelled 
alisertib, which is a specific AURKA inhibitor, as we described in chapter 6. Alisertib 
was labelled with tritium for in vitro evaluation and with carbon-11 for in vivo 
evaluation. Uptake of tritium labelled alisertib was highest in cancer cells with high 
AURKA expression. Downmodulation of AURKA expression using siRNA in these 
cells resulted in significantly decreased uptake. Uptake in cells with low to moderate 
AURKA expression was not representative for AURKA levels in these cells. This 
suggests that additional cellular mechanisms – other than just binding to AURKA 
proteins – underlie accumulation of alisertib in tumour cells. Indeed, when inhibiting 
the common multi-drug efflux pump P-gp, uptake in two of the investigated cell lines 
was significantly increased. Our in vitro data were confirmed by the in vivo models, 
which demonstrated accumulation of carbon-11 labelled alisertib in xenografted 
mice. Furthermore, tracer uptake in the brains of P-gp knockout mice confirmed 
that alisertib is a substrate of P-gp. In conclusion, radiolabelled alisertib could be 
used for the molecular imaging of AURKA expression, particularly when AURKA is 
highly expressed. The exact mechanisms by which alisertib accumulates in tumour 
cells, however, are not yet fully elucidated and need to be further investigated. 
Inhibition of AURKA expression using alisertib is demonstrating beneficial effects 
on tumour growth in clinical trials 51-53,58-61. Given the high selectivity of alisertib for 
inhibiting AURKA activity, but the apparent lack of correlation between cellular 
accumulation of alisertib and AURKA expression in our and other studies, this may 
imply that binding of a small portion of alisertib to intracellular AURKA already 
has a strong kinetic effect 62,63. Nevertheless, radiolabelled alisertib may be used to 
identify CRCLM with high AURKA expression, and thus patients with poor prognosis 
who may benefit from treatment with AURKA inhibitors. However, this needs to be 
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further investigated in clinical setting. Our data emphasize that good inhibitors do 
not automatically qualify as suitable PET tracers upon their radiolabelling.
FUTURE PERSPECTIVES  
Official recommendations for treatment of CRCLM patients are mainly based on the 
clinicopathological profile of the CRCLM. Recommended imaging modalities provide 
anatomical information, but information on tumour biology is mainly static 16. This 
and numerous other studies emphasize that a transition has to occur from stratifying 
patients based on clinicopathological parameters to additionally deciding upon the 
most optimal treatment regimen based on biological parameters 8. To improve 
current clinical practice, validated and clinically applicable prognostic biomarkers 
such as the biomarkers presented here, are required. Our research contributes to 
enable such a transition, however, a change in traditional clinical decision making is 
also needed. At the moment, liver resection, commonly combined with RFA, is the 
only potentially curative treatment option 4,5. Nevertheless, based on the expression 
of prognostic and predictive biomarkers, treatment regimens may become rather 
dynamic and can be adjusted to a patient’s need, for example by adding adjuvant 
targeted therapies. Such personalized treatment strategies are expected to improve 
survival of CRCLM patients.
It may be appealing to base CRCLM treatment on biomarker expression 
in the primary tumour, as genomic characteristics of primary and corresponding 
metastatic CRC lesions are generally similar and specimens of the primary tumour 
are more often readily available 64,65. Although expression of the majority of the 
investigated biomarkers in this study correlated between matched primary tumour 
and CRCLM pairs, their concordance was only 55%-70%. Inter- and intratumoral 
heterogeneity of CRCLM is observed in approximately 40% of patients, based on 
loss of heterozygosity and gene expression assay studies 66. Heterogeneity between 
CRCLM may explain why the observed concordance was not higher, as in the current 
study only one metastatic lesion was obtained per patient, which may have already 
acquired a distinct biological profile compared to the corresponding primary tumour 
66,67. In vitro response to therapy may differ between separate CRCLM specimens 
isolated from individual patients 66. These data imply that CRCLM therapy cannot 
simply be based on the biological profile of the corresponding primary tumour. 
Instead, inter- and intratumoral heterogeneity may be visualized using quantitative 
PET imaging, allowing the determination of the most optimal treatment regimen 
based on the uptake of prognostic and predictive molecular imaging tracers 68. 
The prognostic value of the candidate biomarkers identified in this study was 
internally validated in a cross-validation procedure, however, external validation of 
their prognostic value is still desirable. For example, it would be interesting to assess 
their prognostic value in all patients who have been diagnosed with CRCLM, as 
current results were obtained from a population consisting solely of CRCLM patients 
who underwent resection. Furthermore, predicting survival prospectively instead of 
retrospectively, based on the expression of biomarkers in recently resected tissue 
specimens, is preferred. Such a research set-up requires an efficient infrastructure 
between the clinic and the research lab, which is often lacking. Optimizing the 
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infrastructure involves sharing clinicopathological patient data and facilitating  the 
use of resected tissue specimens for research purposes. In return, sharing research 
data will allow for quick implementation of innovative research. Altogether, this 
will lead to improved and tailored patient care and, as such, may improve clinical 
outcome. 
It would be appealing to assess the predictive value of the investigated 
biomarkers, as targeted therapies related to these biomarkers are emerging. Anti-
EGFR and anti-VEGF therapies have already been added to standard systemic 
treatment regimens and are particularly recommended when CRCLM appear 
irresectable. For patients with resectable CRCLM, however, targeted therapies 
are generally not applied, since data from randomized prospective trials on using 
such therapies for patients with resectable CRCLM is not available 16. Our results 
demonstrate significant survival differences of patients with resectable CRCLM 
with different expression levels of the prognostic biomarkers. This might indicate 
that also patients with resectable CRCLM may benefit from treatment with 
targeted therapies. For instance, by erasing remnant CRCLM in cases of irradical 
resection or by eradicating occult (micro)metastases which were not detected 
using standard diagnostics. The added value of specific inhibitors, that target the 
prognostic biomarkers identified in this study, needs to be further investigated 
in randomized prospective trials. Even though toxicity of targeted therapies is 
generally less compared to standard systemic therapy, more research is needed to 
evaluate whether the potential survival benefit outweighs the toxicity and burden of 
treatment associated with such targeted therapies 16.
The application of tracers for molecular imaging of prognostic and predictive 
biomarkers may facilitate personalized treatment. Development of novel PET 
tracers, based on existing small molecules or monoclonal antibody inhibitors, 
also depends on the willingness of the manufacturers of these inhibitors to share 
their research with academic research institutes. For example, making available 
(intermediate) compounds for radiolabelling will accelerate research progress and 
decrease research costs, which will benefit healthcare. Alternatively, prognostic and 
predictive biomarkers may be measured in blood, for example by the detection of 
circulating tumour cells or via assessment of circulating tumour DNA. Currently, 
wide-scale clinical application of such liquid biopsies is prevented by technical 
challenges. However, technological advances may allow for stratification of patients 
based on biomarker levels in blood in the near future 69. Detection of biomarkers, 
either by molecular imaging or liquid biopsies, may contribute to obtaining a full 
biological tumour profile, which could then be used for determining an optimal 
treatment strategy. 
This research provides another small step towards obtaining a complete 
overview of CRCLM biology. It is our vision that personalization of cancer treatment 
based on the biological profile of the CRCLM will improve survival of patients with 
CRCLM.
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Gepersonaliseerde therapie voor colorectaalkankerpatiënten met levermetastasen
Colorectaalkanker – het type kanker waarbij er zich een tumor gevormd heeft in 
de dikke darm of het rectum – is een wereldwijd probleem: elk jaar wordt deze 
ziekte vastgesteld bij ongeveer 1.4 miljoen mensen. De helft van de patiënten die 
lijdt aan colorectaalkanker (ofwel colorectaal carcinoom; CRC) overlijdt aan de 
gevolgen van de ziekte, vaak door uitzaaiing naar andere organen. In de meeste 
gevallen vormen deze uitzaaiingen – ook wel metastasen genoemd – zich in de 
lever. Operatieve verwijdering (resectie) van CRC levermetastasen (CRCLM), al 
dan niet in combinatie met speciale technieken zoals radiofrequentie ablatie, wordt 
beschouwd als de enige behandelingsmogelijkheid die kan leiden tot genezing. 
Welke patiënten in aanmerking komen voor een dergelijke behandeling wordt in de 
praktijk voornamelijk gebaseerd op een aantal clinicopathologische prognostische 
kenmerken: de kenmerken die met standaardmethoden in de kliniek bepaald kunnen 
worden (clinicopathologische kenmerken) en die mogelijk wat zeggen over de 
overlevingskans (prognose) van een patiënt. Voor CRCLM zijn voorbeelden hiervan 
het aantal en de grootte van de levermetastasen, de aanwezigheid van metastasen 
in lymfeklieren of andere organen dan de lever, bloedwaarden van bepaalde CRC-
markers (bijvoorbeeld CEA) of de tijd tussen de diagnoses van primaire tumor en 
CRCLM. Ook al blijken sommige van deze kenmerken nuttig in het voorspellen van 
de overleving, slechts 36-58% van de patiënten is vijf jaar na resectie nog in leven.
Om een inschatting te kunnen maken van de ernst van de ziekte en het 
bepalen van de mogelijkheid tot operatieve verwijdering, wordt gebruik gemaakt van 
standaard beeldvormende technieken. Computed tomography (CT) en magnetic 
resonance imaging (MRI) zijn beeldvormende technieken die met name geschikt zijn 
voor het in kaart brengen van de anatomie. Wanneer de CRCLM resectabel blijken of 
wanneer CT en MRI niet genoeg duidelijkheid kunnen verschaffen, wordt vaak nog 
een extra scan gemaakt met behulp van positron emission tomography (PET). PET 
is een moleculaire beeldvormingstechniek waarbij een tracer wordt geïnjecteerd die 
het mogelijk maakt om de biologische kenmerken van weefsels zichtbaar te maken. 
Echter, in de praktijk wordt PET vaak slechts gebruikt voor detectie van metastasen 
in andere organen dan de lever. Met behulp van nieuwe tracers kan extra informatie 
verkregen worden over de biologie achter de CRCLM, iets waarvan in de huidige 
beeldvorming van CRCLM nog amper gebruik wordt gemaakt. Gecombineerd met 
de clinicopathologische kenmerken kan deze informatie gebruikt worden om een 
optimale behandelstrategie te bepalen, die specifiek is afgestemd op de individuele 
patiënt. Men spreekt dan van gepersonaliseerde therapie. Voor de ontwikkeling 
van nieuwe tracers zijn biologische markers (biomarkers) nodig, zoals bepaalde 
eiwitten of genetische afwijkingen, die een rol spelen in de biologische processen 
van CRCLM. Met dit doel voor ogen, hebben wij ons gericht op de identificatie en 
validatie van biomarkers met toegevoegde prognostische waarde aan de standaard 
clinicopathologische kenmerken. Het indelen van patiënten in groepen met een 
bepaalde overlevingskans (stratificatie) op basis van hun biologische profiel, in 
combinatie met hun klinische profiel, en het afstemmen van de behandelstrategie 
op basis van deze informatie, zal naar verwachting leiden tot een betere overleving 
van de patiëntenpopulatie.
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De biologie achter CRCLM: prognostische biomarkers
De prognostische waarde van een aantal kandidaat-biomarkers hebben we 
onderzocht in CRCLM van 507 patiënten die resectie hebben ondergaan tussen 
1990 en 2010 in één van de zeven ziekenhuizen die geaffilieerd zijn met de DeCoDe 
PET groep. Uit deze CRCLM en van 234 patiënten ook uit de bijbehorende primaire 
tumoren hebben we enkele weefselmonsters genomen en deze verwerkt in zogeheten 
tissue micro-arrays (TMA’s): kleine paraffineblokjes met daarin ingebed een raster 
van weefselmonstertjes. Deze TMA’s maken het mogelijk om in een korte tijd een 
groot aantal weefselmonsters met behulp van immunohistochemische technieken 
te onderzoeken op expressie van de kandidaat-biomarkers. Vervolgens hebben we 
de expressieniveau’s van de kandidaat-biomarkers vergeleken met overlevingsdata 
van de patiënten om zo te bepalen welke geschikt zijn voor het voorspellen van de 
overleving na CRCLM-resectie.
De kandidaat-biomarkers die we in hoofdstuk 2 hebben onderzocht op 
prognostische waarde, waren de eiwitten SLC2A1, VEGFA en HIF1α. Hoge expressie 
van SLC2A1 bleek gerelateerd aan een goede overleving, terwijl hoge expressie van 
VEGFA juist gerelateerd was aan een slechte overleving. Met name in patiënten 
die behandeld waren met systemische therapie (hieronder vallen bijvoorbeeld 
chemotherapie en therapie met antilichamen die een specifiek eiwit remmen), bleek 
SLC2A1-expressie prognostische waarde te hebben. In patiënten die niet behandeld 
waren met systemische therapie, had VEGFA-expressie juist prognostische waarde. 
De overleving van patiënten die zowel een lage SLC2A1-expressie als een hoge 
VEGFA-expressie hadden, was erg slecht, ongeacht of de patiënten behandeld 
waren met systemische therapie. HIF1α-expressie was niet statistisch significant 
gerelateerd aan overleving. Uit deze resultaten kon geconcludeerd worden dat 
SLC2A1 en VEGFA geschikt zijn als prognostische biomarkers voor patiënten met 
resectabele CRCLM.
In hoofdstuk 3 hebben we de prognostische waarde van de eiwitten EGFR en 
PTGS2 onderzocht en gevonden dat hoge expressie van beide eiwitten afzonderlijk 
gerelateerd was aan een slechte overleving. Met name de overleving van patiënten 
die zowel een hoge expressie van EGFR hadden als van PTGS2 was slecht. EGFR en 
PTGS2 bleken alleen prognostisch in de subgroep van patiënten die niet behandeld 
waren met systemische therapie. Samengenomen toonden deze resultaten aan dat 
zowel EGFR als PTGS2 prognostische biomarkers zijn voor patiënten met CRCLM.
Hoofdstuk 4 beschrijft de prognostische waarde van het eiwit AURKA. In 
patiënten met CRCLM was een hoge AURKA-expressie geassocieerd met een 
slechte overleving en bleek er geen verschil te zijn in prognostische waarden 
tussen patiënten die wel en niet behandeld waren met systemische therapie.Ook 
AURKA-expressie in CRCLM is dus een biomarker die gebruikt kan worden voor het 
voorspellen van de overleving na CRCLM-resectie.
Naast de hierboven beschreven biomarkers, zijn er nog vele andere eiwitten 
die betrokken zijn in de ontwikkeling en progressie van CRC. In hoofdstuk 5 hebben 
we de prognostische waarde onderzocht van een aantal (kandidaat-)biomarkers en 
bepaald of het mogelijk is om een nog betere voorspeller voor overleving te maken 
door de expressie van een aantal van deze eiwitten met elkaar te combineren. 
De eiwitten die we onderzocht hebben, waren: EGFR, PI3K, AURKA, Ki-67, TK1, 
KCNQ1, IGF2, VEGFA, PDGFRβ, CEA, MMP9, CXCR4, CXCL12, MLH1, MSH6, 
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PTGS2, SLC2A1 en HIF1α. Naast de prognostische waarde voor SLC2A1, VEGFA, 
EGFR, PTGS2 en AURKA, toonden we aan dat ook expressie van KCNQ1, CEA en 
MMP9 in zekere mate gerelateerd was aan overleving, al was dit – net zoals we 
eerder zagen voor HIF1α – niet statistisch significant. Gezien de associaties tussen 
expressie en overleving voor deze negen eiwitten, hebben we deze gecombineerd 
in een classification and regression tree (CART) analyse, waarmee bepaald kon 
worden welke combinatie van eiwitten de meest optimale voorspeller opleverde 
voor drie-jaarsoverleving na CRCLM-resectie Zo’n combinatie van prognostische 
eiwitten wordt een classifier genoemd. De resulterende classifier bestond uit 
een combinatie van AURKA-, PTGS2- en MMP9-expressie en was in staat om de 
overleving na CRCLM-resectie significant beter te voorspellen dan het huidige 
model, gebaseerd op de standaard clinicopathologische prognostische parameters. 
We toonden ook aan dat de expressie van de meerderheid van de onderzochte 
eiwitten gerelateerd (of in statistische termen: gecorreleerd) was aan de expressie 
van die eiwitten in de primaire tumor, wat het mogelijk maakt om overleving na 
CRCLM-resectie te voorspellen op basis van de classifier in de primaire tumor. 
Desondanks bleek een meer nauwkeurige voorspelling voor overleving gebaseerd 
te kunnen worden op expressie in de primaire tumor van alleen AURKA. Individueel, 
maar ook gecombineerd in een classificatiesysteem, kunnen dergelijke biomarkers 
biologische informatie verschaffen die normaal gesproken genegeerd wordt in 
klinische scoringssystemen. Stratificatie van patiënten op basis van de biologische 
kenmerken van een tumor, gecombineerd met hun klinische profiel, kan bijdragen 
aan het verbeteren van de overleving na CRCLM-resectie.
Moleculaire beeldvorming van prognostische biomarkers
Visualisatie van de prognostische biomarkers met behulp van PET maakt het mogelijk 
om patiënten non-invasief (dus zonder de patiënten inwendig te onderzoeken) te 
stratificeren op basis van tumorbiologie. De tracer die standaard gebruikt wordt 
voor beeldvorming met PET is [18F]fluorodeoxyglucose ([18F]FDG): een met het 
radioactieve fluorine-18 gelabeld suikermolecuul. Deze tracer wordt voor een groot 
deel via SLC2A1 opgenomen in tumorcellen, maar de prognostische waarde van 
[18F]FDG staat ter discussie. Voor patiëntstratificatie is het daarom waarschijnlijker 
dat nieuwe PET-tracers, gericht op de visualisatie van andere veelbelovende 
biomarkers, beter klinisch toepasbaar zullen zijn. Voor VEGF, EGFR en PTGS2 zijn al 
PET-tracers ontwikkeld en de prognostische en predictieve waarde van deze tracers 
wordt momenteel getest in (pre)klinische setting. Voor AURKA, daarentegen, 
bestaan nog geen tracers voor PET. Gezien de prognostische waarde van AURKA-
expressie in patiënten met CRCLM, hebben wij een specifieke remmer van AURKA-
expressie, genaamd alisertib, gelabeld met radioactieve isotopen en onderzocht of 
het mogelijk is AURKA-expressie met deze PET-tracer te visualiseren. De synthese 
en preklinische evaluatie van het radioactief gelabeld alisertib beschrijven we in 
hoofdstuk 6. Voor evaluatie in gekweekte kankercellen (in vitro) hebben we alisertib 
gelabeld met het isotoop tritium. Voor evaluatie in diermodellen (in vivo) hebben we 
alisertib gelabeld met het isotoop koolstof-11. Opname van het met tritium gelabelde 
alisertib was het hoogst in kankercellen met hoge AURKA-expressie. Het remmen 
van AURKA-expressie in deze cellen met behulp van small interfering RNA (dit 
wordt downmodulatie genoemd) resulteerde in een significant lagere opname. In 
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kankercellen met lage tot middelmatige AURKA-expressie bleek de opname niet 
representatief te zijn voor de AURKA-niveaus in deze cellen. Dit impliceert dat de 
opname van alisertib in tumorcellen niet alleen bepaald wordt door het AURKA-
niveau, maar dat ook andere mechanismen hierin een rol spelen. De in vitro-resultaten 
werden bevestigd door de in vivo-modellen, waar het gelabeld alisertib duidelijk 
werd opgenomen in geïmplanteerde tumorcellen (xenografts). Deze data laten zien 
dat radioactief gelabeld alisertib gebruikt zou kunnen worden voor de moleculaire 
beeldvorming van AURKA-expressie, met name wanneer AURKA-expressieniveaus 
hoog zijn., De prognostische en mogelijk ook predictieve waarden van gelabeld 
alisertib (kan de tracer niet alleen gebruikt worden om de overlevingskans te 
bepalen, maar ook om de respons op systemische therapie te voorspellen?) en de 
precieze mechanismen die aan de opname van alisertib ten grondslag liggen dienen 
echter eerst verder onderzocht te worden in klinische setting.
TOEKOMSTVISIE
Momenteel wordt de behandelstrategie voor patiënten met CRCLM standaard 
gebaseerd op de clinicopathologische kenmerken van de CRCLM. De aanbevolen 
beeldvormende technieken bewijzen hun nut in het voorzien van anatomische 
informatie, maar gaan voorbij aan de biologische informatie. Niet alleen ons onderzoek, 
maar ook vele andere, benadrukken dat een verschuiving moet plaatsvinden in het 
stratificeren van patiënten op basis van alleen clinicopathologische kenmerken naar 
het bepalen van een optimaal behandelplan ook op basis van biologische parameters. 
Daarvoor zijn echter wel gevalideerde en klinisch toepasbare biomarkers nodig, 
waarvan wij er hier een aantal beschreven hebben. Prognostische en predictieve 
biomarkers kunnen gebruikt worden om te bepalen welke patiënten bijvoorbeeld 
baat zullen hebben bij adjuvante targeted therapieën. Op die manier kan een 
behandelplan heel doelgericht afgestemd worden op de individuele patiënt, wat 
naar verwachting zal bijdragen aan een verbeterde levensverwachting van patiënten 
met CRCLM.
Gepersonaliseerde behandeling kan vergemakkelijkt worden door de 
toepassing van tracers voor moleculaire beeldvorming. Visualisatie van biomarkers 
zal bijdragen aan het samenstellen van een volledig biologisch profiel van de CRCLM. 
Met behulp van deze informatie, samen met de clinicopathologische informatie, kan 
vervolgens de meest optimale behandelstrategie bepaald worden.
Met dit onderzoek hebben we geprobeerd een bijdrage te leveren aan het 
verkrijgen van een beter inzicht in de biologie achter CRCLM. Door de behandeling 
af te stemmen op de individuele patiënt, daarbij gebruikmakend van niet alleen de 
clinicopathologische, maar ook de biologische informatie, kan de overleving van 
patiënten met CRCLM verbeterd worden.
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AAN IEDEREEN: BEDANKT!
Zo, dan ben ik in ieder geval niemand vergeten! Want dit proefschrift was nooit tot 
stand gekomen zonder de hulp, de steun, het begrip, maar vooral ook de liefde (als je 
goed leest, vind je deze tussen de regels door!) waarmee iedereen uit mijn omgeving 
in de afgelopen jaren heeft bijgedragen aan de voltooiing van mijn onderzoek en de 
bundeling van alle bevindingen in dit proefschrift. De hulp, die ik gekregen heb bij de 
uitvoering van experimenten, bij de daaropvolgende analyses, bij het presenteren 
van de data, bij het opschrijven van de resultaten in wetenschappelijke publicaties 
en bij al het andere wat daaromheen komt kijken. De steun, waar elke onderzoeker 
vroeg of laat een beroep op zal doen, aangezien geen enkel onderzoek loopt zoals 
het van tevoren bedacht is. Het begrip, met name in de maanden voorafgaand 
aan de afronding, als ik weer eens moest afzeggen voor uitjes, borrels, etentjes, de 
voetbal of geplande avondjes thuis samen op de bank, omdat ik dan mijn tijd weer 
moest besteden aan schrijven of andere noodzakelijke dingetjes. En natuurlijk de 
liefde, waarmee de mensen uit mijn omgeving luisterden naar de – ja, ja, vaak lange 
– verhalen over wat ik nu eigenlijk precies doe in het verre Amsterdam. Dat alles 
heeft eraan bijgedragen dat ik mijn onderzoek in de afgelopen jaren met erg veel 
plezier heb kunnen uitvoeren en hopelijk hebben jullie – of althans, degenen die niet 
het boekje openslaan en gelijk met deze bladzijde beginnen – dat terug kunnen zien 
in dit proefschrift.
Desalniettemin verdienen enkelen een speciale vermelding in dit dankwoord 
(aan de volgorde kunnen geen rechten worden ontleend, deze is ooit bedacht door 
de eerste proefschriftschrijver en wie ben ik dan om mij daar niet aan te houden?).
Om te beginnen natuurlijk mijn promotoren en copromotoren. Beste promotor prof.
dr. O.S. Hoekstra, beste Otto, wat was het fijn om een promotor te hebben die zo 
efficiënt werkt als jij. Elke e-mail werd altijd – al was het soms wat staccato (gelukkig 
heb ik in een ver verleden nog een klassieke taal geleerd, dat was ook regelmatig wat 
puzzelen tot de boodschap duidelijk werd) – op korte termijn beantwoord, zodat 
ik direct weer verder kon met waar ik mee bezig was. Ook in meetings waren de 
soms wat lange verhalen over pathways en celbiologie (van niet nader te benoemen 
personen :P) niet aan jou besteed: gewoon ineens to the point en dan weer verder 
met het volgende! Soms was het wel wat lastig dat we elkaar niet vaak spraken, 
als er een experiment niet helemaal goed gegaan was of er langdurige problemen 
waren met software en apparatuur, maar jij alleen merkte dat de resultaten te laat 
binnen waren. Ik hoop dat dit geen negatieve invloed heeft gehad op jouw beeld 
van mij en ik denk dat dit boekje het bewijs is dat we trots mogen zijn op waarin het 
uiteindelijk allemaal geresulteerd heeft! 
Beste promotor prof.dr. G.A. Meijer, beste Gerrit, het was een voorrecht om 
het grootste deel van mijn onderzoek onder jouw hoede uit te mogen voeren. Als 
onwetende ingenieur kwam ik binnen (althans, als het op klinisch relevante kennis 
aankomt), als een soort mix van volleerd klinisch moleculair biologisch nucleair onco-
pathologisch onderzoeker, die ook nog wat weet van statistiek en programmeren, 
ga ik weer weg. Al waren onze maandelijkse meetings – die we eens in de twee 
à drie maanden hadden – aanvankelijk vooral gericht op politiek geneuzel en het 
opzetten van het netwerk van ziekenhuizen, van jouw enthousiaste maar kritische 
feedback in de TP-meetings heb ik veel geleerd. Daarbovenop heb ik genoten van je 
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humor en vrolijkheid, waarmee je er altijd voor zorgde dat ik vol goede moed en met 
veel plezier mijn onderzoek bleef uitvoeren. Ook het jaarlijkse uitje naar de suburbs 
van Hattem heb ik steeds met genoegen bijgewoond. Het was een eer om jouw gast 
te mogen zijn, zowel in Meijer Residence als in jouw onderzoeksgroep!
Beste copromotor dr. R.J.A. Fijneman, beste Remond. Onder jouw directe 
begeleiding heb ik mijn onderzoek mogen uitvoeren, vanaf dag één tot nu bij 
het schrijven en afronden van mijn proefschrift. Je bent zonder twijfel de beste 
begeleider die een promovendus zich kan wensen. Niet alleen stond je deur altijd 
open om te praten over de resultaten of wat er dan ook op dat moment de aandacht 
vroeg, ook kon ik altijd bij je terecht voor nuttige feedback en welgemeend advies. 
Je hebt me geleerd om de positieve boodschap uit elk resultaat te halen, zelfs al 
zag ik zelf even door de bomen het bos niet meer, waarmee je ervoor zorgde dat ik 
steeds weer met een goed gevoel verder kon. Voor een meeting met jou mocht ik 
meestal wel wat extra tijd uittrekken, mede dankzij de vaak wat lange verhalen over 
pathways en celbiologie, maar mijn directe omgeving zal waarschijnlijk betwisten 
of dit kwam door jouw aanleg voor lange verhalen of die van mij. Ook al zijn er wel 
meer parallellen te trekken (denk aan: oorsprong in gemeente Oosterhout, verhuisd 
naar anti-voetbal-bolwerk Eindhoven, terechtgekomen in de stad der voetbalgoden 
Amsterdam, wie weet wat de nabije toekomst brengt?), over één ding zullen we het 
nooit eens worden, maar dat zullen we maar in het midden laten (al spreken die drie 
sterren op het shirt toch wel in mijn voordeel :P). Remond, bedankt voor alles!
Beste copromotor dr. A.A. Geldof, beste Ab. Al kon ik me pas in het laatste 
deel van mijn promotieonderzoek gaan richten op het in vitro werk, vanaf het eerste 
moment ben je erg begaan geweest met het verloop van het onderzoek. Je nuttige 
tips en commentaar hebben voortdurend een grote rol gespeeld in mijn onderzoek 
en bijgedragen aan de totstandkoming van dit proefschrift. Waar we elkaar in het 
begin één keer in de twee weken zagen, in het laatste anderhalf jaar zagen we elkaar 
minstens twee keer per week in het kweeklab. Voor de goede orde spraken we 
steeds braaf af om te beginnen zo rond een uur of negen, maar uiteindelijk werd dit 
meestal minstens een uur of half tien (zie representatief voorbeeld van hoe dat vaak 
ging; Ab/Jeroen: “Sorry, ik ben wat later!”, Ab/Jeroen: “Geeft niet, ik ben ook wat 
later!”). Ik heb genoten van onze gemoedelijke gesprekken tijdens het pipetteren, 
doorgaans over wat we het afgelopen weekend gedaan hadden of het komende 
zouden gaan doen. Ab, je bent oprecht één van de aardigste personen die ik in mijn 
leven ben tegengekomen en ik ben blij dat ik zo vaak naast je heb mogen werken. 
Al zal ik het kweken voor geen seconde gaan missen, onze gesprekken des te meer!
Ook wil ik een woord van dank richten aan de leden van de lees- en 
promotiecommissies. Beste dr. Koop Bosscha, prof.dr Guus van Dongen, prof.dr. 
Lioe-Fee de Geus-Oei, prof.dr. Geert Kazemier, dr. Onno Kranenburg, prof.dr. Hans 
Morreau, prof.dr. Iris Nagtegaal en prof.dr Henk Verheul, hartelijk bedankt voor de 
tijd die jullie besteed hebben aan de kritische beoordeling van mijn proefschrift en 
het vertrouwen dat jullie hebben uitgesproken door zitting te willen nemen in mijn 
promotiecommissie. 
Dit onderzoek was niet mogelijk geweest zonder de weefselmonsters en 
bijbehorende clinicopathologische informatie van het patiëntencohort. Daarom 
wil ik alle betrokkenen van de verschillende ziekenhuizen bedanken die toegezegd 
hebben om als lid van de DeCoDe PET groep zich toe te leggen op de samenstelling 
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van dit cohort en het kritisch becommentariëren van de resulterende data en 
artikelen. Daarom: Nicole van Grieken, Willemien Menke - Van der Houven van Oordt, 
Cemile Karga, Lars Perk, Petrousjka van den Tol, Lisette te Velde, Bert Windhorst, 
Jim Baas, Arjen Rijken, Mike van Beek, Rik Pijpers, Herman Bril, Hein Stockmann, 
Ton Zwijnenburg, Koop Bosscha, Adriaan van den Brule, Corneline Hoekstra, Hans 
van der Linden, Inne Borel Rinkes, Paul van Diest, Richard van Hillegersberg, Onno 
Kranenburg, Marnix Lam, Nikol Snoeren, Ing Han Liem, Rudi Roumen, Wouter 
Vening, bedankt! 
Een speciaal dankwoord richt ik ook aan de twee dames die mij zullen 
flankeren tijdens de verdediging van mijn proefschrift. Pien, jij bent gedurende mijn 
gehele promotietraject in en om het lab mijn rots in de branding geweest. Is er 
eigenlijk wel iets dat jij niet kunt? Snijden, plakken, kleuren, fixeren, inbedden, TMA’s 
maken, aftekenen, coupes scannen, celkweek, Western blotten, blokjes verzamelen, 
waarschijnlijk vergeet ik nog de helft! Ik voel me vereerd dat ik in het lab steeds naast 
je heb mogen staan en het is niet meer dan logisch dat jij, als één van mijn paranimfen, 
ook tijdens de promotie naast me zult staan. Marique, lieve zus van mij, ook al had je 
nog nooit van een paranimf gehoord en associeerde je dit – net als zoveel anderen 
– misschien met één of ander mythisch wezentje, ik ben supertrots dat ook jij naast 
me zult staan tijdens de verdediging. Je bent altijd erg geïnteresseerd geweest in 
mijn onderzoek en met jouw achtergrond in de zorg daarbij opgeteld, heb ik geen 
moment getwijfeld om ook jou als paranimf te vragen (zelfs ondanks die vingers 
tussen de deur in onze vroegere jaren :P).
En dan natuurlijk iedereen van de Tumor Profiling (TP). Gezamenlijk hebben 
jullie waarschijnlijk de grootste invloed gehad op mijn promotieonderzoek en 
zonder jullie was deze periode in mijn leven ab-so-luut niet zo gezellig geweest als 
nu het geval was. Ja, ik weet het, ik was vaak niet bij de vrijdagmiddagborrels (doe 
die borrels dan ook niet op dagen waarop ik nog bepakt en bezakt richting Dorst 
moest reizen!) en ook bij andere uitjes heb ik wel eens verstek laten gaan, maar 
desondanks heb ik echt genoten van de borrels, etentjes, congressen en andere 
uitjes waar ik wél bij ben geweest! Remond en Beatriz, met jullie aan het roer als 
stuurmannen van Gerrit, twijfel ik er niet aan dat jullie ook in je nieuwe functie weer 
volop geweldige bevindingen zullen gaan genereren. Aan jullie positieve instelling 
en enthousiasme (ik kan me niet herinneren dat ik jullie ooit níet vrolijk heb gezien) 
zal het in ieder geval niet liggen. Pien, Anne, Marianne en Sandra (“spa” en “sma” :P), 
jullie bijdragen, zowel in het lab als daaromheen, zijn van grote waarde voor iedereen 
bij de TP! Mijn voormalige roomies Meike en Anke (die mij altijd – of ik dat nu wilde 
of niet – van goede adviezen konden voorzien), Linda, Eric, Cindy, Begoña, Rinus 
(alias Herr Voorhamm), Eriënne (alias dokter De Cuba), Evert, Annemieke, Lisette 
(alias Lysate alias Mirna), Florence (alias Fio (van Fiorentina, red.)), Oscar, Josien, 
Mariska, George, Nicole, Martijn, Sara, Gosia, Sietze en Ilhame, als de (voormalige) 
pijlers waarop het onderzoek van de TP berust(te) wil ik jullie bedanken voor alle 
gesprekken en discussies, maar vooral ook alle leuke momenten die ik met jullie heb 
mogen delen. 
Ik heb ook het geluk gehad dat ik twee uitmuntende studentes mocht 
begeleiden (of was het nu andersom?) tijdens hun stage. Annemieke, met jouw 
nooit afwezige kritische kijk op zaken kom je er wel, in welke richting dan ook. Een 
deel van je stage bestond nog uit het verzamelen van blokjes en klinische data, 
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waarvoor we onder andere nog lange dagen gemaakt hebben in de donkere 
krochten van ziekenhuizen elders in het land. Na je stage heb je je als analistisch 
promozoeker (bij dezen, dat is je functie) langer verbonden aan de TP en ook nu 
nog blijk je van onmisbare waarde (ook als het aankomt op het becommentariëren 
van onze artikelen; gelukkig gaat het plannen van meetings – mede dankzij een 
handige planning-mok – me nu wat beter af). Wendy, jij hebt je tijdens je stage 
vooral beziggehouden met praktisch labwerk en het bleek al snel dat je daarin 
onovertroffen bent. Voor mijn promotieonderzoek heb ook jij erg waardevol werk 
verricht en het is dan ook niet meer dan terecht dat dit geresulteerd heeft in een 
aanstelling bij de Diagnostiek. Beiden bedankt en vooral ook succes in de toekomst!
Daarnaast zijn er nog degenen die vanuit een andere hoek een voortdurende 
bijdrage leveren aan onderzoek binnen de TP. Mark, iedereen kan altijd met vragen 
bij je terecht en je zult je geen moeite besparen om iedereen zo goed mogelijk van 
dienst te zijn. Dank daarvoor! Mireille, bedankt voor je assistentie op het lab. Jeroen, 
Rolanda, Cuneyt, Ron en Jaap dank voor jullie assistentie bij het digitaliseren van alle 
TMA’s en coupes. Pauline, bedankt voor alles, want zonder jou waren heel wat zaken 
in de soep gelopen! Janneke, ik heb jou eens genomineerd als vrolijkste collega van 
de Pathologie, want ja, dat ben je nu eenmaal! Bedankt voor al het geregel in het 
kader van CTMM! Ellen en Mike, vooral in het begin was het een terugkerend ritueel: 
mijn maandelijkse declaraties voor de reizen naar al die ziekenhuizen in Nederland, 
bedankt voor jullie hulp hiermee!
Buiten de TP hebben nog veel meer collega’s bijgedragen aan de (werk)sfeer 
rondom mijn promotieonderzoek. Of dit nu was via hulp met experimenten, even 
een gesprekje op de gang of bij activiteiten buiten het werk om, bedankt voor het 
plezier, de hulp en interesse: Jasmijn, Robert, Suzanne, Denise, Lise, Saskia W, Wina, 
Maaike (als voormalig roomie!), Bauke, Daoud, Paul, François, Dirk, Ilari, Renske, 
Leontien, Sylvia, Annelieke, Saskia C, Erik, Annelies, Mariëtte, Maarten en Tieneke.
 Zoals jullie hebben kunnen lezen in de voorgaande hoofdstukken, zit er een klein 
statistisch tintje aan een groot deel van de hoofdstukken. Ondanks dat ik ooit tijdens 
mijn studie de biostatistiek heb afgezworen, heb ik mij hier toch noodgedwongen 
opnieuw in moeten verdiepen. Veerle, dit was me absoluut nooit gelukt zonder 
jouw uitgebreide hulp. Al zijn de experimenten nog zo mooi, zonder een gedegen 
statistische onderbouwing zijn de resultaten een stuk minder waard. We hebben 
de analyses met veel pijn en moeite opgezet, maar we kunnen naar mijn idee 
trots zijn op de validatiemethode die we hebben opgezet voor de analyse van 
immunohistochemische kleuringen. Mark, ook jij hebt hierin een belangrijke rol 
gespeeld, jouw statistische know-how is ongeëvenaard. Bedankt!
Al beschrijft een groot deel van mijn proefschrift de pathologie achter 
levermetastasen, één van de hoofddoelen was ook het ontwikkelen van een 
nieuwe tracer voor moleculaire imaging. Vandaar dat het promotieonderzoek een 
samenwerking betrof tussen de Pathologie-afdeling en de afdeling Radiologie 
& Nucleaire Geneeskunde. Van die laatste afdeling wil ik twee personen expliciet 
bedanken die veel werk voor en met mij hebben verricht. Amanda, je hebt ongelooflijk 
veel dingen voor me geregeld. Bedankt voor de tijd en moeite die je besteed hebt 
aan alle zaken die bij mijn project kwamen kijken! Cemile, samen met jou heb ik 
zowat het hele land doorgereisd om klinische data te verzamelen: onder andere 
Breda, Eindhoven, Haarlem, ’s-Hertogenbosch, Utrecht en Veldhoven hebben we 
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bezocht. Het was een hels karwei (gezien de hoeveelheid data die we per patiënt 
verzamelden, hebben ooit berekend dat we per persoon ongeveer 7 à 8 patiënten 
per dag konden invullen – en dat voor een cohort van uiteindelijk 507 patiënten, om 
nog maar te zwijgen over de hoeveelheid patiënten die níet geïncludeerd werden), 
maar volgens mij hebben we het altijd erg naar ons zin gehad. Zonder jouw hulp 
zat ik nu waarschijnlijk nog steeds ergens in een stoffig kamertje dossiers door te 
pluizen! 
En uiteraard wil ik ook graag iedereen op het Radionuclidencentrum bedanken. 
Prof.dr. A.D. Windhorst, of liever gewoon Bert, in de loop van mijn promotieproject 
ben je bij het onderzoek betrokken geraakt en dankzij jouw hulp en goede wil is 
hoofdstuk 6 van dit proefschrift geworden tot wat het nu is. Je wist dat ik graag ook 
zelf de kneepjes van het radiochemie-vak wilde leren en daarom ben ik je enorm 
dankbaar dat je me de kans hebt gegeven om na mijn promotieonderzoek als 
postdoc in jouw lab aan de slag te gaan. Joost, jij hebt het radioactieve werk van dit 
proefschrift voor je rekening genomen, en hoe! Binnen twee maanden nadat je met 
dit project begonnen was, had je de tracers al klaar en konden we aan de slag met de 
preklinische validatie. We komen elkaar ongetwijfeld nog eens tegen in Enkhuizen 
en dat biertje aan de steiger houd ik dan van je tegoed! Carla, Marijke, Kevin, Inge 
en Ricardo, dank voor jullie hulp bij de in vivo experimenten. Ook de anderen wil ik 
graag bedanken, met name voor jullie feedback wat betreft de preklinische validatie 
van de tracer en de overige zaken die komen kijken bij het doen van radioactief 
onderzoek: Daniëlle, Ulrike, Uta, Bieneke, Alexandra, Renske, Lonneke, Paul, Niels, 
Dennis W, Berend, Dion, Frank, Kanar, Marije, Sjoerd, Jos, Johan, Rob, Rolph, Dennis 
L, Ger, Martien, Joey, Thijs, Anneloes, Claudia, Gerard, Annemieke, Jan, Gertrüd, 
Tjaard, Annelies, Fred, Arjan, Maarten, Peter, Roy, Wesley en Mariska, dank jullie wel!
Stephen and Daniel, thank you for providing the precursors and for sharing 
your knowledge. This collaboration certainly facilitated the development of the 
tracer!
Tot slot wil ik mijn familie en vrienden bedanken voor de interesse die zij altijd 
getoond hebben in mijn promotieonderzoek. Zoals een echte Brabander misschien 
wel betaamt, is mijn familie ietwat aan de grote kant (in persoonlijke kringen dan ook 
wel gekscherend “de andere grootste familie van Nederland” genoemd) en kan ik 
onmogelijk alle ooms en tantes, neefjes en nichtjes en alle anderen die nu ook tot de 
familie behoren op gaan noemen. Hetzelfde geldt voor alle personen die ik met eer 
tot mijn vriendengroep mag rekenen. Daarom wil ik graag volstaan met te zeggen 
dat ik ongelooflijk trots ben dat jullie deel uitmaken van mijn leven en ik het enorm 
waardeer dat jullie altijd op de hoogte willen blijven van mijn Amsterdamse reilen en 
zeilen. Bedankt voor jullie nooit aflatende steun!
In het bijzonder wil ik ook graag mijn schoonouders bedanken. Nancy, het is 
altijd een klein feestje als jij over de vloer komt. Of we nu een spelletje doen, ergens 
een drankje drinken of samen op pad gaan, ik heb het altijd geweldig naar mijn zin! 
En Richard, wat mij betreft ben je sowieso een blijvertje (:P)! Edwin, je bent een 
man met een gouden hart en speelt een enorm belangrijke rol in ons leven. Ik ben 
supertrots dat ik me jullie (lease-)schoonzoon mag noemen!
Ook mijn broers en zussen (inmiddels al heel wat!) en andere aangewaaide 
gezinsleden wil ik bedanken. Marique, mijn grote zus waar ik ook ongelooflijk trots 
op ben. Laat je niet kennen, als je wilt, kun je echt de hele wereld aan! Stijn, mijn 
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grote kleine broer, je bent altijd een cadeautje geweest en wat ben ik ook trots op 
jou. Bij je grote broer zul je altijd terecht kunnen! Irene, mijn zusje, jij bent het lieve 
kleine zusje dat ik nooit heb gehad (en waar ik ongelooflijk blij mee ben). Anti-kater-
pannekoeken en zwarte wodka - fristi’s zijn aan ons wel besteed! Coen en Jasper, 
we zien elkaar niet zo vaak, maar ik ben er echt wel trots op dat jullie mijn broers 
zijn! Maria, je bent altijd enorm zorgzaam voor papa en iedereen uit je omgeving en 
ook zorg je ervoor dat wij ons altijd meer dan welkom voelen als we weer eens een 
nachtje in Dorst blijven slapen. Je bent een moeder uit duizenden! Edgar, je bent een 
geweldige vader voor Stijn en misschien moet ik ondertussen toch ook wel zeggen 
dat je dat ook wel een beetje voor mij bent geworden. Met jou hebben we altijd de 
grootste lol en ik ben enorm blij dat je in ons leven bent gekomen.
Lieve papa en mama, het is niet te beschrijven wat jullie allemaal voor mij 
betekend hebben. Pap, met goede raad heb je mij mijn hele leven al bijgestaan 
en ook nu nog help je me steeds in de juiste richting. Je positieve instelling werkt 
aanstekelijk en ik weet dat je er altijd voor me zult zijn. Mam, je bent de beste moeder 
die ik me kan wensen en altijd sta je voor me klaar. Je helpt me met relativeren als 
de situatie daar om vraagt en bent mijn vertrouwde klankbord wanneer ik daar 
behoefte aan heb. Papa en mama, dankzij jullie sta ik waar ik nu sta. Dank jullie wel 
dat jullie zijn wie je bent!
Lieve Sam, mijn knappe vrouw. Tijdens mijn promotieonderzoek kwam jij mijn 
leven (lees: een bar in Alanya) binnengewandeld. Het spreekt voor zich wat voor 
effect dat gehad heeft op mijn leven, aangezien je nu inmiddels iets meer dan een 
jaar mijn ring om jouw vinger draagt. Je bent mijn steun en toeverlaat en je geeft 
me het gevoel dat ik alles en iedereen aankan. Verander alsjeblieft nooit, je bent de 
liefde van mijn leven, mijn maatje voor altijd en ik kan niet wachten om samen met 
jou de rest van ons leven tegemoet te gaan, welke avonturen er ook op ons pad 
zullen komen. 

